0001628280-23-006315.txt : 20230303 0001628280-23-006315.hdr.sgml : 20230303 20230303165100 ACCESSION NUMBER: 0001628280-23-006315 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc CENTRAL INDEX KEY: 0000727207 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841072256 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-31822 FILM NUMBER: 23705220 BUSINESS ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 BUSINESS PHONE: 303-863-8088 MAIL ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 FORMER COMPANY: FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: HYDRO SEEK INC DATE OF NAME CHANGE: 19880802 10-Q/A 1 axdx-20220930.htm 10-Q/A axdx-20220930
0000727207trueDecember 31Q32022P1YP2Y0.03234280.022640.032342800007272072022-01-012022-09-3000007272072022-11-10xbrli:shares00007272072022-09-30iso4217:USD00007272072021-12-31iso4217:USDxbrli:shares00007272072022-07-012022-09-3000007272072021-07-012021-09-3000007272072021-01-012021-09-3000007272072020-12-3100007272072021-09-300000727207us-gaap:PreferredStockMember2022-06-300000727207us-gaap:PreferredStockMember2021-06-300000727207us-gaap:PreferredStockMember2021-12-310000727207us-gaap:PreferredStockMember2020-12-310000727207us-gaap:PreferredStockMember2021-07-012021-09-300000727207us-gaap:PreferredStockMember2021-01-012021-09-300000727207us-gaap:PreferredStockMember2022-09-300000727207us-gaap:PreferredStockMember2021-09-300000727207us-gaap:CommonStockMember2022-06-300000727207us-gaap:CommonStockMember2021-06-300000727207us-gaap:CommonStockMember2021-12-310000727207us-gaap:CommonStockMember2020-12-310000727207us-gaap:CommonStockMember2022-07-012022-09-300000727207us-gaap:CommonStockMember2021-07-012021-09-300000727207us-gaap:CommonStockMember2022-01-012022-09-300000727207us-gaap:CommonStockMember2021-01-012021-09-300000727207us-gaap:CommonStockMember2022-09-300000727207us-gaap:CommonStockMember2021-09-300000727207us-gaap:AdditionalPaidInCapitalMember2022-06-300000727207us-gaap:AdditionalPaidInCapitalMember2021-06-300000727207us-gaap:AdditionalPaidInCapitalMember2021-12-310000727207us-gaap:AdditionalPaidInCapitalMember2020-12-310000727207srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310000727207us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000727207us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000727207us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000727207us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000727207us-gaap:AdditionalPaidInCapitalMember2022-09-300000727207us-gaap:AdditionalPaidInCapitalMember2021-09-300000727207us-gaap:RetainedEarningsMember2022-06-300000727207us-gaap:RetainedEarningsMember2021-06-300000727207us-gaap:RetainedEarningsMember2021-12-310000727207us-gaap:RetainedEarningsMember2020-12-310000727207srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2021-12-310000727207us-gaap:RetainedEarningsMember2022-07-012022-09-300000727207us-gaap:RetainedEarningsMember2021-07-012021-09-300000727207us-gaap:RetainedEarningsMember2022-01-012022-09-300000727207us-gaap:RetainedEarningsMember2021-01-012021-09-300000727207us-gaap:RetainedEarningsMember2022-09-300000727207us-gaap:RetainedEarningsMember2021-09-300000727207us-gaap:TreasuryStockCommonMember2022-06-300000727207us-gaap:TreasuryStockCommonMember2021-06-300000727207us-gaap:TreasuryStockCommonMember2021-12-310000727207us-gaap:TreasuryStockCommonMember2020-12-310000727207us-gaap:TreasuryStockCommonMember2022-09-300000727207us-gaap:TreasuryStockCommonMember2021-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-09-30xbrli:pure0000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Membersrt:ScenarioPreviouslyReportedMemberus-gaap:ConvertibleDebtMember2022-09-300000727207srt:ScenarioPreviouslyReportedMember2022-09-300000727207srt:RestatementAdjustmentMember2022-09-300000727207srt:ScenarioPreviouslyReportedMember2022-07-012022-09-300000727207srt:RestatementAdjustmentMember2022-07-012022-09-300000727207srt:ScenarioPreviouslyReportedMember2022-01-012022-09-300000727207srt:RestatementAdjustmentMember2022-01-012022-09-3000007272072022-06-3000007272072021-06-300000727207srt:MinimumMember2022-01-012022-09-300000727207srt:MaximumMember2022-01-012022-09-300000727207axdx:InstrumentsMember2022-01-012022-09-300000727207srt:MinimumMember2022-09-300000727207srt:MaximumMember2022-09-300000727207us-gaap:EquipmentMember2022-09-300000727207us-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-01-010000727207us-gaap:CashAndCashEquivalentsMemberaxdx:FinancialInstitutionsOneMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-09-300000727207axdx:FinancialInstitutionsTwoMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-09-300000727207axdx:FinancialInstitutionsThreeMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:CreditConcentrationRiskMember2022-01-012022-09-300000727207us-gaap:CashAndCashEquivalentsMemberaxdx:FinancialInstitutionsOneMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310000727207axdx:FinancialInstitutionsTwoMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310000727207us-gaap:AccountsReceivableMemberaxdx:OneCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300000727207us-gaap:AccountsReceivableMemberaxdx:OneCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-12-310000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-08-150000727207us-gaap:FairValueInputsLevel3Memberaxdx:EmbededWarrantMemberaxdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMember2022-08-150000727207us-gaap:CertificatesOfDepositMember2022-09-300000727207us-gaap:USTreasuryAndGovernmentMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMember2022-09-300000727207us-gaap:CertificatesOfDepositMember2021-12-310000727207us-gaap:USTreasuryAndGovernmentMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMember2021-12-310000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012021-09-300000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-07-012022-09-300000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000727207us-gaap:ComputerEquipmentMember2022-09-300000727207us-gaap:ComputerEquipmentMember2021-12-310000727207us-gaap:TechnologyEquipmentMember2022-09-300000727207us-gaap:TechnologyEquipmentMember2021-12-310000727207us-gaap:LeaseholdsAndLeaseholdImprovementsMember2022-09-300000727207us-gaap:LeaseholdsAndLeaseholdImprovementsMember2021-12-310000727207axdx:InstrumentsMember2022-09-300000727207axdx:InstrumentsMember2021-12-310000727207us-gaap:ConstructionInProgressMember2022-09-300000727207us-gaap:ConstructionInProgressMember2021-12-310000727207axdx:ProductsandServicesnotYetDeliveredMember2022-09-300000727207axdx:ProductsandServicesnotYetDeliveredMember2021-12-310000727207us-gaap:NotesPayableOtherPayablesMemberaxdx:OtherLoansMember2020-01-012020-12-31axdx:loan0000727207srt:MinimumMemberus-gaap:NotesPayableOtherPayablesMemberaxdx:OtherLoansMember2020-12-310000727207srt:MaximumMemberus-gaap:NotesPayableOtherPayablesMemberaxdx:OtherLoansMember2020-12-310000727207us-gaap:NotesPayableOtherPayablesMemberaxdx:OtherLoansMember2022-09-300000727207us-gaap:NotesPayableOtherPayablesMemberaxdx:OtherLoansMember2021-12-310000727207axdx:PaycheckProtectionProgramMemberus-gaap:UnsecuredDebtMember2020-04-140000727207axdx:PaycheckProtectionProgramMemberus-gaap:UnsecuredDebtMember2021-07-152021-07-150000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-30axdx:day0000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-07-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-07-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:ConvertibleNotesExchangeAgreementMemberus-gaap:ConvertibleDebtMember2022-07-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:ConvertibleNotesExchangeAgreementMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:ConvertibleNotesExchangeAgreementMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:ConvertibleNotesExchangeAgreementMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000727207axdx:PrepaidForwardMember2022-01-012022-09-300000727207axdx:PrepaidForwardMember2022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:A2021ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:A2021ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:A2021ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:March2022ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2022-03-212022-03-21axdx:tranche0000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:March2022ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2022-03-210000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:March2022ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2022-03-292022-05-180000727207axdx:ConvertibleNotesExchangeAgreementMemberaxdx:TwoPointFiveZeroNewConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroNewConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-09-300000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroNewConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:August2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:JackWSchulerLivingTrustMemberus-gaap:ConvertibleDebtMember2022-08-152022-08-150000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-08-152022-08-150000727207axdx:August2022ExchangeTransactionMemberus-gaap:SecuredDebtMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-08-152022-08-150000727207axdx:EmbededWarrantMemberaxdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMember2022-08-150000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-08-150000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-09-300000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-07-012022-09-300000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2021-07-012021-09-300000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2022-01-012022-09-300000727207us-gaap:SeniorNotesMemberaxdx:August2022ExchangeTransactionMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMemberaxdx:JackWSchulerLivingTrustMember2021-01-012021-09-300000727207axdx:EmbededWarrantMemberaxdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMember2022-08-152022-08-150000727207us-gaap:MeasurementInputExpectedTermMemberaxdx:EmbededWarrantMemberaxdx:JackWSchulerLivingTrustMember2022-09-30axdx:year0000727207us-gaap:MeasurementInputPriceVolatilityMemberaxdx:EmbededWarrantMemberaxdx:JackWSchulerLivingTrustMember2022-09-300000727207axdx:EmbededWarrantMemberaxdx:JackWSchulerLivingTrustMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-300000727207axdx:EmbededWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberaxdx:JackWSchulerLivingTrustMember2022-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000727207us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000727207us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000727207us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000727207us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000727207us-gaap:WarrantMember2022-07-012022-09-300000727207us-gaap:WarrantMember2021-07-012021-09-300000727207us-gaap:WarrantMember2022-01-012022-09-300000727207us-gaap:WarrantMember2021-01-012021-09-300000727207us-gaap:SeriesAPreferredStockMember2022-09-300000727207axdx:March2022SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2022-03-24axdx:instrument0000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMember2022-01-012022-09-300000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2021-12-310000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2022-01-012022-09-300000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2022-09-300000727207us-gaap:CostOfSalesMember2022-07-012022-09-300000727207us-gaap:CostOfSalesMember2021-07-012021-09-300000727207us-gaap:CostOfSalesMember2022-01-012022-09-300000727207us-gaap:CostOfSalesMember2021-01-012021-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2022-09-300000727207srt:MinimumMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300000727207srt:MaximumMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300000727207us-gaap:PerformanceSharesMember2022-01-012022-09-300000727207us-gaap:PerformanceSharesMember2020-01-012020-12-310000727207us-gaap:PerformanceSharesMember2022-09-300000727207us-gaap:PerformanceSharesMember2021-01-012021-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMembersrt:MinimumMember2022-01-012022-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMembersrt:MaximumMember2022-01-012022-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2022-01-012022-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2020-12-310000727207axdx:PerformanceBasedRestrictedStockUnitsMember2021-12-310000727207axdx:PerformanceBasedRestrictedStockUnitsMember2021-01-012021-09-3000007272072022-04-30axdx:segment0000727207us-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-07-012022-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:AccountsReceivableMemberus-gaap:GeographicConcentrationRiskMember2022-09-300000727207us-gaap:GeographicDistributionForeignMemberus-gaap:AccountsReceivableMemberus-gaap:GeographicConcentrationRiskMember2021-12-310000727207us-gaap:GeographicDistributionDomesticMember2022-07-012022-09-300000727207us-gaap:GeographicDistributionDomesticMember2021-07-012021-09-300000727207us-gaap:GeographicDistributionDomesticMember2022-01-012022-09-300000727207us-gaap:GeographicDistributionDomesticMember2021-01-012021-09-300000727207us-gaap:GeographicDistributionForeignMember2022-07-012022-09-300000727207us-gaap:GeographicDistributionForeignMember2021-07-012021-09-300000727207us-gaap:GeographicDistributionForeignMember2022-01-012022-09-300000727207us-gaap:GeographicDistributionForeignMember2021-01-012021-09-300000727207axdx:AcceleratePhenoMember2022-07-012022-09-300000727207axdx:AcceleratePhenoMember2021-07-012021-09-300000727207axdx:AcceleratePhenoMember2022-01-012022-09-300000727207axdx:AcceleratePhenoMember2021-01-012021-09-300000727207axdx:OtherRevenueMember2022-07-012022-09-300000727207axdx:OtherRevenueMember2021-07-012021-09-300000727207axdx:OtherRevenueMember2022-01-012022-09-300000727207axdx:OtherRevenueMember2021-01-012021-09-300000727207us-gaap:ProductMember2022-07-012022-09-300000727207us-gaap:ProductMember2021-07-012021-09-300000727207us-gaap:ProductMember2022-01-012022-09-300000727207us-gaap:ProductMember2021-01-012021-09-300000727207us-gaap:ServiceMember2022-07-012022-09-300000727207us-gaap:ServiceMember2021-07-012021-09-300000727207us-gaap:ServiceMember2022-01-012022-09-300000727207us-gaap:ServiceMember2021-01-012021-09-300000727207us-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionDomesticMemberus-gaap:GeographicConcentrationRiskMember2022-09-300000727207us-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionDomesticMemberus-gaap:GeographicConcentrationRiskMember2021-12-310000727207us-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMember2022-09-300000727207us-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionForeignMemberus-gaap:GeographicConcentrationRiskMember2021-12-310000727207us-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicConcentrationRiskMember2022-09-300000727207us-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicConcentrationRiskMember2021-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMemberaxdx:CertainDirectorsAndOfficersOrAffiliatesMembersrt:AffiliatedEntityMember2020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMemberaxdx:JackWSchulerLivingTrustMembersrt:AffiliatedEntityMember2020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMemberaxdx:CertainDirectorsAndOfficersOrAffiliatesMembersrt:AffiliatedEntityMember2020-12-012020-12-31axdx:entity0000727207axdx:December2020SecuritiesPurchaseAgreementMemberaxdx:JackWSchulerLivingTrustMembersrt:AffiliatedEntityMember2020-12-012020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-012020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-02-192021-04-090000727207axdx:September2021RescissionAgreementMembersrt:AffiliatedEntityMember2021-09-172021-09-170000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-09-302021-09-300000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-01-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-09-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-09-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-07-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-09-012021-09-3000007272072021-09-220000727207axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-10-292021-10-290000727207axdx:August2022ExchangeTransactionMemberus-gaap:SecuredDebtMemberaxdx:ExtinguishedNotesMemberaxdx:JackWSchulerLivingTrustMember2022-07-012022-09-300000727207us-gaap:FairValueInputsLevel3Memberaxdx:EmbededWarrantMemberaxdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMember2022-08-152022-08-150000727207axdx:August2022PublicOfferingMemberus-gaap:CommonStockMember2022-08-222022-08-220000727207axdx:August2022PublicOfferingMember2022-08-220000727207axdx:August2022PublicOfferingMember2022-08-222022-08-220000727207axdx:ConvertibleNotePurchasesMemberaxdx:SchulerFamilyFoundationMemberaxdx:A2021ExchangeTransactionMembersrt:AffiliatedEntityMember2021-09-300000727207axdx:ConvertibleNotePurchasesMemberaxdx:A2021ExchangeTransactionMembersrt:AffiliatedEntityMember2021-09-222021-09-220000727207axdx:ConvertibleNotePurchasesMemberaxdx:A2021ExchangeTransactionMembersrt:AffiliatedEntityMember2021-07-012021-09-300000727207axdx:SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-240000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-01-012021-09-300000727207us-gaap:SeriesAPreferredStockMemberaxdx:March2022SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2022-03-240000727207axdx:August2022ExchangeTransactionMemberus-gaap:SecuredDebtMemberaxdx:ExtinguishedNotesMemberaxdx:JackWSchulerLivingTrustMember2022-01-012022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____

Commission file number: 001-31822
ACCELERATE DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware84-1072256
(State or other jurisdiction(I.R.S. Employer Identification No.)
of incorporation or organization)
3950 South Country Club Road, Suite 470
Tucson,Arizona85714
(Address of principal executive offices)(Zip Code)

(520) 365-3100
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 parAXDXThe Nasdaq Stock Market LLC
value per share(The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐
Accelerated filer☐
Non-accelerated filer☑
Smaller reporting company☑
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

As of November 10, 2022, there were 99,099,480 shares of the registrant’s common stock outstanding.



EXPLANATORY NOTE

In this Amendment No. 1 to the Quarterly Report on Form 10-Q (this “Form 10-Q/A”), all references to “we” or “us” or “our” or “Accelerate” or the “Company” refer to Accelerate Diagnostics, Inc. and its consolidated subsidiaries.    

Restatement Overview

On February 6, 2023, the Audit Committee of the Company’s Board of Directors (the “Board”), in consultation with members of the Company’s management, determined that the Company’s previously issued interim unaudited financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022 (collectively, the “2022 Interim Financial Statements”), should no longer be relied upon due to the error in the balance sheet classification of the Company’s 2.50% Senior Convertible Notes due 2023 (the “Notes”) described below. For additional information, please refer to our Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 9, 2023.

This Form 10-Q/A amends and restates certain items noted below in the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2022, as originally filed with the SEC on November 14, 2022 (the “Original Filing”). Except as described below, no other material changes have been made to the Original Filing. Unless otherwise noted, this Form 10-Q/A speaks as of the date of the Original Filing and does not reflect other events that may have occurred after the date of the Original Filing or modify or update any disclosures that may have been affected by subsequent events. Accordingly, this Form 10-Q/A should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, including any amendment to those filings.

Background of Restatement

In March and April 2018, the Company issued $171.5 million aggregate principal amount of Notes, which have a maturity date of March 15, 2023, unless earlier converted or repurchased. Between September 2021 and August 2022, the Company entered into certain exchange transactions pursuant to which the Company exchanged $114.9 million aggregate principal amount of Notes for one or a combination of: shares of the Company’s common stock, a secured promissory note and/or warrants to purchase the Company’s common stock. As of the date of the filing of this Form 10-Q/A, $56.6 million aggregate principal amount of Notes remain outstanding.

The balance sheets contained in each of the 2022 Interim Financial Statements classified the Notes as a non-current liability with a net carrying amount of $115.8 million, $105.8 million and $56.3 million as of March 31, 2022, June 30, 2022 and September 30, 2022, respectively. Pursuant to Accounting Standards Codification (“ASC”) 210-10-45, current classification is required for convertible debt if the settlement in cash is expected to occur within 12 months, subject to the issuer’s intent and ability to refinance the debt on a long-term basis pursuant to ASC 470-10-45. The identification of the error arose in connection with the Company’s year-end close for the year ended December 31, 2022, whereby the Company determined that, as of the respective balance sheet dates for each of the 2022 Interim Financial Statements, its intent to refinance the Notes on a long-term basis was not supported by an ability to consummate the refinancing of all or a portion of the Notes in accordance with ASC 470-10-45. Accordingly, the Notes (or a portion thereof, as applicable in the specific period) should have been classified as a current liability in the balance sheets contained in each of the 2022 Interim Financial Statements.

The “as restated” classification of the Notes is further described and the impact of the restatement is included in Note 1 and Note 10 of the “Notes to the Condensed Consolidated Financial Statements” included in Part I, Item 1. “Financial Statements” of this Form 10-Q/A.

Control Considerations

In connection with the restatement, management concluded that there was a deficiency in our internal control over financial reporting that constituted a material weakness as of September 30, 2022. For a discussion of management's consideration of our disclosure controls and procedures and the material weakness identified, see Part I, Item 4, Controls and Procedures of this Form 10-Q/A.

2

Items Amended in this Filing

For the convenience of the reader, this Form 10-Q/A sets forth the Original Filing, as amended, in its entirety; however, this Form 10-Q/A amends and restates only the following Items of the Original Filing to the extent necessary to reflect the adjustments discussed above and to make corresponding adjustments to the Company’s financial data and disclosures cited elsewhere in this Form 10-Q/A:

-Part I, Item 1 - Financial Statements
-Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
-Part I, Item 4 - Controls and Procedures
-Part II, Item 6 - Exhibits

In addition, in connection with the preparation of this Form 10-Q/A, the Company has evaluated its financial condition as of the date of filing this Form 10-Q/A. Based on this evaluation, the Company has determined that there is substantial doubt about its ability to continue as a going concern as of the date of the filing of this Form 10-Q/A, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A. The assessment of going concern is further discussed in Note 1 of the “Notes to the Condensed Consolidated Financial Statements” included in Part I, Item 1. “Financial Statements” of this Form 10-Q/A.

Further, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing (Exhibits 31.1, 31.2 and 32), and the Company has provided its restated condensed consolidated financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibit 101.

Restatement of Other Financial Statements

In addition to the restated financial information for the quarter ended September 30, 2022 included in this Form 10-Q/A, we are also restating our interim condensed consolidated financial statements and related disclosures for the quarters ended March 31, 2022 and June 30, 2022. Concurrently with the filing of this Form 10-Q/A, we are filing amended Quarterly Reports on Form 10-Q with the SEC with respect to these periods to address the error in the balance sheet classification of the Notes described above.
3

TABLE OF CONTENTS


4

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS
(in thousands, except share data)
September 30,December 31,
20222021
(As Restated)
Unaudited
ASSETS
Current assets:
Cash and cash equivalents$38,987 $39,898 
Investments16,407 23,720 
Trade accounts receivable, net2,393 2,320 
Inventory5,392 5,067 
Prepaid expenses1,119 768 
Other current assets1,974 1,558 
Total current assets66,272 73,331 
Property and equipment, net3,621 5,389 
Finance lease assets, net2,319 — 
Operating lease right of use assets, net2,012 2,510 
Other non-current assets1,623 1,817 
Total assets$75,847 $83,047 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable$2,819 $1,983 
Accrued liabilities4,491 2,853 
Accrued interest118 909 
Deferred revenue524 451 
Current portion of convertible notes56,325 — 
Current portion of long-term debt80 80 
Finance lease, current953 — 
Operating lease, current774 669 
Total current liabilities66,084 6,945 
Finance lease, non-current 698 — 
Operating lease, non-current 1,775 2,381 
Other non-current liabilities759 808 
Accrued interest related-party220 — 
Long-term debt related-party16,299 — 
Convertible notes— 107,984 
Total liabilities$85,835 $118,118 
Commitments and contingencies

See accompanying notes to condensed consolidated financial statements.

5

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS (CONTINUED)
(in thousands, except share data)
September 30,December 31,
20222021
(As Restated)
Unaudited
Stockholders’ deficit:
Preferred shares, $0.001 par value;
5,000,000 preferred shares authorized and 3,954,546 outstanding as of September 30, 2022 and December 31, 2021
4 4 
Common stock, $0.001 par value;
200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021
97 68 
Contributed capital627,853 580,652 
Treasury stock(45,067)(45,067)
Accumulated deficit(592,630)(570,668)
Accumulated other comprehensive loss(245)(60)
Total stockholders’ deficit(9,988)(35,071)
Total liabilities and stockholders’ deficit$75,847 $83,047 

See accompanying notes to condensed consolidated financial statements.

6

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
(in thousands, except per share data)
Three Months EndedNine Months Ended
September 30,September 30,September 30,September 30,
2022202120222021
(As Restated)(As Restated)
Net sales$2,960 $3,122 $9,780 $8,439 
Cost of sales2,381 2,136 7,318 5,502 
Gross profit579 986 2,462 2,937 
Costs and expenses:
Research and development7,285 4,712 20,885 17,341 
Sales, general and administrative8,255 10,806 30,422 37,744 
Total costs and expenses15,540 15,518 51,307 55,085 
Loss from operations(14,961)(14,532)(48,845)(52,148)
Other (expense) income:
Interest expense(203)(4,211)(1,833)(12,477)
Interest expense related-party(495)— (495)— 
Gain on extinguishment of debt— 9,840 3,565 9,840 
Foreign currency exchange loss(261)(78)(221)(238)
Interest income73 — 151 55 
Other (expense) income, net(49)(5)(206)69 
Total other (expense) income, net(935)5,546 961 (2,751)
Net loss before income taxes(15,896)(8,986)(47,884)(54,899)
Provision for income taxes— — — — 
Net loss$(15,896)$(8,986)$(47,884)$(54,899)
Basic and diluted net loss per share$(0.18)$(0.15)$(0.62)$(0.91)
Weighted average shares outstanding87,011 61,146 77,049 60,250 
Other comprehensive loss:
Net loss$(15,896)$(8,986)$(47,884)$(54,899)
Net unrealized gain (loss) on debt securities available-for-sale48 (3)(84)(21)
Foreign currency translation adjustment139 (27)(101)(87)
Comprehensive loss$(15,709)$(9,016)$(48,069)$(55,007)

See accompanying notes to condensed consolidated financial statements.

7

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
Unaudited
(in thousands)
Nine Months Ended
September 30,September 30,
20222021
(As Restated)
Cash flows from operating activities:
Net loss$(47,884)$(54,899)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,207 1,875 
Amortization of investment discount94 153 
Equity-based compensation8,179 19,058 
Amortization of debt discount and issuance costs386 9,250 
Amortization of debt discount related-party275 — 
Loss (gain) on disposal of property and equipment74 (202)
Unrealized loss (gain) on equity investments206 (39)
Gain on extinguishment of debt(3,565)(9,840)
(Increase) decrease in assets:
Contributions to deferred compensation plan(174)(304)
Accounts receivable(73)(719)
Inventory(245)(527)
Prepaid expense and other(491)860 
Increase (decrease) in liabilities:
Accounts payable1,221 1,017 
Accrued liabilities and other1,153 (436)
Accrued interest(785)(1,059)
Accrued interest from related-party220 — 
Deferred revenue and income73 93 
Deferred compensation(49)343 
Net cash used in operating activities(39,178)(35,376)
Cash flows from investing activities:
Purchases of equipment(446)(202)
Purchase of marketable securities(27,506)(22,345)
Maturities of marketable securities34,527 33,601 
Net cash provided by investing activities6,575 11,054 
Cash flows from financing activities:
Proceeds from issuance of common stock32,872 22,640 
Payments on finance leases(1,109)— 
Proceeds from exercise of options7 1,456 
Proceeds from issuance of common stocks under employee purchase plan184 245 
Transaction costs related to debt exchange(192)— 
Payment of debt(6)(6)
Net cash provided by financing activities31,756 24,335 

See accompanying notes to condensed consolidated financial statements.

8

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS (CONTINUED)
Unaudited
(in thousands)
Nine Months Ended
September 30,September 30,
20222021
(As Restated)
Effect of exchange rate on cash(64)(69)
Decrease in cash and cash equivalents(911)(56)
Cash and cash equivalents, beginning of period39,898 35,781 
Cash and cash equivalents, end of period$38,987 $35,725 
Non-cash investing activities:
Net transfer of instruments (to) from inventory to property and equipment$(78)$508 
Non-cash financing activities:
Extinguishment of convertible senior notes through issuance of common stock$10,180 $34,545 
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs$49,624 $— 
Fair value of new note from related-party issued in connection with the exchange transaction$16,024 $— 
Fair value of common stock warrant issued to related-party in connection with exchange transaction$3,753 $— 
Capital contribution from related-party in connection with the exchange transaction$29,847 $— 
Supplemental cash flow information:
Interest paid$2,214 $4,288 

See accompanying notes to condensed consolidated financial statements.

9

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' DEFICIT
Unaudited
(in thousands)
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
(As Restated)(As Restated)
Preferred stock shares outstanding
Beginning3,955 — 3,955 — 
Issuance of preferred stock— 2,636 — 2,636 
Ending3,955 2,636 3,955 2,636 
Preferred stock
Beginning$4 $— $4 $— 
Proceeds from issuance of preferred stock— 3 — 3 
Ending$4 $3 $4 $3 
Common stock shares outstanding
Beginning79,701 61,489 67,649 57,608 
Issuance of common stock17,500 67 17,500 2,937 
Restricted stock awards released and exercise of options6 62 1,134 1,052 
Issuance of common stock under employee purchase plan34 16 159 37 
Rescission of common stock— (2,643)— (2,643)
Issuance of shares to retire convertible notes— 5,946 10,799 5,946 
Ending97,241 64,937 97,241 64,937 
Common stock
Beginning$80 $61 $68 $58 
Proceeds from issuance of common stock17 1 17 3 
Restricted stock awards released and exercise of options— — 1 1 
Rescission of common stock— (3)— (3)
Issuance of shares to retire convertible notes— 6 11 6 
Ending$97 $65 $97 $65 
Contributed capital
Beginning$560,185 $514,122 $580,652 $475,072 
Cumulative effect of accounting changes— — (37,438)— 
Proceeds from issuance of common stock32,855 517 32,855 22,637 
Exercise of options— 234 6 1,455 
Issuance of common stock under employee purchase plan47 84 184 245 
Issuance of shares to retire Convertible Notes— 34,539 10,169 34,539 
Capital contribution from related-party in connection with exchange transaction29,847 — 29,847 — 
Warrant issued to related-party3,753 — 3,753 — 
Equity-based compensation1,166 3,638 7,825 19,186 
Ending$627,853 $553,134 $627,853 $553,134 

See accompanying notes to condensed consolidated financial statements.

10


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' DEFICIT (CONTINUED)
Unaudited
(in thousands)
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
(As Restated)(As Restated)
Accumulated deficit
Beginning$(576,734)$(538,879)$(570,668)$(492,966)
Cumulative effect of accounting changes— — 25,922 — 
Net loss(15,896)(8,986)(47,884)(54,899)
Ending$(592,630)$(547,865)$(592,630)$(547,865)
Treasury stock
Beginning$(45,067)$(45,067)$(45,067)$(45,067)
Ending$(45,067)$(45,067)$(45,067)$(45,067)
Accumulated other comprehensive (loss) income
Beginning$(432)$13 $(60)$91 
Net unrealized gain (loss) on debt securities available-for-sale48 (3)(84)(21)
Foreign currency translation adjustment139 (27)(101)(87)
Ending$(245)$(17)$(245)$(17)
Total stockholders' deficit$(9,988)$(39,747)$(9,988)$(39,747)

See accompanying notes to condensed consolidated financial statements.

11

ACCELERATE DIAGNOSTICS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.

The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.

Restatement of Previously Issued Financial Statements

Background on the restatement

The Company’s previously issued interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022 classified its 2.50% Senior Convertible Notes due 2023 (the “Notes”) as a non-current liability with a net carrying amount of $56.3 million as of September 30, 2022. Pursuant to Accounting Standards Codification (“ASC”) 210-10-45, Balance Sheet, the Notes should have been classified as a current liability in the balance sheet as of September 30, 2022. In addition, the Company recorded an adjustment to correct a previously identified immaterial error related to the Company’s warranty obligations as of and for the three and nine months ended September 30, 2022.


12

Effect of the restatement

The effects of the correction of the prior-period misstatements on our Condensed Consolidated Balance Sheet relating to the Notes are reflected in the table below (in thousands). The Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Cash Flows, and the Condensed Consolidated Statements of Stockholders’ Equity were also corrected for the other previously identified immaterial error as reflected in the tables below (in thousands).

September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Accrued liabilities4,300 191 4,491 
Current portion of convertible notes— 56,325 56,325 
Total current liabilities9,568 56,516 66,084 
Convertible notes56,325 (56,325)— 
Total liabilities85,644 191 85,835 
Accumulated deficit ending balance(592,439)(191)(592,630)
Total stockholders’ deficit ending balance(9,797)(191)(9,988)

Three Months Ended
September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cost of sales2,190 191 2,381 
Gross profit770 (191)579 
Loss from operations(14,770)(191)(14,961)
Net loss before income taxes(15,705)(191)(15,896)
Net loss(15,705)(191)(15,896)
Comprehensive loss(15,518)(191)(15,709)

Nine Months Ended
September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cost of sales7,127 191 7,318 
Gross profit2,653 (191)2,462 
Loss from operations(48,654)(191)(48,845)
Net loss before income taxes(47,693)(191)(47,884)
Net loss(47,693)(191)(47,884)
Comprehensive loss(47,878)(191)(48,069)

Total net cash used in operating activities was not impacted by the error corrections.

In addition to correcting the consolidated financial statements, related revisions and updates have been made to “Liquidity & Going Concern (As Restated)”, Warranty Reserve (As Restated) and Note 10, Convertible Notes (As Restated).

13

Liquidity & Going Concern (As Restated)

Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company’s accumulated deficit totaled $592.6 million as of September 30, 2022. For the three and nine months ended September 30, 2022, the Company had net losses of approximately $15.9 million and $47.9 million, respectively, and had negative cash flows from operations of approximately $39.2 million for the nine months ended September 30, 2022. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises and the issuance of debt (see Note 9, Long-Term Debt, Note 10, Convertible Notes and Note 18, Stockholders' Equity for additional details).

At September 30, 2022, the Company held cash, cash equivalents, and marketable securities of $55.4 million and current liabilities of $66.1 million, including $56.3 million of Notes due on March 15, 2023. Based on its evaluation pursuant to ASC 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, the Company has determined that, as of the date of this Form 10-Q/A filing, there is substantial doubt about its ability to continue as a going concern, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A.

While the Company continues to explore additional funding in the form of potential equity and/or debt financing arrangements or similar transactions, as well as non-cash means to settle or refinance the Notes, there can be no assurance the necessary financing will be available on terms acceptable to the Company, or at all. If the Company raises funds by issuing equity securities, dilution to stockholders may result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of common stock. If the Company raises funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of preferred and common stockholders. The terms of debt securities or borrowings could impose significant restrictions on our operations. Similarly, there can be no assurance that market conditions and refinancing alternatives will be sufficient to settle or refinance the Notes on or prior to their maturity on March 15, 2023. The capital markets have in the past, and may in the future, experience periods of upheaval that could impact the availability and cost of equity and debt financing. In addition, recent and anticipated future increases in federal fund rates set by the Federal Reserve, which serve as benchmark rates on borrowing, and other general economic conditions may impact the cost of debt financing or refinancing existing debt.

Although we are actively considering all available strategic alternatives to maximize value, if we are unable to obtain adequate capital resources to fund operations and address the upcoming maturity of the Notes, we would not be able to continue to operate our business pursuant to our current plans. This may require us to, among other things, materially modify our operations to reduce spending; sell assets or operations; delay the implementation of, or revising certain aspects of, our business strategy; file a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring; or discontinue our operations entirely.

The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.

14

Estimated Fair Value of Financial Instruments

The Company follows ASC 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.

The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.

The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and
15

the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.

See Note 6, Inventory, for further information and related disclosures.

Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.

The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$150 $213 140 445 
(Reversals) provisions, net
(12)78 18 114 
Write-offs
— (77)(20)(345)
$138 $214 $138 $214 

The write-offs recorded during the nine months ended September 30, 2021 were in connection with a one-time restructuring activity of the Company's Europe, Middle East and Africa (“EMEA”) business. These credit losses were incurred as part of the Company terminating agreements with select distributors in geographies it exited and did not pursue collection of these accounts receivables.

16

Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.

The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.

See Note 7, Property and Equipment, for further information and related disclosures.

Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.

Warranty Reserve (As Restated)

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.

17

Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
As Restated
As Restated
Beginning balance$255 $169 $139 $232 
Provisions (reversals), net
187 (31)325 (41)
Warranty cost incurred
(29)(17)(51)(70)
Ending balance$413 $121 $413 $121 

Convertible Notes

On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.

See Note 2, Recently Issued Accounting Pronouncements and Note 10, Convertible Notes, for further information and related disclosures.

Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.
18


Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.

Gross Profit and Gross Margin

Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.

The Company’s overall gross margin was 20% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 25% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.

Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Leases as Lessee

Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.

19

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.

Leases as Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.

Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.

Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.

Equity-Based Compensation

The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

•Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.

•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.
20


The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.

The Company accounts for forfeitures as they occur rather than on an estimated basis.

The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.

See Note 13, Employee Equity-Based Compensation for further information.

Deferred Tax

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.

Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.

Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

See Note 12, Loss Per Share, for further information.

21

Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.

NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Standards that were recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.

Standards not yet adopted

In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not
22

expect the update to have a material effect on our condensed consolidated financial statements.

NOTE 3. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.

The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2022, three of the Company's financial institutions held 74%, 12% and 13% of the Company’s cash and cash equivalents. As of December 31, 2021, two of the Company's financial institutions held 72% and 13% of the Company’s cash and cash equivalents.

The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company had one customer that accounted for 16% and 13% of the Company’s net accounts receivable balance as of September 30, 2022 and December 31, 2021, respectively.

The Company did not have any customers that represented 10% or more of the Company’s total revenue for the three and nine months ended September 30, 2022 and 2021.

NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,145 $— $— $5,145 
Total cash and cash equivalents5,145 — — 5,145 
Equity investments:
Mutual funds808 — — 808 
Total equity investments808 — — 808 
Debt securities available-for-sale:
Certificates of deposit— 3,382 — 3,382 
U.S. Treasury securities5,228 — — 5,228 
Commercial paper— 2,893 — 2,893 
Corporate notes and bonds— 4,096 — 4,096 
Debt securities available-for-sale5,228 10,371 — 15,599 
Total assets measured at fair value$11,181 $10,371 $— $21,552 

23

December 31, 2021
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,563 $— $— $5,563 
Commercial paper— 200 — 200 
Total cash and cash equivalents5,563 200 — 5,763 
Equity investments:
Mutual funds841 — — 841 
Total equity investments841 — — 841 
Debt securities available-for-sale:
Certificates of deposit— 1,351 — 1,351 
U.S. Treasury securities250 — — 250 
Commercial paper— 8,046 — 8,046 
Corporate notes and bonds— 13,232 — 13,232 
Debt securities available-for-sale250 22,629 — 22,879 
Total assets measured at fair value$6,654 $22,829 $— $29,483 

Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

At September 30, 2022, the Notes had an outstanding principal amount of $56.6 million with a fair value of $51.7 million. At December 31, 2021, the Notes had an outstanding principal amount of $120.5 million with a fair value of $89.4 million. The fair value of the Notes represents a Level 2 measurement. The fair value of the Notes is typically correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. See Note 10, Convertible Notes for further detail on the Notes.

The Secured Note is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note.

The warrant is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the warrant on August 15, 2022 was $3.8 million. See Note 11, Long-Term Debt Related-Party for further detail on the Company’s warrant with a related-party.

24

NOTE 5. INVESTMENTS

The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$3,400 $— $(18)$3,382 
U.S. Treasury securities5,266 — (38)5,228 
Commercial paper2,901 — (8)2,893 
Corporate notes and bonds4,131 — (35)4,096 
Total$15,698 $— $(99)$15,599 

December 31, 2021
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$1,351 $— $— $1,351 
U.S. Treasury securities250 — — 250 
Commercial paper8,048 — (2)8,046 
Corporate notes and bonds13,245 — (13)13,232 
Total$22,894 $— $(15)$22,879 

The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022December 31, 2021
Amortized
Cost		Fair ValueAmortized
Cost		Fair Value
Due in less than 1 year$15,698 $15,599 $22,663 $22,649 
Due in 1-3 years— — 231 230 
Total
$15,698 $15,599 $22,894 $22,879 

There were no proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three and nine months ended September 30, 2022 and 2021. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2022 and 2021. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021. No unrealized losses on debt securities available-for-sale have been recognized in income for the three and nine months ended September 30, 2022 and 2021, as the issuers of such securities held by us were of high credit quality.

As of September 30, 2022, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%.

As of September 30, 2022 the Company did not carry any debt securities available-for-sale that were below the Company's minimum credit rating. All debt securities available-for-sale had a credit rating of A- or better as of September 30, 2022.

Equity securities are comprised of investments in mutual funds. The fair value of equity securities for each of the periods ended September 30, 2022 and December 31, 2021 was $0.8 million.
25


Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Unrealized (loss) gain on equity investments$(50)$(5)$(206)$39 

These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for each of the three and nine months ended September 30, 2022 and 2021.

NOTE 6. INVENTORY

Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Raw materials$1,769 $1,343 
Work in process2,133 1,625 
Finished goods1,490 2,099 
$5,392 $5,067 

NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Computer equipment$3,866 $3,181 
Technical equipment3,259 3,285 
Facilities3,674 3,675 
Instruments3,594 5,364 
Capital projects in progress48 683 
Total property and equipment$14,441 $16,188 
Accumulated depreciation(10,820)(10,799)
Property and equipment, net$3,621 $5,389 

Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$381 $487 $1,284 $1,540 

Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

26

September 30,December 31,
20222021
Instruments at cost under operating leases$2,452 $3,110 
Accumulated depreciation under operating leases(1,109)(1,165)
Net property and equipment under operating leases$1,343 $1,945 

NOTE 8. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS

Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):

September 30,December 31,
20222021
Products and services not yet delivered$524 $451 

We recognized $0.2 million and $0.4 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2021, respectively. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.

Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2022, $9.0 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.

The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

NOTE 9. LONG-TERM DEBT

The Company entered into two loan agreements with one financing company in 2020. Loan proceeds were $0.2 million, with interest rates ranging from 9.8% to 12.4% and maturities becoming due through 2022.

As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):

September 30,December 31,
20222021
Loans - various interest$80 $80 
Current portion of long-term debt80 80 
Long-term debt$— $— 

27

The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):

Remainder of 2022$80 
2023— 
2024— 
2025— 
2026— 
Thereafter— 
Total$80 

Paycheck Protection Program (PPP) Loan

On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million made to the Company under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act.

On July 15, 2021, the Small Business Administration (“SBA”) informed the Company of its full forgiveness for the entire PPP Note amount plus accrued interest, which was $4.8 million as of the date of forgiveness. The SBA’s determination of loan forgiveness does not preclude further investigation by the SBA according to its rules and regulations. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of the entire PPP Note amount of $4.8 million during the three and nine months ended September 30, 2021.

NOTE 10. CONVERTIBLE NOTES (As Restated)

The Notes are the Company’s senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, pursuant to the terms and conditions of the Notes. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The Company’s Notes have a fixed coupon rate of 2.5% per annum on the principal amount.

The Company incurred issuance costs related to the issuance of the Notes which is amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par was 3.2%.

The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:

•if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;

•during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or

•the occurrence of certain corporate events, such as a change of control, merger or liquidation.

At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the
28

Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of September 30, 2022 and December 31, 2021, no Notes were convertible pursuant to their original terms.

Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 

Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Gain on extinguishment$— $4,999 $3,565 $4,999 

The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 

As of September 30, 2022 the Notes consisted of the following (in thousands):

September 30,
2022
(As Restated)
Current portion of convertible notes$56,325 
Non-current portion of convertible notes— 
Total convertible notes$56,325 

In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its
29

counterparty to a major financial institution.

2021 Exchange Transactions

In September 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by them for shares of the Company’s common stock (the “2021 Exchange Transactions”). During the nine months ended September 30, 2021, such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock. The net carrying value of the Notes exchanged was $40.4 million which the Company repurchased for $34.5 million of common stock. The Company also incurred $0.8 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. The 2021 Exchange Transaction resulted in a net gain of $5.0 million reflected in other income (expense), net for the three and nine months ended September 30, 2021. See Note 18, Stockholders' Equity for additional information.

March 2022 Exchange Transaction

On March 21, 2022, the Company entered into a privately negotiated exchange agreement (the “March 2022 Exchange Agreement”) with a holder of the Notes. Under the terms of the March 2022 Exchange Agreement, the note holder agreed to exchange with the Company $14.0 million in aggregate principal amount of Notes held by it in eight equal tranches as follows for each tranche: (a) 22.64 shares per $1,000 principal amount of Notes exchanged, plus (b) an additional number of shares of the Company’s common stock per $1,000 principal amount of Notes exchanged equal to the sum, for each of the trading days during a separate agreed upon reference period for each tranche commencing on March 21, 2022 for the first tranche, of the quotient of (i) $155.67 divided by (ii) the daily volume-weighted average price for such trading day (collectively, the “March 2022 Exchange Transaction”). The closing of the March 2022 Exchange Transaction occurred in eight tranches (“Obligation to Exchange”), with the first closing occurring on March 29, 2022 and the last closing on May 18, 2022.

On March 21, 2022 the Obligation to Exchange the $14.0 million of Notes in the March 2022 Exchange Transaction was accounted for as an extinguishment and was replaced by new notes with an embedded feature (the “New Notes”). The New Notes were elected to be carried using the fair value option. The New Notes were recorded at fair value on initial measurement and remeasured at fair value (“mark to market”) at each reporting period with changes in fair value reported in other income and expense, net. This fair value election was exclusive to the New Notes and did not extend to other Notes. The embedded feature was no longer outstanding on September 30, 2022 as the New Notes were exchanged and the Obligation to Exchange retired on May 18, 2022.

During the nine months ended September 30, 2022 the holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company’s common stock pursuant to the March 2022 Exchange Agreement. The net carrying value of the Notes exchanged was $14.0 million which the Company repurchased for $10.2 million of common stock. The Company also incurred $0.2 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. This exchange transaction resulted in a net gain of $3.6 million reflected in other income (expense), net for the nine months ended September 30, 2022. See Note 18, Stockholders' Equity for additional information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”), as discussed in Note 11, Long-Term Debt Related-Party. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. The difference between the fair values of the new instruments and the net carrying amount of the Notes being extinguished was included in the calculation of gain. The gain from the extinguishment of the Notes was treated as a capital transaction. The Secured Note includes various features that were advantageous to the Company, including a lower interest rate compared to current market rates and a share conversion feature. There were no other negotiating parties that had similar terms or economic outcomes. As such, the exchange was considered not to be an arm’s length transaction, and therefore the resulting gain was accounted
30

for as a capital transaction. The net carrying amount of the extinguished Notes was $49.6 million. The estimated fair value of the Secured Note and the Warrant on August 15, 2022 was $16.0 million and $3.8 million, respectively, which resulted in a net gain of $29.8 million that was recorded to contributed capital. See Note 18, Stockholders' Equity and Note 11, Long-Term Debt Related-Party for additional information.

NOTE 11. LONG-TERM DEBT RELATED-PARTY

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust, a holder of the Notes. Jack Schuler, who serves as a member of the Company’s board of directors, is the sole trustee of the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a Warrant to acquire the Company’s common stock at an exercise price of $2.12 per share (the “Warrant”).

The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. See Note 10, Convertible Notes for additional information. The Secured Notes is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. To estimate the Secured Note’s fair value, the Company applied a Monte Carlo simulation which simulated the share price of the Company over the remaining term to the maturity date of the Secured Note. The simulated per-share price in a given iteration determined if the Company settled in cash or shares. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. This valuation estimated an issuance discount of $18.9 million. The effective interest rate on the Secured Note is 24.60%.

The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 

Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 

31

Warrant

The Warrant may be exercised from February 15, 2023 through the earlier of (i) August 15, 2029 and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in the Warrant. The Warrant is exercisable for up to 2,471,710 shares of common stock. The Warrant meets the criteria for classification in stockholders’ equity and was recorded in equity and initially measured at fair value. The Warrant was measured at fair value on a non-recurring basis using Level 3 inputs. The fair value of the warrant on August 15, 2022 was $3.8 million.

The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:

Contractual term (in years)
7.0
Volatility76.10 %
Expected dividends— 
Risk free interest rates2.86 %

NOTE 12. LOSS PER SHARE

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Shares issuable upon the release of RSUs4,619 2,320 4,619 2,320 
Shares issuable upon exercise of stock options5,665 7,634 5,665 7,634 
Shares issuable upon the exercise of the Warrant2,472 — 2,472 — 
12,756 9,954 12,756 9,954 

Potentially dilutive common shares would include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 10, Convertible Notes, upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock. As of September 30, 2022, no Notes were convertible pursuant to the original terms. The number of shares of common stock issuable upon conversion of the outstanding Notes based on the initial conversion rate was approximately 1,830,441 shares as of September 30, 2022. Historically the Company has engaged in privately negotiated exchanges of Notes for a substantially greater number of shares than the initial conversion rate of the Notes described above because the Company’s stock price at the time of such exchanges was significantly less than the $30.92 initial conversion price of the Notes.

In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for
32

corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.

Potentially dilutive common shares include common shares that would be outstanding if Series A Preferred Stock were converted into common stock. Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock. Additionally, each share of Series A Preferred Stock will automatically be converted into one share of the Company’s common stock immediately upon a sale of all outstanding stock of the Company or a merger of the Company into another corporation where the pre-merger Company’s stockholders cease to be the controlling stockholders of the post-merger corporation. The number of shares of common stock issuable upon conversion of the Series A Preferred Stock is 3,954,546 as of September 30, 2022.

As discussed in Note 18, Stockholders' Equity, the Company entered into a securities purchase agreement with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock. The closing of the transaction is expected to occur on December 30, 2022, subject to the satisfaction of customary closing conditions and is considered an equity forward agreement. The shares to be issued from this agreement were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.

As discussed in Note 11, Long-Term Debt Related-Party, the Company may, at its option, repay the Secured Note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The number of shares of common stock issuable upon conversion of the Secured Note and accrued interest was approximately 16,478,066 and 103,834 shares respectively, as of September 30, 2022. The shares issuable in connection with a repayment of the Secured Note were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.

NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION

The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:

Number of SharesWeighted Average Exercise Price per Share
Options outstanding January 1, 20227,192,540 $13.89 
Granted140,000 3.05 
Forfeited(204,232)12.49 
Exercised(6,105)1.04 
Expired(1,457,019)10.33 
Options outstanding September 30, 20225,665,184 $14.60 

No stock options were granted during the three months ended September 30, 2022 and 2021.

33

The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:

Options
Outstanding		Options
Exercisable
Number of options5,665,184 4,422,595 
Weighted average remaining contractual term (in years)5.545.04
Weighted average exercise price$14.60 $15.32 
Weighted average fair value$9.10 $9.44 
Aggregate intrinsic value (in thousands)$— $— 

The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 20222,090,182 $10.77 
Granted4,107,083 1.55 
Forfeited(451,703)8.68 
Released(1,127,017)3.43 
Outstanding September 30, 20224,618,545 $4.57 

The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of sales$167 $82 $570 $257 
Research and development151 266 1,052 4,340 
Sales, general and administrative911 3,281 6,557 14,461 
$1,229 $3,629 $8,179 $19,058 

The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost capitalized to inventory
$69 $77 $186 $319 

As of September 30, 2022, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $2.3 million and $7.8 million, respectively. This is expected to be recognized over the years 2022 through 2027.

Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based
34

options issued under the Company's equity incentive plans. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted 105,000 performance-based stock options. Of these performance-based stock options, performance obligations had been met for 90,000 options which became exercisable in a prior period. Of these performance-based stock options, 90,000 options expired during the nine months ended September 30, 2022. No performance-based stock options were outstanding as of September 30, 2022.

The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based stock option expense
$— $230 

Included in the above-noted RSU and restricted stock award outstanding amounts are performance-based RSUs which vest only upon the achievement of certain targets. Performance-based RSUs contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted performance-based RSUs of which 165,974 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.

During 2021, the Company granted performance-based RSUs of which 111,806 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.

The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based RSU expense
$— $818 

NOTE 14. INCOME TAXES

For the nine months ended September 30, 2022, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2022 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $47.9 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions due to the valuation allowance. At September 30, 2022, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.

The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2022, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.

35

NOTE 15. COMMITMENTS

During April 2022, the Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of $11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. This commitment was entered into to ensure proper material quantities to develop and commercialize our next generation AST platform.

As of September 30, 2022 the commitment remains $11.9 million as the Company has not taken delivery of any inventory.

NOTE 16. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 

The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%.

The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 

36

The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):

Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 

NOTE 17. GEOGRAPHIC AND REVENUE DISAGGREGATION

The Company operates as one operating segment. Sales to customers outside the U.S. represented 14% and 8% for the three months ended September 30, 2022 and 2021, respectively, and 14% and 12% for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022 and December 31, 2021, balances due from foreign customers, in U.S. dollars, were $0.6 million and $0.7 million, respectively.

The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Domestic$2,551 $2,874 $8,390 $7,406 
Foreign409 248 1,390 1,033 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accelerate Pheno revenue
$2,933 $3,084 $9,669 $8,324 
Other revenue27 38 111 115 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Products$2,532 $2,773 $8,554 $7,474 
Services428 349 1,226 965 
$2,960 $3,122 $9,780 $8,439 

37

Lease revenue included in net sales was $0.2 million and $0.5 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million for each of the nine months ended September 30, 2022 and 2021.

The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20222021
Domestic$3,383 $5,014 
Foreign238 375 
$3,621 $5,389 

NOTE 18. STOCKHOLDERS' EQUITY

December 2020 Securities Purchase Agreement

During December 2020, the Company entered into a securities purchase agreement (the “December 2020 Securities Purchase Agreement”) with Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips, or entities affiliated with such persons (collectively, the “Original Purchasers”), for the issuance and sale by the Company of an aggregate of 4,166,663 shares of the Company’s common stock. Each of Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips is a member of the Company’s board of directors. Mr. Phillips also serves as the Company’s President and Chief Executive Officer.

The Schuler Trust, which was the entity affiliated with Jack W. Schuler that originally entered into the December 2020 Securities Purchase Agreement for the purchase of 3,964,843 shares for an aggregate purchase price of approximately $30.5 million, subsequently entered into an assignment and assumption agreement whereby it assigned all of its rights and obligations as an Original Purchaser to three other entities under the December 2020 Securities Purchase Agreement (collectively, the “Schuler Purchasers”). These three entities are related to Jack W. Schuler but are not affiliates of his.

Pursuant to the December 2020 Securities Purchase Agreement, the Original Purchasers agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $7.68 per share, for an aggregate purchase price of approximately $32 million.

The December 2020 Securities Purchase Agreement contemplated that the closing of the purchase and sale of the shares would occur in three tranches, with the first and second tranches having closed on February 19, 2021 and April 9, 2021, respectively, whereby the Company received total proceeds of approximately $21.3 million which were recorded to contributed capital.

On September 17, 2021, the Company entered into a rescission agreement (the “Rescission Agreement”) with the Schuler Purchasers and the Schuler Trust pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 shares in the first two tranche closings and the third tranche (as discussed below) under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The 2,643,228 Shares re-acquired by the Company from the Schuler Purchasers as a result of the Rescission Agreement were treated as a reduction to contributed capital and were not outstanding for purposes of the calculation of basic and diluted earnings per share.

On September 30, 2021, the Company closed the final third tranche in connection with the December 2020 Securities Purchase Agreement and received total proceeds of approximately $0.5 million. In accordance with the Rescission Agreement, the Schuler Purchasers did not participate in the third tranche. During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement, which were recorded to contributed capital, after giving effect to the Rescission Agreement.

38

September 2021 Securities Purchase Agreement

During September 2021, the Company entered into a new securities purchase agreement (the “September 2021 Securities Purchase Agreement”) with the Schuler Purchasers for the issuance and sale by the Company of an aggregate of 3,954,546 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Shares”). Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock.

Pursuant to the September 2021 Securities Purchase Agreement, the Schuler Purchasers agreed to purchase the Series A Preferred Shares at a purchase price of $7.70 per share for an aggregate purchase price of approximately $30.5 million.

The September 2021 Securities Purchase Agreement contemplated the closing of the purchase and sale of the Series A Preferred Shares would occur in two tranches. The first tranche closed on the date of the execution of the September 2021 Securities Purchase Agreement whereby an aggregate of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Purchasers. The Company received total proceeds of approximately $20.3 million, which was recorded to contributed capital during the three months ended September 30, 2021.

The second tranche (the “Tranche Right”) had not closed by September 30, 2021 and was concluded to be an obligation of the Schuler Purchasers to acquire, and the Company to sell an additional 1,318,182 Series A Preferred Shares at a purchase price of $7.70 per share for proceeds of $10.2 million, subsequent to the September 30, 2021 balance sheet date. The Company concluded the Tranche Right met the definition of a freestanding financial instrument which was recorded within stockholder’s equity. The value of this Tranche Right as September 30, 2021 was $2.5 million. The estimated fair value of the Tranche Right represented a Level 3 measurement as this financial instrument has no market activity. The estimated fair value of the Tranche Right was determined as the excess value of the forward contract when compared to the underlying asset. The fair value of this forward contract can be represented by the difference between the contractual forward price of $7.70 and the prevailing exchange-traded common stock price ($5.81 at September 22, 2021 and $5.83 at September 30, 2021), multiplied by 1,318,182 Series A Preferred Shares. On October 29, 2021, the Company closed the final second tranche in connection with the September 2021 Securities Purchase Agreement whereby the Company issued and sold an aggregate of 1,318,182 Series A Preferred Shares to the Schuler Purchasers and received total proceeds of approximately $10.2 million.

2021 Exchange Transactions

During the nine months ended September 30, 2021, certain holders of the Notes exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock pursuant to their respective exchange agreement. Using the closing stock price on September 22, 2021 of $5.81, the 5,945,718 shares of the Company’s common stock were determined to have a value of $34.5 million, which was recorded to contributed capital during the nine months ended September 30, 2021. See Note 10, Convertible Notes, for additional information.

March 2022 Exchange Transaction

During the nine months ended September 30, 2022, a holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company's common stock pursuant to the March 2022 Exchange Agreement. The 10,798,482 shares of the Company’s common stock were determined to have a value of $10.2 million, which was recorded to contributed capital during the nine months ended September 30, 2022. See Note 10, Convertible Notes for additional information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.

39

Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, for an aggregate purchase price of $4.0 million.

On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock. The gain from the extinguishment of the Notes was treated as a capital transaction. The net gain on extinguishment was $29.8 million during the three months ended months ended September 30, 2022, and was recorded to contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

The Warrant meets the criteria for classification in stockholders’ equity and was recorded in contributed capital at fair value of $3.8 million on August 15, 2022.

August 2022 Public Offering

On August 23, 2022, the Company completed a public offering 17,500,000 shares of its common stock at a public offering price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.

NOTE 19. RELATED-PARTY TRANSACTIONS

2021 Exchange Transactions

As discussed in Note 10, Convertible Notes, the Company carries Notes. The Schuler Family Foundation (the “Foundation”) previously held an aggregate of $42.0 million of the Notes. Jack W. Schuler, a member of the Company’s board of directors, is the President of the Foundation.

During the three months ended September 30, 2021, the Foundation transferred by gift the $42.0 million aggregate principal amount of Notes held by the Foundation to the Schuler Initiative Supporting Charitable Trust (the “Supporting Organization”), a tax-exempt organization that is not an affiliate of Jack W. Schuler.

In connection with the 2021 Exchange Transactions the Supporting Organization exchanged $42.0 million in aggregate principal amount of Notes held by it for 5,428,699 shares of the Company's common stock. Using the closing stock price on September 22, 2021 of $5.81, the 5,428,699 shares of the Company's common stock were determined to have a value of $31.5 million which was recorded to contributed capital for the three months ended September 30, 2021. The Supporting Organization had the same or similar terms as the other counter parties. The Company determined the 2021 Exchange Transactions did not meet the criteria of a capital transaction and was recorded as a gain on extinguishment of debt. See Note 10, Convertible Notes and Note 18, Stockholders' Equity, for additional information.

December 2020 Securities Purchase Agreement

On December 24, 2020, the Company entered into the December 2020 Securities Purchase Agreement with the Original Purchasers for the issuance and sale by the Company of 4,166,663 shares of the Company’s common stock. The Original Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons. See Note 18, Stockholders' Equity, for further information.

On September 17, 2021, the Company entered into the Rescission Agreement with the Schuler Purchasers and the Schuler Trust, an entity affiliated with Jack W. Schuler, pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase
40

Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 Shares in the first two tranche closings and the third tranche under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. See Note 18, Stockholders' Equity, for further information.

During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement after giving effect to the Rescission Agreement.

September 2021 Securities Purchase Agreement

On September 22, 2021, the Company entered into the September 2021 Securities Purchase Agreement with the Schuler Purchasers for the issuance and sale by the Company of 3,954,546 Series A Preferred Shares. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his.

During the nine months ended September 30, 2021, the Company issued 2,636,364 Series A Preferred Shares and received total proceeds of approximately $20.3 million under the September 2021 Securities Purchase Agreement. See Note 18, Stockholders' Equity, for further information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into the March 2022 Securities Purchase Agreement with the Schuler Trust for the issuance and sale by the Company of 2,439,024 shares of the Company’s common stock. Jack Schuler serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust. See Note 18, Stockholders’ Equity, for further information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for the Secured Note in an aggregate principal amount of $34.9 million and a warrant to acquire the Company’s common stock. The net gain on extinguishment was $29.8 million during the nine months ended September 30, 2022, and was recorded as contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

41


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introductory Note

Except as otherwise indicated by the context, references in this Form 10-Q/A to the “Company,” “Accelerate,” “we,” “us” or “our” are references to the combined business of Accelerate Diagnostics, Inc. The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) summarizes the significant factors affecting our results of operations, liquidity, capital resources and contractual obligations. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere herein.

All amounts in the MD&A have been rounded to the nearest thousand unless otherwise indicated.

Forward-Looking Statements

This Form 10-Q/A contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements, which can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue,” or variations thereon or comparable terminology, include but are not limited to, statements about our future development plans and growth strategy, including plans and objectives relating to our future operations, products and performance; projections as to when certain key business milestones may be achieved; expectations regarding the potential or benefits of our products and technologies; projections of future demand for our products; our continued investment in new product development to both enhance our existing products and bring new ones to market; the anticipated impacts from the COVID-19 pandemic on the Company, including to our business, results of operations, cash flows and financial position, as well as our future responses to the COVID-19 pandemic; our expectations relating to current supply chain impacts; and inflationary pressures, including our belief that we currently have sufficient inventory of Accelerate Pheno system instruments to limit the impact of cost increases on such devices; our expectations regarding our commercial partnership with Becton, Dickinson and Company (“BD”), including anticipated benefits from such collaboration; our belief that we will obtain approval from the U.S. Food and Drug Administration (“FDA”) to market our Accelerate Arc product; and our liquidity and capital requirements, including, without limitation, as to our ability to continue as a going concern and our belief that we do not currently have adequate financial resources to pay our outstanding debt obligation under the Notes and to fund our forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A. In addition, all statements other than statements of historical facts that address activities, events, or developments the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.

Future events and actual results could differ materially from those set forth in, contemplated or suggested by, or underlying the forward-looking statements. There can be no assurances that results described in forward-looking statements will be achieved, and actual results could differ materially from those suggested by the forward-looking statements. The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties, including the duration and severity of the ongoing COVID-19 pandemic, including any new variants that may become predominant; government and other third-party responses to it and the consequences for the global economy and the businesses of our suppliers and customers, such as the possibility of customer demand fluctuations, supply chain constraints and inflationary pressures; and its ultimate effect on our business, results of operations, cash flows and financial position, as well as our ability (or inability) to execute on our plans to respond to the COVID-19 pandemic; and difficulties in resolving our continuing financial condition and ability to obtain additional capital to meet our financial obligations, including, without limitation, difficulties in obtaining adequate capital resources to fund our operations and address the upcoming maturity of the Notes. Other important factors that could cause our actual results to differ materially from those in our forward-looking statements include those discussed herein, and in other reports filed with the U.S. Securities and Exchange Commission (the “SEC”) including but not limited to the risks in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 10-K”), the section entitled “Risk Factors” in this Form 10-Q and in the Company's subsequent filings with the SEC. These forward-looking statements are also based on certain additional assumptions, including, but not limited to, that the Company will retain key management personnel, the Company will be successful in the commercialization of the Accelerate
42

Pheno® system and the Accelerate Arc™ system, the Company will obtain sufficient capital to commercialize the Accelerate Pheno system and the Accelerate Arc system and continue development of complementary products, the Company will be successful in obtaining marketing authorization for its products from the FDA and other regulatory agencies and governing bodies, the Company will be able to protect its intellectual property, the Company’s ability to respond effectively to technological change, the Company will accurately anticipate market demand for the Company’s products and there will be no material adverse change in the Company’s operations or business and general market and industry conditions. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. Any forward-looking statements made by us in this Form 10-Q speak only as of the date on which they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

Accelerate is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Microbiology laboratories need new tools to address what the U.S. Centers for Disease Control and Prevention (the “CDC”) calls one of the most serious healthcare threats of our time, antibiotic resistance. A significant contributing factor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results. The delay of identification and antibiotic susceptibility results is often due to the reliance by microbiology laboratories on traditional culture-based tests that often take two to three days to complete. Our technology platform is intended to address these challenges by delivering significantly faster testing of infectious pathogens in various patient sample types.

Our first system to address these challenges is the Accelerate Pheno® system. The Accelerate PhenoTest® BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. The device provides identification (“ID”) results followed by antibiotic susceptibility testing (“AST”) for certain pathogenic bacteria commonly associated with or causing bacteremia. This test kit utilizes genotypic technology to identify infectious pathogens and phenotypic technology to conduct AST, which determines whether live bacterial cells are resistant or susceptible to a particular antimicrobial. This information can be used by physicians to rapidly modify antibiotic therapy to lessen adverse events, improve clinical outcomes, and help preserve the useful life of antibiotics.

On June 30, 2015, we declared our conformity to the European In Vitro Diagnostic Directive 98/79/EC and applied a CE mark to the Accelerate Pheno system and the Accelerate PhenoTest BC Kit for in vitro diagnostic use. On February 23, 2017, the U.S. Food and Drug Administration (the “FDA”) granted our de novo classification request to market the first version of our Accelerate Pheno system and Accelerate PhenoTest BC Kit.

In 2017, we began selling the Accelerate Pheno system in hospitals in the United States, Europe, and the Middle East. Consistent with our “razor” / “razor-blade” business model, revenues to date have principally been generated from the sale or leasing of the instruments and the sale of single use consumable test kits.

In July 2021, we launched our second test for use on the Accelerate Pheno system, the Accelerate PhenoTest BC Kit, AST configuration. This test kit runs antibiotic susceptibility testing following the input of an ID result from another system or methodology. In August 2021, we announced that this new AST only configuration had been CE marked for use in Europe. We believe this new AST only configuration may be attractive to prospective customers who already have a rapid ID system but still need fast susceptibility results to support getting patients on an optimal antibiotic therapy as soon as possible.

In March and May 2022, we announced the launch and commercialization of the Accelerate ArcTM system and BC Kit (“Accelerate Arc Products”). This instrument and associated one-time-use test kit automates the clean-up and concentration of microbial cells from positive blood culture samples. In May 2022, we announced IVD registration of the Accelerate Arc system and BC Kit with the FDA as a Class I device exempt from FDA clearance requirements, and in June 2022 we received CE IVDR registration for use in Europe.

43

On October 21, 2022, the “Company announced it has been in recent discussions with the FDA regarding its Accelerate Arc Products. Pursuant to such discussions, the FDA has challenged the Company’s commercialization of this product in the United States as a Class I device exempt from 510(k) clearance requirements. The Company is in active dialogue with the FDA to determine the appropriate regulatory pathway. While these discussions are ongoing the Company has put on hold in the United States its sales and marketing efforts of Accelerate Arc Products. The Company will continue marketing and distributing the Accelerate Arc Products in Europe pursuant to its existing CE In Vitro Diagnostic Regulation (IVDR) registration.

In August 2022, we entered into a sales and marketing agreement (the “Sales and Marketing Agreement”) with BD pursuant to which BD will perform certain sales, tactical marketing, technical service call forwarding, order preparation, research and development support and/or regulatory activities on our behalf as our exclusive sales agent for certain of our products, including the Accelerate Pheno system, Accelerate Arc Products. The Sales and Marketing Agreement also grants to BD certain other rights to certain of our future products. We entered into the Sales and Marketing Agreement in order to leverage BD’s expansive global sales team, benefit from natural synergies between BD’s existing products and those from us, and reduce our sales and marketing expenses.

We continue to invest in new product development to both enhance our existing products and bring new ones to market. Current research and development areas of focus include the potential addition, if authorized by the FDA, of new AST content to our Accelerate Pheno system, additional applications for the Accelerate Arc Products, and a next generation AST platform, which is being developed with the goal to have lower costs, higher throughput, and capability to test a broader set of sample types compared to the current Accelerate Pheno system.

COVID-19 and Supply Chain Impacts Update

In late 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China, and spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 outbreak resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, shelter-in-place, stay-at-home or total lock-down (or similar) orders and business limitations and shutdowns. New cases and hospitalizations have risen and fallen throughout the course of this pandemic. More recently, the emergence and spread of new variants of COVID-19 that are significantly more contagious than previous strains initially led many government authorities and businesses to reimplement prior restrictions in an effort to lessen the spread of COVID-19 and its variants. While most of these restrictions have been lifted, uncertainty remains as to whether additional restrictions may be initiated or again reimplemented in response to surges in COVID-19 cases. The lingering impact of the COVID pandemic continues to create significant volatility throughout the global economy, including supply chain constraints, labor supply issues and higher inflation. Accordingly, it is unclear at this point the full impact COVID-19 and its variants will have on the global economy and on our Company.

The COVID-19 pandemic, containment measures, and downstream impacts to hospital staffing and financial stability have caused, and are continuing to cause, business slowdowns in affected areas, both regionally and worldwide, as well as disruptions to global supply chains and workforce participation. These effects have significantly impacted our business and results of operations, starting in the first quarter of 2020 and continuing through the current quarter, albeit to a lesser degree. For example, we have experienced diminished access to our customers, including hospitals, which has severely limited our ability to sell and, to a lesser degree, implement previously contracted Accelerate Pheno systems. Hospital turnover resulting from burnout and vaccine mandates have further diverted the attention of hospital decision makers. In addition, in certain months with high rates of COVID-19 hospitalization, our Accelerate PhenoTest BC Kit orders declined as many hospitals curtailed elective surgeries to respond to COVID-19.

The reduced new instrument sales and implementations caused by the COVID-19 pandemic lowered our realized and expected revenue growth for 2020 and 2021. In 2022, we began to see many of the detrimental effects of the pandemic on our business discussed above start to ease. For example, in recent quarters, we have seen bloodstream infection testing regain normalcy, which has in turn lessened the adverse impact of the COVID-19 pandemic on our recurring revenues through the sale of Accelerate PhenoTest BC Kits. However, with the emergence of COVID-19 variants, including the Omicron variant and its sub-variants, vaccine hesitancy and the prevalence of breakthrough cases of infection among fully vaccinated people, there remains uncertainty regarding our access to customers and prospects, demand for our products, and ability to implement our products.

44

As a medical device company, we have not experienced any disruptions to our ability to manufacture our products at our Tucson, Arizona headquarters under the various State of Arizona executive orders relating to the COVID-19 pandemic because we were classified as an essential service. We continue to expect that, should future orders be issued, we would be able to sustain our essential operations. Our third-party manufacturing supply chain for Accelerate Pheno systems and consumable test kits remains stable despite a high-degree of unpredictability in the broader supply chain environment. However, like many industries experiencing inflationary pressures in raw materials, the direct costs to manufacture our products are increasing and delivery schedules elongating.

For example, we are currently experiencing unprecedented cost increases from many of our suppliers primarily as a result of the ongoing COVID-19 pandemic, labor and supply disruptions and increased inflation. The areas of cost increases include raw materials, components, and value-add supplier labor. We believe that we currently have sufficient inventory of Accelerate Pheno system instruments to limit the impact of cost increases on such devices. However, we are being impacted by cost increases to components and raw materials necessary for the production of our Accelerate Pheno kits. Our ability to pass increased material costs to many of our customers is limited because of long-term sales agreements with limits on price increases. Accordingly, we are closely monitoring the ability of all our suppliers to provide us with necessary materials and services at reasonable costs. See “Risk Factors— Risks Related to Our Business and Strategy—Disruptions in the supply of raw materials, consumable goods or other key product components, or issues associated with their quality from our single source suppliers, could result in a significant disruption in sales and profitability” in Part I, Item 1A of 2021 10-K for additional information.

We continue to monitor the evolving impacts to our business caused by the COVID-19 pandemic. We may take further actions required by governmental authorities or that we determine are prudent to support the well-being of our employees, customers, suppliers, business partners and others. The degree to which the COVID-19 pandemic ultimately impacts our business, results of operations, cash flows and financial position will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted. This includes, but is not limited to, the duration and spread of the pandemic and its severity; the emergence and severity of its variants, including the Omicron variant and its subvariants; the actions to contain the virus or treat its impact, such as the availability and efficacy of vaccines (particularly with respect to emerging strains of the virus) and potential hesitancy to use them; the financial impact of COVID-19 on hospitals, including to their budget priorities; hospital staffing issues; general economic factors, such as increased inflation; global supply chain constraints and the related increase in costs; labor supply issues; and how quickly and to what extent normal economic and operating conditions can resume.

Accordingly, our current results and financial condition discussed herein may not be indicative of future operating results and trends. Refer to the section entitled “Risk Factors” in the 2021 10-K for additional risks we face due to the COVID-19 pandemic, including risks relating to our supply chain.

Changes in Results of Operations: Three and nine months ended September 30, 2022 compared to three and nine months ended September 30, 2021

The following analysis of our operating results contains corrections of errors identified in previously reported amounts. See Part I, Item 1, Note 1, Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies, for a discussion of the impact of such corrections of errors on our consolidated financial statements.

The Company has provided enhanced information in a tabular format which presents some of the captions presented on the statement of operations less non-cash equity-based compensation expense. These figures are reconciled to the statement of operations and are intended to add additional clarity on the operating performance of the business. The Company believes providing such figures less non-cash equity-based compensation expense provides helpful information for investors in understanding and evaluating our operating results in the same manner as our management and our board of directors.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Net sales$2,960 $3,122 $(162)(5)%$9,780 $8,439 $1,341 16 %
45


For the three months ended September 30, 2022, total revenues decreased due to lower sales of Accelerate PhenoTest instruments compared to the three months ended September 30, 2021.

For the nine months ended September 30, 2022, total revenues increased primarily due to higher sales of Accelerate PhenoTest BC Kits and service contract revenue, partially offset by a decrease in sales of Accelerate PhenoTest instruments compared to the nine months ended September 30, 2021. Accelerate PhenoTest BC Kit revenue increased as customers completed their instrument verifications and began purchasing kits. Service contract revenue increased as a higher number of customers entered into multi-year service agreements following the expiration of their warranty periods.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Cost of sales$2,381 $2,136 $245 11 %$7,318 $5,502 $1,816 33 %
Non-cash equity-based compensation as a component of cost of sales
167 82 85 104 %570 257 313 122 %
Cost of sales less non-cash equity-based compensation
$2,214 $2,054 $160 8 %$6,748 $5,245 $1,503 29 %

For the three months ended September 30, 2022, cost of sales increased as compared to the three months ended September 30, 2021, primarily due to higher non-cash equity-based compensation expense, partially offset by lower sales of Accelerate PhenoTest instruments.

For the nine months ended September 30, 2022, cost of sales increased as compared to the nine months ended September 30, 2021, primarily due to higher Accelerate Pheno recurring revenues, increases to our cost of manufacturing consumables and higher non-cash equity-based compensation expense. Our cost of manufacturing has increased as we are experiencing cost increases from many of our suppliers primarily as a result of the ongoing COVID-19 pandemic, labor and supply disruptions and increased inflation. The areas of cost increases include raw materials, components, and value-add supplier labor.

Cost of sales includes non-cash equity-based compensation expense of $0.2 million and $0.1 million for the three months ended September 30, 2022 and 2021, respectively, and $0.6 million and $0.3 million for the nine months ended September 30, 2022 and 2021, respectively. Non-cash equity-based compensation expense increased for the three and nine months ended September 30, 2022 when compared to the three and nine months ended September 30, 2021. Non-cash equity-based compensation expense is a component of manufacturing overhead and service cost of sales. Manufacturing overhead is capitalized as inventory and relieved to cost of sales when products are sold to a customers, or when instruments under reagent rentals are amortized to cost of sales.

Cost of sales expenses excluding non-cash equity-based compensation expense for the three months ended September 30, 2022 decreased compared to the three months ended September 30, 2021, primarily due to lower sales of Accelerate PhenoTest instruments.

Cost of sales expenses excluding non-cash equity-based compensation expense for the nine months ended September 30, 2022 increased compared to the nine months ended September 30, 2021, primarily due to higher sales of Accelerate PhenoTest BC Kits and service contract revenue, partially offset by a decrease in sales of Accelerate PhenoTest instruments. Other factors include increases to our cost of manufacturing consumables, as described above.

46

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Gross profit$579 $986 $(407)(41)%$2,462 $2,937 $(475)(16)%
Non-cash equity-based compensation as a component of gross profit
167 82 85 104 %570 257 313 122 %
Gross profit less non-cash equity-based compensation
$746 $1,068 $(322)(30)%$3,032 $3,194 $(162)(5)%

The Company’s overall gross margin was 20% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 25% and 35% for the nine months ended September 30, 2022 and 2021, respectively.

For the three months ended September 30, 2022, gross profit decreased as compared to the three months ended September 30, 2021, primarily due to lower sales of Accelerate PhenoTest instruments and higher non-cash equity-based compensation expense.

For the nine months ended September 30, 2022, gross profit decreased as compared to the nine months ended September 30, 2021, primarily due to higher non-cash equity-based compensation expense, a decrease in our average unit sales price of test kits, and increases to our cost of manufacturing consumables, as described above.

Gross profit excluding non-cash equity-based compensation expense for the three months ended September 30, 2022 decreased compared to the three months ended September 30, 2021, as a result of lower sales of Accelerate PhenoTest instruments.

Gross profit excluding non-cash equity-based compensation expense for the nine months ended September 30, 2022 remained flat compared to the nine months ended September 30, 2021, primarily due to higher Accelerate Pheno recurring revenues, offset by a decrease in our average unit sales price, and increases to our cost of manufacturing consumables, as described above.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Research and development$7,285 $4,712 $2,573 55 %$20,885 $17,341 $3,544 20 %
Non-cash equity-based compensation as a component of research and development
151 266 (115)(43)%1,052 4,340 (3,288)(76)%
Research and development less non-cash equity-based compensation
$7,134 $4,446 $2,688 60 %$19,833 $13,001 $6,832 53 %

Research and development expenses for the three and nine months ended September 30, 2022 increased as compared to the three and nine months ended September 30, 2021 primarily due to increased expenses to develop our next generation AST platform, partially offset by decreases in non-cash equity-based compensation expense.

Research and development expenses include non-cash equity-based compensation expense of $0.2 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $1.1 million and $4.3
47

million for the nine months ended September 30, 2022 and 2021, respectively. Non-cash equity-based compensation expense decreased for the three and nine months ended September 30, 2022 when compared to the three and nine months ended September 30, 2021, due to the reversal of non-cash equity-based compensation expense as a result of employees separating from the Company and a decrease in the fair value of new awards being granted.

Research and development expenses excluding non-cash equity-based compensation expense for the three and nine months ended September 30, 2022 increased compared to the three and nine months ended September 30, 2021, primarily due to increases in contracted service costs for the development of our next generation AST platform.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Sales, general and administrative$8,255 $10,806 $(2,551)(24)%$30,422 $37,744 $(7,322)(19)%
Non-cash equity-based compensation as a component of sales, general and administrative
911 3,281 (2,370)(72)%6,557 14,461 (7,904)(55)%
Sales, general and administrative less non-cash equity-based compensation
$7,344 $7,525 $(181)(2)%$23,865 $23,283 $582 2 %

Sales, general and administrative expenses for the three and nine months ended September 30, 2022 decreased as compared to the three and nine months ended September 30, 2021 primarily due to a decrease in non-cash equity-based compensation expense.

Sales, general and administrative expenses include non-cash equity-based compensation expense of $0.9 million and $3.3 million for the three months ended September 30, 2022 and 2021, respectively, and $6.6 million and $14.5 million for the nine months ended September 30, 2022 and 2021, respectively. Non-cash equity-based compensation expense decreased for the three and nine months ended September 30, 2022 when compared to the three and nine months ended September 30, 2021, primarily due to the reversal of non-cash equity-based compensation expense as a result of employees separating from the Company and a decrease in the fair value of new awards being granted.

Sales, general and administrative expenses excluding non-cash equity-based compensation expense for the three months ended September 30, 2022 decreased compared to the three months ended September 30, 2021, primarily due to decreases in employee related expenses, including ordinary salaries and commissions, partially offset by one-time severance expenses. During the three months ended September 30, 2022, the Company restructured its commercial sales team by reducing the number of employees in consideration of the Company’s new commercial partnership with BD.

Sales, general and administrative expenses excluding non-cash equity-based compensation expense for the nine months ended September 30, 2022 increased compared to the nine months ended September 30, 2021, primarily due to increases in costs related to marketing, promotional activities and one-time severance expenses discussed above. These costs were partially offset by decreases in employee related expenses, including ordinary salaries and commissions.

48

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Loss from operations$(14,961)$(14,532)$(429)3 %$(48,845)$(52,148)$3,303 (6)%
Non-cash equity-based compensation as a component of loss from operations
1,229 3,629 $(2,400)(66)%8,179 19,058 $(10,879)(57)%
Loss from operations less non-cash equity-based compensation
$(13,732)$(10,903)$(2,829)26 %$(40,666)$(33,090)$(7,576)23 %

For the three months ended September 30, 2022, our loss from operations increased as compared to the three months ended September 30, 2021. The increase was primarily the result of increased research and development expenses to develop our next generation AST platform, partially offset by decreases in non-cash equity-based compensation expense.

For the nine months ended September 30, 2022, our loss from operations decreased as compared to the nine months ended September 30, 2021. The decrease was primarily due to a decrease in non-cash equity-based compensation which was partially offset by an increase in research and development expenses.

Loss from operations excluding non-cash equity-based compensation expense for the three and nine months ended September 30, 2022 increased compared to the three and nine months ended September 30, 2021, primarily due to increases in product development costs related to the Accelerate Arc and the next generation AST platform, as discussed above.

This loss and further losses are anticipated and was the result of our continued investments in sales and marketing, key research and development personnel, related costs associated with product development, and commercialization of the Company’s products.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Total other (expense) income, net$(935)$5,546 $(6,481)(117)%$961 $(2,751)$3,712 (135)%

For the three months ended September 30, 2022 the Company incurred other expense, net compared to other income, net for the three months ended September 30, 2021. This change was the result of certain gains on extinguishments of debt for the three months ended September 30, 2021.

For the three months ended September 30, 2021, the Company entered into a privately negotiated exchange agreements with a holders of the Company’s 2.50% Senior Convertible Notes due 2023 (the “Notes”) pursuant to which such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company's common stock. The gain on extinguishment of exchanged Notes was $5.0 million for the three months ended September 30, 2022.

For the three months ended September 30, 2021, the Small Business Administration informed the Company of its full forgiveness for the entire Paycheck Protection Program loan amount plus accrued interest, which was $4.8 million. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of $4.8 million during the three months ended September 30, 2021.

For the nine months ended September 30, 2022 the Company recognized other income, net compared to other expense, net for the nine months ended September 30, 2021. This change was the result of higher interest expense and a gain recognized upon extinguishment of the Company’s Notes during the nine months ended September 30, 2021.

49

The Company adopted ASU 2020-06 on January 1, 2022. This change in accounting principle resulted in a decrease in interest expense for the three and nine months ended September 30, 2022 compared to the three and nine months ended September 30, 2021. Other factors include a decrease in aggregate principal amount of the Company’s Notes outstanding. Interest expense was $0.2 million and $4.2 million for the three months ended September 30, 2022 and 2021, respectively, and $1.8 million and $12.5 million for the nine months ended September 30, 2022 and 2021, respectively.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Provision for income taxes$— $— $— NM$— $— $— NM

NM indicates percentage is not meaningful

For the three and nine months ended September 30, 2022 and 2021, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions.

Capital Resources and Liquidity

Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company’s accumulated deficit totaled $592.6 million as of September 30, 2022. For the three and nine months ended September 30, 2022, the Company had net losses of approximately $15.9 million and $47.9 million, respectively, and had negative cash flows from operations of approximately $39.2 million for the nine months ended September 30, 2022. As of September 30, 2022, the Company had $55.4 million in cash and cash equivalents and investments, a decrease of $8.2 million from $63.6 million at December 31, 2021. The primary reason for the decrease was due to cash used in operations during the period. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises and the issuance of debt (see below and Note 9, Long-Term Debt, Note 10, Convertible Notes and Note 18, Stockholders' Equity in Part I, Item 1 of this Form 10-Q/A for additional details).

In connection with the preparation of this Form 10-Q/A, the Company is required to evaluate its financial condition as of the date of filing this Form 10-Q/A pursuant to the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are reissued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are reissued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are reissued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are reissued.

Based on its evaluation pursuant to ASC 205-40, the Company has determined that, as of the date of this Form 10-Q/A filing, there is substantial doubt about its ability to continue as a going concern, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A.

Our primary use of capital has been for the development and commercialization of the Accelerate Pheno system and development of complementary products. While the Company continues to explore additional funding in the form of potential equity and/or debt financing arrangements or similar transactions, as well as non-cash means to settle or refinance the Notes, there can be no assurance the necessary financing will be available on
50

terms acceptable to the Company, or at all. If the Company raises funds by issuing equity securities, dilution to stockholders may result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of common stock. If the Company raises funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of preferred and common stockholders. The terms of debt securities or borrowings could impose significant restrictions on our operations. Similarly, there can be no assurance that market conditions and refinancing alternatives will be sufficient to settle or refinance the Notes on or prior to their maturity on March 15, 2023. The capital markets have in the past, and may in the future, experience periods of upheaval that could impact the availability and cost of equity and debt financing. In addition, recent and anticipated future increases in federal fund rates set by the Federal Reserve, which serve as benchmark rates on borrowing, and other general economic conditions may impact the cost of debt financing or refinancing existing debt.

Although we are actively considering all available strategic alternatives to maximize value, if we are unable to obtain adequate capital resources to fund operations and address the upcoming maturity of the Notes, we would not be able to continue to operate our business pursuant to our current plans. This may require us to, among other things, materially modify our operations to reduce spending; sell assets or operations; delay the implementation of, or revising certain aspects of, our business strategy; file a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring; or discontinue our operations entirely.

The Company is also subject to lease agreements. The future minimum lease payments under these lease agreements are included in Part I, Item 1, Note 16, Leases.

For more information on the Company’s liquidity please see Part I, Item 1, Note 1, Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies.


As of September 30, 2022, our contractual material cash requirements were as follows:

Payments due by Period
(in thousands)
Material Cash RequirementsTotal20222023202420252026Thereafter
Operating lease obligations$2,826 $227 $968 $1,047 $584 $— $— 
Purchase obligation 1)
11,900 — — — — — 11,900 
Finance lease obligations1,795 180 721 721 173 — — 
Long term debt80 80 — — — — — 
Deferred compensation808 — — — 406 402 — 
Convertible notes
56,595 — 56,595 — — — — 
Convertible notes interest
707 — 707 — — — — 
Secured Note with related-party 2)
34,934 — — — — — 34,934 
Secured Note accrued interest with related-party 2)
220 — — — — — 220 
Total$109,865 $487 $58,991 $1,768 $1,163 $402 $47,054 

1) The Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of $11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. As of September 30, 2022 the commitment remains $11.9 million as the Company has not taken delivery of any inventory.

2) The Company may, at its option, repay the note and accrued interest in (i) cash or (ii) in the form of common stock of the Company.

Until such time as we can generate substantial product revenue, we expect to finance our cash requirements, beyond what is currently available or on hand, through a combination of equity offerings and debt financings, or exclusive license fees from BD paid pursuant to the Sales and Marketing Agreement.

51

Summary of Cash Flows

The following summarizes selected items in the Company’s condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:

Cash Flow Summary
Nine Months Ended September 30,
(in thousands)
20222021$ Change
Net cash used in operating activities$(39,178)$(35,376)$(3,802)
Net cash provided by investing activities6,575 11,054 (4,479)
Net cash provided by financing activities31,756 24,335 7,421 

Cash flows from operating activities

During the nine months ended September 30, 2022, net cash used in operating activities was primarily the result of net losses and gain on extinguishment of debt, partially offset by equity-based compensation, and depreciation and amortization.

During the nine months ended September 30, 2021, net cash used in operating activities was primarily the result of net losses and gain on extinguishment of debt, partially offset by equity-based compensation, amortization of debt discount and issuance costs, and depreciation and amortization.

The Company adopted ASU 2020-06 on January 1, 2022. This change in accounting principle resulted in a decrease in amortization of debt discount and issuance costs for the nine months ended September 30, 2022.

Cash flows from investing activities

The net cash provided by investing activities was $6.6 million for the nine months ended September 30, 2022. The Company had maturities of marketable securities of $34.5 million which were offset in part by purchases of marketable securities of $27.5 million.

The net cash provided by investing activities was $11.1 million for the nine months ended September 30, 2021. The Company had maturities of marketable securities of $33.6 million which were offset in part by purchases of marketable securities of $22.3 million.

Cash flows from financing activities

The net cash provided by financing activities was $31.8 million for the nine months ended September 30, 2022, which was primarily from the proceeds from the issuance of common stock in connection with a public offering in August 2022.

The net cash provided by financing activities was $24.3 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2021, the Company received $22.6 million in proceeds from the issuance of common stock in connection with a private placement offering and $1.5 million from the exercise of stock options.

52

Convertible Notes

On March 27, 2018, the Company issued $150.0 million aggregate principal amount of the Notes. In connection with the offering of the Notes, the Company granted the initial purchasers an option to purchase additional amounts. The option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes mature on March 15, 2023, unless earlier repurchased or converted into shares of common stock subject to certain conditions. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company's election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. We pay interest on the Notes semi-annually in arrears on March 15 and September 15 of each year with interest payments beginning on September 15, 2018.

During the year ended December 31, 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by it for shares of the Company’s common stock. During the year ended December 31, 2021, $51.0 million in aggregate principal amount of Notes were exchanged for 6,602,974 shares of the Company's common stock in these exchange transactions.

During the nine months ended September 30, 2022, the Company entered into an exchange agreement with one holder of the Notes. Under the terms of the exchange agreement, the holder agreed to exchange Notes held by them for shares of the Company’s common stock. During the nine months ended September 30, 2022, $14.0 million in aggregate principal amount of Notes were exchanged for 10,798,482 shares of the Company's common stock in this exchange transaction.

On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”). Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a warrant to acquire the Company’s common stock. After giving effect to the exchange transactions described above, the Notes had an outstanding principal amount of $56.6 million as of September 30, 2022. See “—Capital Resources and Liquidity—Secured Note” below for additional information regarding the Secured Note.

In connection with the Notes offering, we entered into a prepaid forward stock repurchase transaction (the “Prepaid Forward”) with a financial institution. Pursuant to the Prepaid Forward, we used approximately $45.1 million of the proceeds from the offering of the Notes to pay the prepayment amount. The aggregate number of our common stock underlying the Prepaid Forward is approximately 1,858,500 shares (based on the sale price of $24.25). The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to us the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward were treated as treasury stock on the condensed consolidated balance sheet (and not outstanding for purposes of the calculation of basic and diluted earnings per share), but remain outstanding for corporate law purposes, including for purposes of any future stockholders' votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to us.

See Part I, Item 1, Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

At-The-Market Equity Sales Agreement

On May 28, 2021, the Company entered into an Equity Sales Agreement (the “ATM Sales Agreement”) with William Blair pursuant to which it may sell shares of the Company’s common stock having an aggregate offering price of up to $50 million, from time to time, through an “at-the-market” equity offering program under which William Blair will act as sales agent. Subject to the terms and conditions of the ATM Sales Agreement, William Blair may sell shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act. The Company is not obligated to sell any shares under the ATM Sales Agreement. William Blair is entitled to a commission of 3% of the aggregate gross proceeds from each sale of shares occurring pursuant to the ATM Sales Agreement. During the nine months ended September 30, 2022, the Company did not sell any shares of common
53

stock under the ATM Sales Agreement. As of September 30, 2022, the Company had an aggregate of $39.1 million available for future sales under its at-the-market equity offering program.

Sales of Equity Securities

On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust (the “Private Placement”). Jack Schuler, serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust.

Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust has agreed to purchase the Shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, which is equal to the consolidated closing bid price reported by Nasdaq immediately preceding the time the Company entered into the March 2022 Securities Purchase Agreement, for an aggregate purchase price of $4.0 million. On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022.

On August 23, 2022, the Company completed a public offering of 17,500,000 shares of its common stock at a price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.

Secured Note

For additional information regarding other sales of equity securities completed by the Company in 2020 and 2021, see “Capital Resources and Liquidity—Other sales of equity securities” in Part II, Item 7 of the 2021 10-K.

The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.

For additional information regarding other sales of equity securities completed by the Company in 2020 and 2021, see “Capital Resources and Liquidity—Other sales of equity securities” in Part II, Item 7 of the 2021 10-K.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2022.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our estimates on an ongoing basis, including those related to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and are not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in the 2021 10-K.

54


Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.


Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including the Principal Executive Officer and the Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In connection with the preparation of this Form 10-Q/A, management, under the supervision and with the participation of the Principal Executive Officer and the Principal Financial Officer, conducted a re-evaluation of the effectiveness of the design and operations of our disclosure controls and procedures as of September 30, 2022. Based on that evaluation, due to a material weakness in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) described below, the Principal Executive Officer and the Principal Financial Officer have concluded that our disclosure controls and procedures, were not effective as of September 30, 2022.

Material Weakness in Internal Control Over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management identified a material weakness in our internal control over financial reporting as of September 30, 2022 that prevented us from identifying the misclassification of the Notes on the Condensed Consolidated Balance Sheet and gave rise to the necessity to file this Form 10-Q/A. The Company’s internal control structure did not have a control to review the evaluation of the classification of its outstanding debt instruments in accordance with applicable accounting guidance at each reporting period.

Remediation Plan

With oversight from the Audit Committee and input from management, the Company has begun designing and implementing changes in processes and controls to remediate the material weakness described above and to enhance our internal control over financial reporting, including a control to review the accounting treatment of outstanding debt instruments on a quarterly basis in accordance with applicable accounting guidance.

Changes in Internal Control Over Financial Reporting

Other than as described above, there was no change in the Company’s internal control over financial reporting during the quarter ended September 30, 2022 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
55

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are from time to time subject to various claims and legal actions in the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations or financial condition.


Item 1A. Risk Factors

In addition to the other information set forth in this Form 10-Q, you should carefully consider the risks discussed in the section entitled “Risk Factors” in the 2021 10-K and the risk factor described below, which could materially affect our business, financial condition or future results. The risks described in the 2021 10-K and below are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, results of operations, cash flows and financial position.

Risks Related to Our Business and Strategy

We have entered into the Sales and Marketing Agreement with BD and will substantially depend on BD for the successful commercialization of our products.

As part of our collaboration with BD pursuant to the Sales and Marketing Agreement, BD will perform certain sales, tactical marketing, technical service call forwarding, order preparation, research and development support and/or regulatory activities on our behalf as our exclusive sales agent for certain of our products, including the Accelerate Pheno system, Accelerate Arc system and related BC Kits. The successful commercialization of our products, including our ability to generate revenue from our arrangement with BD, will depend on BD’s ability to successfully perform the responsibilities assigned to it pursuant to the Sales and Marketing Agreement. While BD is largely responsible for the speed and scope of sales and marketing efforts, we cannot assure you that BD will dedicate the resources necessary to successfully perform its responsibilities pursuant to the Sales and Marketing Agreement, and our ability to cause BD to increase the speed and scope of its efforts may be limited. In addition, sales and marketing efforts could be negatively impacted by the delay or failure by us to obtain additional supportive clinical trial data for our products. We cannot predict the success of our collaboration with BD, and there can be no assurance that the efforts of BD will meet our expectations or result in any significant product sales or cost savings within the anticipated time frame or at all.

In the event that BD fails to perform under the Sales and Marketing Agreement, or if the Sales and Marketing Agreement is terminated, this could delay our product commercialization efforts, which would materially and adversely affect our business, financial condition, results of operations and cash flows. The termination of the Sales and Marketing Agreement could also require us to revise our commercialization and business strategy going forward and divert management attention and resources. In addition, the termination of the Sales and Marketing Agreement could materially impact our ability to enter into additional collaboration agreements with new partners on favorable terms, if at all.

Risks Related to Our Common Stock

Our stock price has been volatile and may continue to be volatile and traded on low volumes.

The trading price of our common stock has been, and is likely to continue to be, highly volatile. Factors that may contribute to volatility in the price of our common stock include, but are not limited to:

•low trading volume currently prevailing in the market for our shares;
•concentration of our stock with one individual large shareholder who could decide to materially reduce his position;
•the substantial current short interest in our stock;
56

•the duration and severity of the COVID-19 pandemic and its effects on our business, financial condition, results of operations and cash flows;
•adverse regulatory decisions, including failure to receive regulatory approvals for any of our product candidates;
•our success in commercializing our product candidates, if and when approved;
•the introduction of new products or product enhancements by us or others in our industry;
•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or restructurings;
•disputes or other developments with respect to our or others’ intellectual property rights;
•product liability claims or other litigation;
•quarterly variations in our results of operations or those of others in our industry;
•sales of large blocks of our common stock, including sales by our executive officers and directors;
•changes in senior management or key personnel;
•changes in laws or regulations which adversely affect our industry or us;
•changes in earnings estimates or recommendations by securities analysts; and
•changes in general market, economic, and political conditions in the U.S., and global economies or financial markets, including those resulting from natural disasters, terrorist attacks, acts of war (including Russia’s invasion of Ukraine), other geopolitical uncertainties, public health concerns (including health epidemics or outbreaks of communicable diseases, such as the COVID-19 pandemic),and responses to such events.

The market value of your investment in our common stock may rise or fall sharply at any time because of this volatility and also because of significant short positions that may be taken by investors from time to time in our common stock. During the nine months ended September 30, 2022, the closing price for our common stock ranged from $0.54 to $5.15 per share, during the year ended December 31, 2021, the closing price for our common stock ranged from $4.27 to $15.00 per share, and during the year ended December 31, 2020, the closing price for our common stock ranged from $4.62 to $18.74 per share. The market prices for securities of medical technology companies like us historically have been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies.

In addition, in the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our product offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management’s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the quarter ended September 30, 2022 other than as reported in our Current Reports on Form 8-K filed with the SEC.


Item 3. Defaults Upon Senior Securities

Not applicable.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.
57


Item 6. Exhibits

Exhibit No.DescriptionFiling Information
3.1Incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012
3.1.1Incorporated by reference to Exhibit A to the Registrant’s Definitive Information Statement on Schedule 14C filed on July 12, 2013
3.1.2Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 15, 2016
3.1.3Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 15, 2019
3.1.4
Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 13, 2021
3.1.5
Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on September 23, 2021
3.1.6
Incorporate by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 17, 2022
3.2Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on August 8, 2019
3.2.1
Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 3, 2022
10.1
Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.2
Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.3
Incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.4
Incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.5+
Incorporated by reference to Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q filed on November 14, 2022
31.1Filed herewith
31.2Filed herewith
32Furnished herewith

58



101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentFiled herewith
101.SCH Inline XBRL Taxonomy Extension Schema DocumentFiled herewith
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled herewith
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith
104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)Filed herewith


+ Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. An unredacted copy of this exhibit will be furnished supplementally to the SEC upon request.
59

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


ACCELERATE DIAGNOSTICS, INC.

March 3, 2023/s/ Jack Phillips
Jack Phillips
President and Chief Executive Officer
(Principal Executive Officer)
March 3, 2023/s/ Steve Reichling
Steve Reichling
Chief Financial Officer
(Principal Financial and Accounting Officer)
60
 EX-31.1 2 a09302022-exh311a.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jack Phillips, certify that:

1.I have reviewed this quarterly report on Amendment No. 1 to the Quarterly Report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

March 3, 2023
/s/ Jack Phillips
 
Jack Phillips
President and Chief Executive Officer
 (Principal Executive Officer)


 EX-31.2 3 a09302022-exh312a.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steve Reichling, certify that:

1.I have reviewed this quarterly report on Amendment No. 1 to the Quarterly Report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

March 3, 2023/s/ Steve Reichling
 Steve Reichling
Chief Financial Officer
 (Principal Financial and Accounting Officer)


 EX-32 4 a09302022-exh32a.htm EX-32 Document

Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of Accelerate Diagnostics, Inc. (the “Company”) hereby certifies that, to his knowledge, the Company’s Quarterly Report on Amendment No. 1 to the Quarterly Report on Form 10-Q for the period ended September 30, 2022 to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 3, 2023/s/ Jack Phillips
Jack Phillips
President and Chief Executive Officer
(Principal Executive Officer)
 
March 3, 2023/s/ Steve Reichling
Steve Reichling
Chief Financial Officer
(Principal Financial and Accounting Officer)


 EX-101.SCH 5 axdx-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Deferred Revenue and Remaining Performance Obligations link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Long-Term Debt Related-Party link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Employee Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Geographic and Revenue Disaggregation link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Long-Term Debt Related-Party (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Employee Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Geographic and Revenue Disaggregation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Effect of Restatement (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Recently Issued Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Investments - Unrealized Losses or Gains on Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Property and Equipment - Property and Equipment at Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Long-Term Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Convertible Notes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Convertible Notes - Gain on Extinguishment (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Convertible Notes - Schedule of Notes and New Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Long-Term Debt Related-Party - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Loss Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Employee Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Leases - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Geographic and Revenue Disaggregation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 axdx-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 axdx-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 axdx-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic concentration Geographic Concentration Risk [Member] Due in less than 1 year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Reclassified from out of accumulated other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Revision of Prior Period [Axis] Revision of Prior Period [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total lease payments Lessee, Operating Lease, Liability, to be Paid Foreign Currency Translation and Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Facilities Leaseholds and Leasehold Improvements [Member] (Reversals) provisions, net Accounts Receivable, Credit Loss Expense (Reversal) Related Party Transactions [Abstract] Related Party Transactions [Abstract] Outstanding principal at par Outstanding principal Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Tranche right value Stockholders' Equity, Tranche Right Stockholders' Equity, Tranche Right Finance lease assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Aggregate purchase price Preferred Stock, Value, Subscriptions Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Funded prepaid forward Payments To Fund Prepaid Forward Stock Repurchase Payments To Fund Prepaid Forward Stock Repurchase Preferred Stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Preferred Stock, Shares Outstanding 2024 Long-Term Debt, Maturity, Year Two Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] Finance lease obligation Finance Lease, Liability Property and equipment Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Other revenue Other Revenue [Member] Other Revenue [Member] Lease income Lease Income Decrease in additional paid in capital Additional Paid in Capital Thereafter Finance Lease, Liability, to be Paid, after Year Four Finance Lease, Liability, to be Paid, after Year Four Other loans Loans - various interest Other Loans [Member] Other Loans Financial Instruments [Domain] Financial Instruments [Domain] 2026 Finance Lease, Liability, to be Paid, Year Four Statistical Measurement [Domain] Statistical Measurement [Domain] Increase (decrease) in liabilities: Increase (Decrease) in Accrued Liabilities [Abstract] Provisions (reversals), net Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments Depreciation and amortization Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Contractual coupon interest Contractual interest Interest Expense, Debt, Excluding Amortization Weighted average discount rate (%) Operating Lease, Weighted Average Discount Rate, Percent Interest rate Debt Instrument, Interest Rate, Stated Percentage Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Net property and equipment under operating leases Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation Issuance of shares to retire convertible notes Stock Issued During Period, Value, Conversion of Convertible Securities Contributed capital Additional Paid in Capital, Common Stock Payment of debt Repayments of Debt Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization 2025 Finance Lease, Liability, to be Paid, Year Three Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Non-affiliate related entities Related Party, Number of Related Entities Related Party, Number of Related Entities Antidilutive common stock instruments outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2021 Exchange Transaction 2021 Exchange Transaction [Member] 2021 Exchange Transaction [Member] Remainder of 2022 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Document Information [Line Items] Document Information [Line Items] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Operating Lessee, Operating Lease, Liability, to be Paid [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Agreement to purchase shares (in shares) Common Stock, Shares Subscribed but Unissued Net transfer of instruments (to) from inventory to property and equipment Inventory Transferred to Fixed Assets Inventory Transferred to Fixed Assets Financial Institutions Three Financial Institutions Three [Member] Financial Institutions Three Equity Component [Domain] Equity Component [Domain] Secured Debt Secured Debt [Member] Repurchase principal balance Debt Instrument, Redemption Price, Percentage Total assets measured at fair value Assets, Fair Value Disclosure Interest income Investment Income, Interest and Dividend Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Leases Lessee, Operating Leases [Text Block] Related Party [Domain] Related Party [Domain] Estimated Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Treasury stock Treasury Stock, Common, Value Debt securities available-for-sale: Fair Value Fair Value Debt Securities, Available-for-Sale Expected dividends Measurement Input, Expected Dividend Rate [Member] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Unrecognized equity-based compensation cost, restricted stock units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Capital contribution from related-party in connection with exchange transaction Capital contribution from related-party in connection with exchange transaction Adjustment to Additional Paid-in Capital, Convertible Debt Instrument Issued at Substantial Premium Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Common stock, $0.001 par value; 200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021 Common Stock, Value, Outstanding Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Issuable upon conversion of the notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Current portion of long-term debt Other Long-Term Debt, Current Deferred compensation Increase (Decrease) in Deferred Compensation Operating lease, current Operating Lease, Liability, Current Leases Lessor, Sales-type Leases [Text Block] Cash paid for amounts included in lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Expired (in shares) Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Schedule of Maturities of Available-for-Sale Investments Debt Securities, Available-for-Sale [Table Text Block] Lease Cost: Lease, Cost [Abstract] Property and equipment Property, Plant and Equipment [Member] 2025 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Lender Name [Axis] Lender Name [Axis] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Restricted stock awards released and exercise of options (in shares) Exercise Of Options And Restricted Stock Awards Issued Exercise Of Options And Restricted Stock Awards Issued Long-term debt Long-Term Debt, Excluding Current Maturities Certificates of deposit Certificates of deposit Certificates of Deposit [Member] Total liabilities Total liabilities Liabilities Agreement to purchase preferred shares (in shares) Preferred Stock, Shares Subscribed but Unissued Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of investment discount Investment Income, Net, Amortization of Discount and Premium Proceeds from issuance of stock Stock Issued During Period, Value, New Issues Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Reclassified debt securities available-for-sale balances AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Document Type Document Type Realized gain (loss) from debt securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Estimated useful life of assets Property, Plant and Equipment, Useful Life Long-Term Debt Long-Term Debt [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Warranty cost incurred Standard Product Warranty Accrual, Decrease for Payments Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Convertible Notes Debt Disclosure [Text Block] Stock underlying the prepaid forward (in shares) Treasury Stock Acquired, Number Of Shares Prepaid Treasury Stock Acquired, Number Of Shares Prepaid Number of loan agreements Number of Debt Instruments Number of Debt Instruments Finance Finance Lease, Liability, to be Paid [Abstract] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued liabilities and other Increase (Decrease) in Accrued Liabilities Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One (Increase) decrease in assets: Increase (Decrease) in Operating Assets [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] 2025 Long-Term Debt, Maturity, Year Three Affiliated Entity Affiliated Entity [Member] New Notes Two Point Five Zero New Convertible Notes Due 2023 [Member] Two Point Five Zero New Convertible Notes Due 2023 Total revenue Revenue Benchmark [Member] Schedule of Deferred Revenue and Income Summary Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Total assets Assets Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Fair Value Measurement Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Performance-based stock options Performance-based stock option expense Performance Shares [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Equity investments: Fair value of equity securities Equity Securities, FV-NI, Current Accrued liabilities Accrued Liabilities, Current Unsecured obligations Unsecured Debt [Member] Concentration of credit risk Credit Concentration Risk [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Fair value Long-Term Debt, Fair Value Accounting Policies [Abstract] Accounting Policies [Abstract] Domestic Geographic Distribution, Domestic [Member] Total interest expense on convertible notes Interest Expense, Debt August 2022 Public Offering August 2022 Public Offering [Member] August 2022 Public Offering Net loss before income taxes Net loss before income taxes Pre-tax loss Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Loss Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Schedule of Equity-Based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Finance lease, non-current Finance Lease, Liability, Noncurrent Debt instrument, convertible, number of accrued interest Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Leases as Lessor Lessor, Leases [Policy Text Block] Gain on extinguishment of debt Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt Weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds from issuance of common stocks under employee purchase plan Proceeds from Stock Plans Computer equipment Computer Equipment [Member] Gross profit Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Conversion ratio (in shares) Preferred Stock, Convertible, Conversion Ratio Financial Institutions One Financial Institutions One [Member] Financial Institutions One Issuance of stock (in shares) Stock Issued During Period, Shares, New Issues Tranche Right September 2021 Securities Purchase Agreement, Second Tranche Right [Member] September 2021 Securities Purchase Agreement, Second Tranche Right Weighted Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Contractual term (in years) Measurement Input, Expected Term [Member] Mutual funds Mutual Fund [Member] Geographic Distribution [Domain] Geographic Distribution [Domain] Schedule of Effect of Restatement Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Conversion ratio Debt Instrument, Convertible, Conversion Ratio Convertible Note Purchases Convertible Note Purchases [Member] Convertible Note Purchases [Member] Due in less than 1 year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company December 2020 Securities Purchase Agreement December 2020 Securities Purchase Agreement [Member] December 2020 Securities Purchase Agreement [Member] Common Stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Unamortized debt issuance discount Debt Issuance Costs, Net Due in 1-3 years Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury stock Treasury Stock, Common [Member] Outside the U.S. Foreign Geographic Distribution, Foreign [Member] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Share price (in usd per share) Share Price Trading Symbol Trading Symbol Entity File Number Entity File Number Research and development Research and Development Expense Equipment Equipment [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Shares issuable upon the release of RSUs RSUs Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Risk free interest rates Measurement Input, Risk Free Interest Rate [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Other (expense) income: Other Nonoperating Income (Expense) [Abstract] Long-term debt related-party Due to Related Parties, Noncurrent Accounts payable Increase (Decrease) in Accounts Payable Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Risk concentration Concentration Risk, Percentage Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Basic net loss per share (in usd per share) Earnings Per Share, Basic Current portion of convertible notes Convertible Debt, Current 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Schedule of Gain on Extinguishment Schedule of Extinguishment of Debt [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Inventory Inventory, Policy [Policy Text Block] Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement Concentration Risk Type [Domain] Concentration Risk Type [Domain] Fair value of common stock warrant issued to related-party in connection with exchange transaction Warrants Issued Warrants Issued Counterparty Name [Domain] Counterparty Name [Domain] Number of tranches Issuance of Common Stock, Number of Tranches Issuance of Common Stock, Number of Tranches Total stockholders’ deficit Beginning Balance, amount Ending Balance, amount Total stockholders’ deficit ending balance Stockholders' Equity Attributable to Parent Prepaid expenses Prepaid Expense, Current Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 2.50% Convertible notes due 2023 Two Point Five Zero Convertible Notes Due 2023 [Member] Two Point Five Zero Convertible Notes Due 2023 [Member] Entity Interactive Data Current Entity Interactive Data Current Sale of stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Long-Term Debt Related-Party Long Term Debt Related Party [Text Block] Long Term Debt Related Party [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] August 2022 Exchange Transaction August 2022 Exchange Transaction [Member] August 2022 Exchange With Related Party [Member] Money market funds Money Market Funds [Member] March 2022 Exchange Transaction March 2022 Exchange Transaction [Member] March 2022 Exchange Transaction [Member] Accumulated deficit Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Unrecognized equity-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Debt forgiveness Debt Instrument, Decrease, Forgiveness Common stock Common Stock [Member] Schedule of Lease Costs Lease, Cost [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Deferred Tax Income Tax, Policy [Policy Text Block] Statement [Table] Statement [Table] Sale or merger trigger conversion ratio (in shares) Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion Cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments Released (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective interest rate Debt Instrument, Interest Rate, Effective Percentage 5.0% Secured promissory note Five Point Zero Percent Secured Promissory Note [Member] Five Point Zero Percent Secured Promissory Note Commercial paper Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Lease extension Lessee, Operating Lease, Renewal Term Trade accounts receivable, net Receivables, Net, Current Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Operating lease, non-current Operating Lease, Liability, Noncurrent Convertible Debt [Abstract] Convertible Debt [Abstract] Summary of Inputs Used to Calculate Estimated Fair Value Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Realized gains or losses from equity securities Equity Securities, FV-NI, Realized Gain (Loss) Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Decrease in accumulated deficit Retained Earnings (Accumulated Deficit) Original Purchasers Certain Directors And Officers Or Affiliates [Member] Certain Directors And Officers Or Affiliates [Member] U.S. Treasury securities U.S. Treasury securities US Treasury and Government [Member] Equity Components [Axis] Equity Components [Axis] Conversion numerator (in usd per share) Debt Conversion, Conversion Numerator Debt Conversion, Conversion Numerator Fair Value on a Recurring Basis Fair Value, Recurring [Member] Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related-Party Transactions Related Party Transactions Disclosure [Text Block] Number of tranches Debt Conversion, Number Of Tranches Debt Conversion, Number Of Tranches Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Revision of Prior Period [Domain] Revision of Prior Period [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Payments on finance leases Operating cash flows from finance leases Finance Lease, Principal Payments Total other (expense) income, net Nonoperating Income (Expense) Other comprehensive loss: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Sales, general and administrative Selling, General and Administrative Expense Recently Issued Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Products Product [Member] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right of use assets, net Operating Lease, Right-of-Use Asset Rescission of common stock Stock Repurchased During Period, Value Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Series A Preferred Stock Series A Preferred Stock [Member] Financial Institutions Two Financial Institutions Two [Member] Financial Institutions Two 2024 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two Purchases of equipment Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Option Activity under the Company's Equity-Based Compensation Share-Based Payment Arrangement, Option, Activity [Table Text Block] Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs Convertible notes value Debt Conversion, Converted Instrument, Amount Loss from operations Loss from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Instrument warranty term Standard Product Warranty, Instruments, Term Standard Product Warranty, Instruments, Term Standards that were recently adopted and standards not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Prepaid expense and other Increase (Decrease) in Prepaid Expense and Other Assets Document Information [Table] Document Information [Table] Common Stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Outstanding Services Service [Member] Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Beginning balance Ending balance Standard Product Warranty Accrual Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Schedule of Warranty Reserve Schedule of Product Warranty Liability [Table Text Block] Preferred Stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Schedule of Outstanding Options and Options that are Exercisable (Vested) Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] Performance-based RSU expense Performance-based Restricted Stock Units [Member] Performance-based Restricted Stock Units Contact period Revenue, Performance Obligation, Description of Timing Contributed capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Extinguished Notes Extinguished Notes [Member] Extinguished Notes Cost of sales Cost of Goods and Services Sold Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Long-lived Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Convertible notes Non-current portion of convertible notes Convertible Debt, Noncurrent Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Schedule of Available-for-Sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Net accounts receivable Accounts Receivable [Member] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Expected term of award Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award Investments Investments Issuance of common stock under employee purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Ownership Plan Instruments Instruments [Member] Instruments [Member] Notes exchanged Debt Conversion, Original Debt, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Instruments at cost under operating leases Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation Preferred stock Preferred Stock [Member] Purchase price Common Stock, Value, Subscriptions Senior Notes Senior Notes [Member] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Initial conversion price (in usd per share) Debt Instrument, Convertible, Conversion Price Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Contributions to deferred compensation plan Deferred Compensation Arrangement with Individual, Contributions by Employer Convertible notes Convertible Debt [Member] Aggregate intrinsic value (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Short-term leases Short-Term Lease, Cost Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized Schuler Trust Jack W. Schuler Living Trust [Member] Jack W. Schuler Living Trust Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Commitments Commitments and Contingencies Disclosure [Text Block] Warrant issued to related-party Adjustments to Additional Paid in Capital, Warrant Issued Warrants issued, measurement input Warrants and Rights Outstanding, Measurement Input Current liabilities: Liabilities, Current [Abstract] Proceeds from debt Proceeds from Issuance of Long-Term Debt Proceeds from exercise of options Proceeds from Stock Options Exercised Common Stock, shares issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Deferred revenue Products and services not yet delivered Contract with Customer, Liability, Current Schedule of Unrealized Losses or Gains on Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Foreign currency exchange loss Foreign Currency Transaction Gain (Loss), before Tax Warrants fair value Warrants and Rights Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Interest expense Interest Expense, Other Finance lease, current Finance Lease, Liability, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized loss position of debt securities Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating leases Operating Lease, Cost Aggregate principal amount Debt Instrument, Face Amount Investments Investment, Policy [Policy Text Block] Comprehensive loss Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Capital projects in progress Construction in Progress [Member] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status March 2022 Securities Purchase Agreement March 2022 Securities Purchase Agreement [Member] March 2022 Securities Purchase Agreement Other non-current assets Other Assets, Noncurrent Remainder of 2022 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year Carrying amount of convertible notes Total convertible notes Convertible Debt September 2021 Rescission Agreement September 2021 Rescission Agreement [Member] September 2021 Rescission Agreement Number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Present value of lease payments Sales-type and Direct Financing Leases, Lease Receivable 2023 Finance Lease, Liability, to be Paid, Year One Depreciation expense Depreciation, Depletion and Amortization Less imputed interest Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Lease term Lessee, Operating Lease, Term of Contract Counterparty Name [Axis] Counterparty Name [Axis] Weighted average fair value (in usd per shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Interest Expense Schedule of Interest Expense in Connection with the Secured Note Interest Income and Interest Expense Disclosure [Table Text Block] Trading price threshold, percentage Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Technical equipment Technology Equipment [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2024 Finance Lease, Liability, to be Paid, Year Two Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Long-lived assets (excluding intangible assets) Property, Plant and Equipment, Net Operating cash flows from operating leases Operating Lease, Payments Shares issuable upon exercise of stock options Share-Based Payment Arrangement, Option [Member] Notes payable, other payables Loans - various interest Notes Payable, Other Payables [Member] Schedule of Instruments at Cost and Accumulated Depreciation, Lessor Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Restricted stock awards released and exercise of options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Loans - various interest Long-Term Debt Other (expense) income, net Other Nonoperating Income (Expense) One customer One Customer [Member] One Customer Net unrealized gain (loss) on debt securities available-for-sale Net unrealized gain (loss) on debt securities available-for-sale OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Accrued interest Interest and Dividends Payable, Current Share price (in usd per share) Sale of Stock, Price Per Share Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Maximum Maximum [Member] Non-cash financing activities: Other Noncash Investing and Financing Items [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Products and services not yet delivered Products and Services not Yet Delivered [Member] Products and Services not Yet Delivered [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue and income Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Revenues recognized included in contract liabilities balances Contract with Customer, Liability, Revenue Recognized Accumulated depreciation under operating leases Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Purchase of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Weighted average fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value Schedule of Maturities of Sales-type Lease Receivables Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Amortization of the debt discount Amortization of the debt discount Amortization of Debt Discount (Premium) Accrued interest related-party Interest Payable, Related Party, Noncurrent Interest Payable, Related Party, Noncurrent Aggregate intrinsic value (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Warrants issued (in shares) Debt Conversion, Converted Instrument, Warrants or Options Issued Schedule of Supplemental Lease Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security September 2021 Securities Purchase Agreement September 2021 Securities Purchase Agreement [Member] September 2021 Securities Purchase Agreement Accrued interest from related-party Increase (Decrease) Related Party Accrued Interest Increase (Decrease) Related Party Accrued Interest Accelerate Pheno revenue Accelerate Pheno [Member] Accelerate Pheno [Member] Total undiscounted cash flows Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received ROU assets obtained in exchange for lease obligations: Lessee, Operating Lease, Description [Abstract] Repurchase of exchanged amount Debt Instrument, Repurchase Amount Total costs and expenses Costs and Expenses Number of capital asset financing companies Number of Capital Asset Financing Companies Number of Capital Asset Financing Companies Debt Instrument [Line Items] Debt Instrument [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Stock [Line Items] Class of Stock [Line Items] Amendment Description Amendment Description Lessee lease liabilities Operating Lease, Liability Geographic and Revenue Disaggregation Segment Reporting Disclosure [Text Block] Volatility Measurement Input, Price Volatility [Member] Lessor lease term Lessor, Operating Lease, Term of Contract Equity-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Total lease payments Finance Lease, Liability, to be Paid Sales, general and administrative Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] As Previously Reported Previously Reported [Member] Kits and accessories warranty term Standard Product Warranty, Kits And Accessories, Term Standard Product Warranty, Kits And Accessories, Term Total commitments Unrecorded Unconditional Purchase Obligation LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Remainder of 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Net proceeds Sale of Stock, Consideration Received on Transaction Inventory Inventory Inventory, Net Transaction costs related to debt exchange Payments Of Debt Conversion Costs Payments Of Debt Conversion Costs Accounts payable Accounts Payable, Current Unamortized debt issuance Debt Instrument, Unamortized Discount Stock price conversion threshold, percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 2026 Long-Term Debt, Maturity, Year Four Accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization RSUs and RSAs Restricted Stock Units And Restricted Stock Awards [Member] Restricted Stock Units And Restricted Stock Awards [Member] Shares issuable upon the exercise of the Warrant Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Exchange Agreement Convertible Notes Exchange Agreement [Member] Convertible Notes Exchange Agreement 2026 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four Equity-based compensation expense Share-Based Payment Arrangement, Expense Non-cash investing activities: Noncash Investing and Financing Items [Abstract] Commitments and contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Assets Interest expense related-party Interest Expense, Related Party Extinguishment of convertible senior notes through issuance of common stock Stock Issued Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and 3,954,546 outstanding as of September 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Accrued interest Increase (Decrease) in Interest Payable, Net Prepaid Forward Prepaid Forward [Member] Prepaid Forward Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Schedule of Carrying Value of the Notes Schedule of Carrying Value of the Secured Notes Schedule of Debt [Table Text Block] Net sales Net sales Revenue from Contract with Customer, Excluding Assessed Tax Issuance of shares to retire Convertible Senior Notes (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Cash and cash equivalents Cash and Cash Equivalents [Member] Cover page. Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases as Lessee Lessee, Leases [Policy Text Block] Significant Unobservable Inputs (Level 3) Level 3 Fair Value, Inputs, Level 3 [Member] Geographic Distribution [Axis] Geographic Distribution [Axis] Employee Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Due in 1-3 years Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Work in process Inventory, Work in Process, Net of Reserves Gross margin Gross Margin Percentage Gross Margin Percentage Weighted average discount rate finance leases (%) Finance Lease, Weighted Average Discount Rate, Percent Common stock issuable upon conversion of the Series A Preferred Stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Deferred Revenue and Remaining Performance Obligations Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Option one to convert Debt Instrument, Redemption, Period Two [Member] Net investment in leases Net Investment in Lease, before Allowance for Credit Loss Fair value of new note from related-party issued in connection with the exchange transaction Notes Issued Total liabilities and stockholders’ deficit Liabilities and Equity Contractual term Debt Instrument, Term Amortization of debt issuance costs Amortization of Debt Issuance Costs Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Warranty Reserve Standard Product Warranty, Policy [Policy Text Block] Paycheck Protection Program Paycheck Protection Program [Member] Paycheck Protection Program Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Significant Other Observable Inputs (Level 2) Level 2 Fair Value, Inputs, Level 2 [Member] Convertible Notes Debt, Policy [Policy Text Block] Option two to convert Debt Instrument, Redemption, Period One [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted net loss per share (in usd per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Amortization of debt discount related-party Amortization of Debt Issuance Costs, Related Party Amortization of Debt Issuance Costs, Related Party Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Debt instrument, convertible, number of equity instruments Debt Instrument, Convertible, Number of Equity Instruments Equity-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Total current liabilities Liabilities, Current Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Capital contribution from related-party in connection with the exchange transaction Debt Conversion, Converted Instrument, Related Party Contributed Capital Debt Conversion, Converted Instrument, Related Party Contributed Capital 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Customer concentration Customer Concentration Risk [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Revenue expected to be recognized from remaining performance obligations Revenue, Remaining Performance Obligation, Amount Contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Corporate notes and bonds Corporate notes and bonds Corporate Debt Securities [Member] Cumulative effect of accounting changes Cumulative Effect, Period of Adoption, Adjustment [Member] Schedule of Allowance For Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Proceeds from issuance of preferred stock Proceeds from Issuance of Preferred Stock and Preference Stock Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Cost capitalized to inventory Share-Based Payment Arrangement, Amount Capitalized Issuance of common stock under employee purchase plan Stock Issued During Period, Value, Employee Stock Ownership Plan Unrealized loss (gain) on equity investments Unrealized (loss) gain on equity investments Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Weighted average remaining lease term finance leases (years) Finance Lease, Weighted Average Remaining Lease Term Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Proceeds from sales of debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Inventory Inventory Disclosure [Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] 2023 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Equity [Abstract] Equity [Abstract] Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Debt Conversion Description [Axis] Debt Conversion Description [Axis] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Options Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Entity Tax Identification Number Entity Tax Identification Number Schedule of Long-lived Assets by Geographic Territory Long-Lived Assets by Geographic Areas [Table Text Block] Embeded Warrant Embeded Warrant [Member] Embeded Warrant [Member] Outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Rescission of common stock (in shares) Stock Redeemed or Called During Period, Shares Debt Conversion, Name [Domain] Debt Conversion, Name [Domain] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Total property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Nonqualified Cash Deferral Plan Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code ASSETS Assets [Abstract] Adjustments Revision of Prior Period, Adjustment [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Schuler Family Foundation Schuler Family Foundation [Member] Schuler Family Foundation [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Finance leases Finance Lease, Cost Finance Lease, Cost Loss Per Share Earnings Per Share, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Other non-current liabilities Other Liabilities, Noncurrent Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Impairment charges Asset Impairment Charges Thereafter Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Reacquisition costs Debt Conversion, Cost Debt Conversion, Cost Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of sales Cost of Sales [Member] Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Business Description and Basis of Presentation [Text Block] Customer [Domain] Customer [Domain] EX-101.PRE 9 axdx-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Nov. 10, 2022
Cover [Abstract]    
Document Type 10-Q/A  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-31822  
Entity Registrant Name ACCELERATE DIAGNOSTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-1072256  
Entity Address, Address Line One 3950 South Country Club Road,  
Entity Address, Address Line Two Suite 470  
Entity Address, City or Town Tucson,  
Entity Address, State or Province AZ  
Entity Address, Postal Zip Code 85714  
City Area Code 520  
Local Phone Number 365-3100  
Title of 12(b) Security Common Stock, $0.001 par  
Trading Symbol AXDX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   99,099,480
Amendment Description In this Amendment No. 1 to the Quarterly Report on Form 10-Q (this “Form 10-Q/A”), all references to “we” or “us” or “our” or “Accelerate” or the “Company” refer to Accelerate Diagnostics, Inc. and its consolidated subsidiaries.    Restatement OverviewOn February 6, 2023, the Audit Committee of the Company’s Board of Directors (the “Board”), in consultation with members of the Company’s management, determined that the Company’s previously issued interim unaudited financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022 (collectively, the “2022 Interim Financial Statements”), should no longer be relied upon due to the error in the balance sheet classification of the Company’s 2.50% Senior Convertible Notes due 2023 (the “Notes”) described below. For additional information, please refer to our Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 9, 2023.This Form 10-Q/A amends and restates certain items noted below in the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2022, as originally filed with the SEC on November 14, 2022 (the “Original Filing”). Except as described below, no other material changes have been made to the Original Filing. Unless otherwise noted, this Form 10-Q/A speaks as of the date of the Original Filing and does not reflect other events that may have occurred after the date of the Original Filing or modify or update any disclosures that may have been affected by subsequent events. Accordingly, this Form 10-Q/A should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, including any amendment to those filings.Background of RestatementIn March and April 2018, the Company issued $171.5 million aggregate principal amount of Notes, which have a maturity date of March 15, 2023, unless earlier converted or repurchased. Between September 2021 and August 2022, the Company entered into certain exchange transactions pursuant to which the Company exchanged $114.9 million aggregate principal amount of Notes for one or a combination of: shares of the Company’s common stock, a secured promissory note and/or warrants to purchase the Company’s common stock. As of the date of the filing of this Form 10-Q/A, $56.6 million aggregate principal amount of Notes remain outstanding.The balance sheets contained in each of the 2022 Interim Financial Statements classified the Notes as a non-current liability with a net carrying amount of $115.8 million, $105.8 million and $56.3 million as of March 31, 2022, June 30, 2022 and September 30, 2022, respectively. Pursuant to Accounting Standards Codification (“ASC”) 210-10-45, current classification is required for convertible debt if the settlement in cash is expected to occur within 12 months, subject to the issuer’s intent and ability to refinance the debt on a long-term basis pursuant to ASC 470-10-45. The identification of the error arose in connection with the Company’s year-end close for the year ended December 31, 2022, whereby the Company determined that, as of the respective balance sheet dates for each of the 2022 Interim Financial Statements, its intent to refinance the Notes on a long-term basis was not supported by an ability to consummate the refinancing of all or a portion of the Notes in accordance with ASC 470-10-45. Accordingly, the Notes (or a portion thereof, as applicable in the specific period) should have been classified as a current liability in the balance sheets contained in each of the 2022 Interim Financial Statements.The “as restated” classification of the Notes is further described and the impact of the restatement is included in Note 1 and Note 10 of the “Notes to the Condensed Consolidated Financial Statements” included in Part I, Item 1. “Financial Statements” of this Form 10-Q/A.Control ConsiderationsIn connection with the restatement, management concluded that there was a deficiency in our internal control over financial reporting that constituted a material weakness as of September 30, 2022. For a discussion of management's consideration of our disclosure controls and procedures and the material weakness identified, see Part I, Item 4, Controls and Procedures of this Form 10-Q/A.Items Amended in this FilingFor the convenience of the reader, this Form 10-Q/A sets forth the Original Filing, as amended, in its entirety; however, this Form 10-Q/A amends and restates only the following Items of the Original Filing to the extent necessary to reflect the adjustments discussed above and to make corresponding adjustments to the Company’s financial data and disclosures cited elsewhere in this Form 10-Q/A:-Part I, Item 1 - Financial Statements-Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations-Part I, Item 4 - Controls and Procedures-Part II, Item 6 - ExhibitsIn addition, in connection with the preparation of this Form 10-Q/A, the Company has evaluated its financial condition as of the date of filing this Form 10-Q/A. Based on this evaluation, the Company has determined that there is substantial doubt about its ability to continue as a going concern as of the date of the filing of this Form 10-Q/A, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A. The assessment of going concern is further discussed in Note 1 of the “Notes to the Condensed Consolidated Financial Statements” included in Part I, Item 1. “Financial Statements” of this Form 10-Q/A.Further, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing (Exhibits 31.1, 31.2 and 32), and the Company has provided its restated condensed consolidated financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibit 101.Restatement of Other Financial StatementsIn addition to the restated financial information for the quarter ended September 30, 2022 included in this Form 10-Q/A, we are also restating our interim condensed consolidated financial statements and related disclosures for the quarters ended March 31, 2022 and June 30, 2022. Concurrently with the filing of this Form 10-Q/A, we are filing amended Quarterly Reports on Form 10-Q with the SEC with respect to these periods to address the error in the balance sheet classification of the Notes described above.  
Entity Central Index Key 0000727207  
Amendment Flag true  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Document Information [Line Items]    
Title of 12(b) Security Common Stock, $0.001 par  
Trading Symbol AXDX  
Security Exchange Name NASDAQ  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 38,987 $ 39,898
Investments 16,407 23,720
Trade accounts receivable, net 2,393 2,320
Inventory 5,392 5,067
Prepaid expenses 1,119 768
Other current assets 1,974 1,558
Total current assets 66,272 73,331
Property and equipment, net 3,621 5,389
Finance lease assets, net 2,319 0
Operating lease right of use assets, net 2,012 2,510
Other non-current assets 1,623 1,817
Total assets 75,847 83,047
Current liabilities:    
Accounts payable 2,819 1,983
Accrued liabilities 4,491 2,853
Accrued interest 118 909
Deferred revenue 524 451
Current portion of convertible notes 56,325 0
Current portion of long-term debt 80 80
Finance lease, current 953 0
Operating lease, current 774 669
Total current liabilities 66,084 6,945
Finance lease, non-current 698 0
Operating lease, non-current 1,775 2,381
Other non-current liabilities 759 808
Accrued interest related-party 220 0
Long-term debt related-party 16,299 0
Convertible notes 0 107,984
Total liabilities 85,835 118,118
Commitments and contingencies
Stockholders’ deficit:    
Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and 3,954,546 outstanding as of September 30, 2022 and December 31, 2021 4 4
Common stock, $0.001 par value; 200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021 97 68
Contributed capital 627,853 580,652
Treasury stock (45,067) (45,067)
Accumulated deficit (592,630) (570,668)
Accumulated other comprehensive loss (245) (60)
Total stockholders’ deficit (9,988) (35,071)
Total liabilities and stockholders’ deficit $ 75,847 $ 83,047
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred Stock, par value (in usd per share) $ 0.001 $ 0.001
Preferred Stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred Stock, shares outstanding (in shares) 3,954,546 3,954,546
Common Stock, par value (in usd per share) $ 0.001 $ 0.001
Common Stock, shares authorized (in shares) 200,000,000 100,000,000
Common Stock, shares issued (in shares) 97,240,983 67,649,018
Common Stock, shares outstanding (in shares) 97,240,983 67,649,018
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net sales $ 2,960,000 $ 3,122,000 $ 9,780,000 $ 8,439,000
Cost of sales 2,381,000 2,136,000 7,318,000 5,502,000
Gross profit 579,000 986,000 2,462,000 2,937,000
Costs and expenses:        
Research and development 7,285,000 4,712,000 20,885,000 17,341,000
Sales, general and administrative 8,255,000 10,806,000 30,422,000 37,744,000
Total costs and expenses 15,540,000 15,518,000 51,307,000 55,085,000
Loss from operations (14,961,000) (14,532,000) (48,845,000) (52,148,000)
Other (expense) income:        
Interest expense (203,000) (4,211,000) (1,833,000) (12,477,000)
Interest expense related-party (495,000) 0 (495,000) 0
Gain on extinguishment of debt 0 9,840,000 3,565,000 9,840,000
Foreign currency exchange loss (261,000) (78,000) (221,000) (238,000)
Interest income 73,000 0 151,000 55,000
Other (expense) income, net (49,000) (5,000) (206,000) 69,000
Total other (expense) income, net (935,000) 5,546,000 961,000 (2,751,000)
Net loss before income taxes (15,896,000) (8,986,000) (47,884,000) (54,899,000)
Provision for income taxes 0 0 0 0
Net loss $ (15,896,000) $ (8,986,000) $ (47,884,000) $ (54,899,000)
Basic net loss per share (in usd per share) $ (0.18) $ (0.15) $ (0.62) $ (0.91)
Diluted net loss per share (in usd per share) $ (0.18) $ (0.15) $ (0.62) $ (0.91)
Weighted average shares outstanding, basic (in shares) 87,011 61,146 77,049 60,250
Weighted average shares outstanding, diluted (in shares) 87,011 61,146 77,049 60,250
Other comprehensive loss:        
Net loss $ (15,896,000) $ (8,986,000) $ (47,884,000) $ (54,899,000)
Net unrealized gain (loss) on debt securities available-for-sale 48,000 (3,000) (84,000) (21,000)
Foreign currency translation adjustment 139,000 (27,000) (101,000) (87,000)
Comprehensive loss $ (15,709,000) $ (9,016,000) $ (48,069,000) $ (55,007,000)
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (47,884) $ (54,899)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,207 1,875
Amortization of investment discount 94 153
Equity-based compensation 8,179 19,058
Amortization of debt discount and issuance costs 386 9,250
Amortization of debt discount related-party 275 0
Loss (gain) on disposal of property and equipment 74 (202)
Unrealized loss (gain) on equity investments 206 (39)
Gain on extinguishment of debt (3,565) (9,840)
(Increase) decrease in assets:    
Contributions to deferred compensation plan (174) (304)
Accounts receivable (73) (719)
Inventory (245) (527)
Prepaid expense and other (491) 860
Increase (decrease) in liabilities:    
Accounts payable 1,221 1,017
Accrued liabilities and other 1,153 (436)
Accrued interest (785) (1,059)
Accrued interest from related-party 220 0
Deferred revenue and income 73 93
Deferred compensation (49) 343
Net cash used in operating activities (39,178) (35,376)
Cash flows from investing activities:    
Purchases of equipment (446) (202)
Purchase of marketable securities (27,506) (22,345)
Maturities of marketable securities 34,527 33,601
Net cash provided by investing activities 6,575 11,054
Cash flows from financing activities:    
Proceeds from issuance of common stock 32,872 22,640
Payments on finance leases (1,109) 0
Proceeds from exercise of options 7 1,456
Proceeds from issuance of common stocks under employee purchase plan 184 245
Transaction costs related to debt exchange (192) 0
Payment of debt (6) (6)
Net cash provided by financing activities 31,756 24,335
Effect of exchange rate on cash (64) (69)
Decrease in cash and cash equivalents (911) (56)
Cash and cash equivalents, beginning of period 39,898 35,781
Cash and cash equivalents, end of period 38,987 35,725
Non-cash investing activities:    
Net transfer of instruments (to) from inventory to property and equipment (78) 508
Non-cash financing activities:    
Extinguishment of convertible senior notes through issuance of common stock 10,180 34,545
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,624 0
Fair value of new note from related-party issued in connection with the exchange transaction 16,024 0
Fair value of common stock warrant issued to related-party in connection with exchange transaction 3,753 0
Capital contribution from related-party in connection with the exchange transaction 29,847 0
Supplemental cash flow information:    
Interest paid $ 2,214 $ 4,288
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
$ in Thousands
Total
Preferred stock
Common stock
Contributed capital
Contributed capital
Cumulative effect of accounting changes
Accumulated deficit
Accumulated deficit
Cumulative effect of accounting changes
Treasury stock
Accumulated other comprehensive (loss) income
Beginning Balance (in shares) at Dec. 31, 2020   0              
Beginning Balance (in shares) at Dec. 31, 2020     57,608,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)   2,636,000 2,937,000            
Ending Balance (in shares) at Sep. 30, 2021   2,636,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     1,052,000            
Issuance of common stock under employee purchase plan (in shares)     37,000            
Rescission of common stock (in shares)     (2,643,000)            
Issuance of shares to retire Convertible Senior Notes (in shares)     5,946,000            
Ending Balance (in shares) at Sep. 30, 2021     64,937,000            
Beginning Balance, amount at Dec. 31, 2020   $ 0 $ 58 $ 475,072   $ (492,966)   $ (45,067) $ 91
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock   3 3 22,637          
Restricted stock awards released and exercise of options     1 1,455          
Rescission of common stock     (3)            
Issuance of common stock under employee purchase plan       245          
Issuance of shares to retire convertible notes     6 34,539          
Equity-based compensation       19,186          
Net loss $ (54,899)         (54,899)      
Net unrealized gain (loss) on debt securities available-for-sale (21)               (21)
Foreign currency translation adjustment (87)               (87)
Ending Balance, amount at Sep. 30, 2021 (39,747) $ 3 $ 65 553,134   (547,865)   (45,067) (17)
Beginning Balance (in shares) at Jun. 30, 2021   0              
Beginning Balance (in shares) at Jun. 30, 2021     61,489,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)   2,636,000 67,000            
Ending Balance (in shares) at Sep. 30, 2021   2,636,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     62,000            
Issuance of common stock under employee purchase plan (in shares)     16,000            
Rescission of common stock (in shares)     (2,643,000)            
Issuance of shares to retire Convertible Senior Notes (in shares)     5,946,000            
Ending Balance (in shares) at Sep. 30, 2021     64,937,000            
Beginning Balance, amount at Jun. 30, 2021   $ 0 $ 61 514,122   (538,879)   (45,067) 13
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock   3 1 517          
Restricted stock awards released and exercise of options       234          
Rescission of common stock     (3)            
Issuance of common stock under employee purchase plan       84          
Issuance of shares to retire convertible notes     6 34,539          
Equity-based compensation       3,638          
Net loss (8,986)         (8,986)      
Net unrealized gain (loss) on debt securities available-for-sale (3)               (3)
Foreign currency translation adjustment (27)               (27)
Ending Balance, amount at Sep. 30, 2021 $ (39,747) $ 3 $ 65 553,134   (547,865)   (45,067) (17)
Beginning Balance (in shares) at Dec. 31, 2021 3,954,546 3,955,000              
Beginning Balance (in shares) at Dec. 31, 2021 67,649,018   67,649,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)     17,500,000            
Ending Balance (in shares) at Sep. 30, 2022 3,954,546 3,955,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     1,134,000            
Issuance of common stock under employee purchase plan (in shares)     159,000            
Issuance of shares to retire Convertible Senior Notes (in shares)     10,799,000            
Ending Balance (in shares) at Sep. 30, 2022 97,240,983   97,241,000            
Beginning Balance, amount at Dec. 31, 2021 $ (35,071) $ 4 $ 68 580,652 $ (37,438) (570,668) $ 25,922 (45,067) (60)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock     17 32,855          
Restricted stock awards released and exercise of options     1 6          
Issuance of common stock under employee purchase plan       184          
Issuance of shares to retire convertible notes     11 10,169          
Capital contribution from related-party in connection with exchange transaction       29,847          
Warrant issued to related-party       3,753          
Equity-based compensation       7,825          
Net loss (47,884)         (47,884)      
Net unrealized gain (loss) on debt securities available-for-sale (84)               (84)
Foreign currency translation adjustment (101)               (101)
Ending Balance, amount at Sep. 30, 2022 $ (9,988) $ 4 $ 97 627,853   (592,630)   (45,067) (245)
Beginning Balance (in shares) at Jun. 30, 2022   3,955,000              
Beginning Balance (in shares) at Jun. 30, 2022     79,701,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)     17,500,000            
Ending Balance (in shares) at Sep. 30, 2022 3,954,546 3,955,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     6,000            
Issuance of common stock under employee purchase plan (in shares)     34,000            
Ending Balance (in shares) at Sep. 30, 2022 97,240,983   97,241,000            
Beginning Balance, amount at Jun. 30, 2022   $ 4 $ 80 560,185   (576,734)   (45,067) (432)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock     17 32,855          
Issuance of common stock under employee purchase plan       47          
Capital contribution from related-party in connection with exchange transaction       29,847          
Warrant issued to related-party       3,753          
Equity-based compensation       1,166          
Net loss $ (15,896)         (15,896)      
Net unrealized gain (loss) on debt securities available-for-sale 48               48
Foreign currency translation adjustment 139               139
Ending Balance, amount at Sep. 30, 2022 $ (9,988) $ 4 $ 97 $ 627,853   $ (592,630)   $ (45,067) $ (245)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.

The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.

Restatement of Previously Issued Financial Statements

Background on the restatement

The Company’s previously issued interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022 classified its 2.50% Senior Convertible Notes due 2023 (the “Notes”) as a non-current liability with a net carrying amount of $56.3 million as of September 30, 2022. Pursuant to Accounting Standards Codification (“ASC”) 210-10-45, Balance Sheet, the Notes should have been classified as a current liability in the balance sheet as of September 30, 2022. In addition, the Company recorded an adjustment to correct a previously identified immaterial error related to the Company’s warranty obligations as of and for the three and nine months ended September 30, 2022.
Effect of the restatement

The effects of the correction of the prior-period misstatements on our Condensed Consolidated Balance Sheet relating to the Notes are reflected in the table below (in thousands). The Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Cash Flows, and the Condensed Consolidated Statements of Stockholders’ Equity were also corrected for the other previously identified immaterial error as reflected in the tables below (in thousands).

September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Accrued liabilities4,300 191 4,491 
Current portion of convertible notes— 56,325 56,325 
Total current liabilities9,568 56,516 66,084 
Convertible notes56,325 (56,325)— 
Total liabilities85,644 191 85,835 
Accumulated deficit ending balance(592,439)(191)(592,630)
Total stockholders’ deficit ending balance(9,797)(191)(9,988)

Three Months Ended
September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cost of sales2,190 191 2,381 
Gross profit770 (191)579 
Loss from operations(14,770)(191)(14,961)
Net loss before income taxes(15,705)(191)(15,896)
Net loss(15,705)(191)(15,896)
Comprehensive loss(15,518)(191)(15,709)

Nine Months Ended
September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cost of sales7,127 191 7,318 
Gross profit2,653 (191)2,462 
Loss from operations(48,654)(191)(48,845)
Net loss before income taxes(47,693)(191)(47,884)
Net loss(47,693)(191)(47,884)
Comprehensive loss(47,878)(191)(48,069)

Total net cash used in operating activities was not impacted by the error corrections.

In addition to correcting the consolidated financial statements, related revisions and updates have been made to “Liquidity & Going Concern (As Restated)”, Warranty Reserve (As Restated) and Note 10, Convertible Notes (As Restated).
Liquidity & Going Concern (As Restated)

Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company’s accumulated deficit totaled $592.6 million as of September 30, 2022. For the three and nine months ended September 30, 2022, the Company had net losses of approximately $15.9 million and $47.9 million, respectively, and had negative cash flows from operations of approximately $39.2 million for the nine months ended September 30, 2022. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises and the issuance of debt (see Note 9, Long-Term Debt, Note 10, Convertible Notes and Note 18, Stockholders' Equity for additional details).

At September 30, 2022, the Company held cash, cash equivalents, and marketable securities of $55.4 million and current liabilities of $66.1 million, including $56.3 million of Notes due on March 15, 2023. Based on its evaluation pursuant to ASC 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, the Company has determined that, as of the date of this Form 10-Q/A filing, there is substantial doubt about its ability to continue as a going concern, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A.

While the Company continues to explore additional funding in the form of potential equity and/or debt financing arrangements or similar transactions, as well as non-cash means to settle or refinance the Notes, there can be no assurance the necessary financing will be available on terms acceptable to the Company, or at all. If the Company raises funds by issuing equity securities, dilution to stockholders may result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of common stock. If the Company raises funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of preferred and common stockholders. The terms of debt securities or borrowings could impose significant restrictions on our operations. Similarly, there can be no assurance that market conditions and refinancing alternatives will be sufficient to settle or refinance the Notes on or prior to their maturity on March 15, 2023. The capital markets have in the past, and may in the future, experience periods of upheaval that could impact the availability and cost of equity and debt financing. In addition, recent and anticipated future increases in federal fund rates set by the Federal Reserve, which serve as benchmark rates on borrowing, and other general economic conditions may impact the cost of debt financing or refinancing existing debt.

Although we are actively considering all available strategic alternatives to maximize value, if we are unable to obtain adequate capital resources to fund operations and address the upcoming maturity of the Notes, we would not be able to continue to operate our business pursuant to our current plans. This may require us to, among other things, materially modify our operations to reduce spending; sell assets or operations; delay the implementation of, or revising certain aspects of, our business strategy; file a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring; or discontinue our operations entirely.

The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.
Estimated Fair Value of Financial Instruments

The Company follows ASC 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.

The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.

The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and
the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.

See Note 6, Inventory, for further information and related disclosures.

Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.

The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$150 $213 140 445 
(Reversals) provisions, net
(12)78 18 114 
Write-offs
— (77)(20)(345)
$138 $214 $138 $214 

The write-offs recorded during the nine months ended September 30, 2021 were in connection with a one-time restructuring activity of the Company's Europe, Middle East and Africa (“EMEA”) business. These credit losses were incurred as part of the Company terminating agreements with select distributors in geographies it exited and did not pursue collection of these accounts receivables.
Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.

The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.

See Note 7, Property and Equipment, for further information and related disclosures.

Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.

Warranty Reserve (As Restated)

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.
Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
As Restated
As Restated
Beginning balance$255 $169 $139 $232 
Provisions (reversals), net
187 (31)325 (41)
Warranty cost incurred
(29)(17)(51)(70)
Ending balance$413 $121 $413 $121 

Convertible Notes

On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.

See Note 2, Recently Issued Accounting Pronouncements and Note 10, Convertible Notes, for further information and related disclosures.

Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.
Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.

Gross Profit and Gross Margin

Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.

The Company’s overall gross margin was 20% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 25% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.

Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Leases as Lessee

Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.
Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.

Leases as Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.

Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.

Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.

Equity-Based Compensation

The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

•Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.

•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.
The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.

The Company accounts for forfeitures as they occur rather than on an estimated basis.

The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.

See Note 13, Employee Equity-Based Compensation for further information.

Deferred Tax

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.

Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.

Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

See Note 12, Loss Per Share, for further information.
Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Recently Issued Accounting Pronouncements
 9 Months Ended
Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Pronouncements
NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Standards that were recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.

Standards not yet adopted

In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not
expect the update to have a material effect on our condensed consolidated financial statements.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Concentration of Credit Risk
 9 Months Ended
Sep. 30, 2022
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk
NOTE 3. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.

The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2022, three of the Company's financial institutions held 74%, 12% and 13% of the Company’s cash and cash equivalents. As of December 31, 2021, two of the Company's financial institutions held 72% and 13% of the Company’s cash and cash equivalents.

The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company had one customer that accounted for 16% and 13% of the Company’s net accounts receivable balance as of September 30, 2022 and December 31, 2021, respectively.

The Company did not have any customers that represented 10% or more of the Company’s total revenue for the three and nine months ended September 30, 2022 and 2021.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments
NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,145 $— $— $5,145 
Total cash and cash equivalents5,145 — — 5,145 
Equity investments:
Mutual funds808 — — 808 
Total equity investments808 — — 808 
Debt securities available-for-sale:
Certificates of deposit— 3,382 — 3,382 
U.S. Treasury securities5,228 — — 5,228 
Commercial paper— 2,893 — 2,893 
Corporate notes and bonds— 4,096 — 4,096 
Debt securities available-for-sale5,228 10,371 — 15,599 
Total assets measured at fair value$11,181 $10,371 $— $21,552 
December 31, 2021
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,563 $— $— $5,563 
Commercial paper— 200 — 200 
Total cash and cash equivalents5,563 200 — 5,763 
Equity investments:
Mutual funds841 — — 841 
Total equity investments841 — — 841 
Debt securities available-for-sale:
Certificates of deposit— 1,351 — 1,351 
U.S. Treasury securities250 — — 250 
Commercial paper— 8,046 — 8,046 
Corporate notes and bonds— 13,232 — 13,232 
Debt securities available-for-sale250 22,629 — 22,879 
Total assets measured at fair value$6,654 $22,829 $— $29,483 

Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

At September 30, 2022, the Notes had an outstanding principal amount of $56.6 million with a fair value of $51.7 million. At December 31, 2021, the Notes had an outstanding principal amount of $120.5 million with a fair value of $89.4 million. The fair value of the Notes represents a Level 2 measurement. The fair value of the Notes is typically correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. See Note 10, Convertible Notes for further detail on the Notes.

The Secured Note is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note.

The warrant is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the warrant on August 15, 2022 was $3.8 million. See Note 11, Long-Term Debt Related-Party for further detail on the Company’s warrant with a related-party.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments
NOTE 5. INVESTMENTS

The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$3,400 $— $(18)$3,382 
U.S. Treasury securities5,266 — (38)5,228 
Commercial paper2,901 — (8)2,893 
Corporate notes and bonds4,131 — (35)4,096 
Total$15,698 $— $(99)$15,599 

December 31, 2021
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$1,351 $— $— $1,351 
U.S. Treasury securities250 — — 250 
Commercial paper8,048 — (2)8,046 
Corporate notes and bonds13,245 — (13)13,232 
Total$22,894 $— $(15)$22,879 

The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022December 31, 2021
Amortized
Cost		Fair ValueAmortized
Cost		Fair Value
Due in less than 1 year$15,698 $15,599 $22,663 $22,649 
Due in 1-3 years— — 231 230 
Total
$15,698 $15,599 $22,894 $22,879 

There were no proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three and nine months ended September 30, 2022 and 2021. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2022 and 2021. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021. No unrealized losses on debt securities available-for-sale have been recognized in income for the three and nine months ended September 30, 2022 and 2021, as the issuers of such securities held by us were of high credit quality.

As of September 30, 2022, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%.

As of September 30, 2022 the Company did not carry any debt securities available-for-sale that were below the Company's minimum credit rating. All debt securities available-for-sale had a credit rating of A- or better as of September 30, 2022.

Equity securities are comprised of investments in mutual funds. The fair value of equity securities for each of the periods ended September 30, 2022 and December 31, 2021 was $0.8 million.
Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Unrealized (loss) gain on equity investments$(50)$(5)$(206)$39 

These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for each of the three and nine months ended September 30, 2022 and 2021.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Inventory
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory
NOTE 6. INVENTORY

Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Raw materials$1,769 $1,343 
Work in process2,133 1,625 
Finished goods1,490 2,099 
$5,392 $5,067 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Property and Equipment
 9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment
NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Computer equipment$3,866 $3,181 
Technical equipment3,259 3,285 
Facilities3,674 3,675 
Instruments3,594 5,364 
Capital projects in progress48 683 
Total property and equipment$14,441 $16,188 
Accumulated depreciation(10,820)(10,799)
Property and equipment, net$3,621 $5,389 

Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$381 $487 $1,284 $1,540 

Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):
September 30,December 31,
20222021
Instruments at cost under operating leases$2,452 $3,110 
Accumulated depreciation under operating leases(1,109)(1,165)
Net property and equipment under operating leases$1,343 $1,945 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Deferred Revenue and Remaining Performance Obligations
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Deferred Revenue and Remaining Performance Obligations
NOTE 8. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS

Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):

September 30,December 31,
20222021
Products and services not yet delivered$524 $451 

We recognized $0.2 million and $0.4 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2021, respectively. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.

Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2022, $9.0 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.

The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Long-Term Debt
NOTE 9. LONG-TERM DEBT

The Company entered into two loan agreements with one financing company in 2020. Loan proceeds were $0.2 million, with interest rates ranging from 9.8% to 12.4% and maturities becoming due through 2022.

As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):

September 30,December 31,
20222021
Loans - various interest$80 $80 
Current portion of long-term debt80 80 
Long-term debt$— $— 
The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):

Remainder of 2022$80 
2023— 
2024— 
2025— 
2026— 
Thereafter— 
Total$80 

Paycheck Protection Program (PPP) Loan

On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million made to the Company under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act.

On July 15, 2021, the Small Business Administration (“SBA”) informed the Company of its full forgiveness for the entire PPP Note amount plus accrued interest, which was $4.8 million as of the date of forgiveness. The SBA’s determination of loan forgiveness does not preclude further investigation by the SBA according to its rules and regulations. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of the entire PPP Note amount of $4.8 million during the three and nine months ended September 30, 2021.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Notes
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Convertible Notes
NOTE 10. CONVERTIBLE NOTES (As Restated)

The Notes are the Company’s senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, pursuant to the terms and conditions of the Notes. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The Company’s Notes have a fixed coupon rate of 2.5% per annum on the principal amount.

The Company incurred issuance costs related to the issuance of the Notes which is amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par was 3.2%.

The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:

•if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;

•during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or

•the occurrence of certain corporate events, such as a change of control, merger or liquidation.

At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the
Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of September 30, 2022 and December 31, 2021, no Notes were convertible pursuant to their original terms.

Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 

Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Gain on extinguishment$— $4,999 $3,565 $4,999 

The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 

As of September 30, 2022 the Notes consisted of the following (in thousands):

September 30,
2022
(As Restated)
Current portion of convertible notes$56,325 
Non-current portion of convertible notes— 
Total convertible notes$56,325 

In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its
counterparty to a major financial institution.

2021 Exchange Transactions

In September 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by them for shares of the Company’s common stock (the “2021 Exchange Transactions”). During the nine months ended September 30, 2021, such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock. The net carrying value of the Notes exchanged was $40.4 million which the Company repurchased for $34.5 million of common stock. The Company also incurred $0.8 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. The 2021 Exchange Transaction resulted in a net gain of $5.0 million reflected in other income (expense), net for the three and nine months ended September 30, 2021. See Note 18, Stockholders' Equity for additional information.

March 2022 Exchange Transaction

On March 21, 2022, the Company entered into a privately negotiated exchange agreement (the “March 2022 Exchange Agreement”) with a holder of the Notes. Under the terms of the March 2022 Exchange Agreement, the note holder agreed to exchange with the Company $14.0 million in aggregate principal amount of Notes held by it in eight equal tranches as follows for each tranche: (a) 22.64 shares per $1,000 principal amount of Notes exchanged, plus (b) an additional number of shares of the Company’s common stock per $1,000 principal amount of Notes exchanged equal to the sum, for each of the trading days during a separate agreed upon reference period for each tranche commencing on March 21, 2022 for the first tranche, of the quotient of (i) $155.67 divided by (ii) the daily volume-weighted average price for such trading day (collectively, the “March 2022 Exchange Transaction”). The closing of the March 2022 Exchange Transaction occurred in eight tranches (“Obligation to Exchange”), with the first closing occurring on March 29, 2022 and the last closing on May 18, 2022.

On March 21, 2022 the Obligation to Exchange the $14.0 million of Notes in the March 2022 Exchange Transaction was accounted for as an extinguishment and was replaced by new notes with an embedded feature (the “New Notes”). The New Notes were elected to be carried using the fair value option. The New Notes were recorded at fair value on initial measurement and remeasured at fair value (“mark to market”) at each reporting period with changes in fair value reported in other income and expense, net. This fair value election was exclusive to the New Notes and did not extend to other Notes. The embedded feature was no longer outstanding on September 30, 2022 as the New Notes were exchanged and the Obligation to Exchange retired on May 18, 2022.

During the nine months ended September 30, 2022 the holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company’s common stock pursuant to the March 2022 Exchange Agreement. The net carrying value of the Notes exchanged was $14.0 million which the Company repurchased for $10.2 million of common stock. The Company also incurred $0.2 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. This exchange transaction resulted in a net gain of $3.6 million reflected in other income (expense), net for the nine months ended September 30, 2022. See Note 18, Stockholders' Equity for additional information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”), as discussed in Note 11, Long-Term Debt Related-Party. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. The difference between the fair values of the new instruments and the net carrying amount of the Notes being extinguished was included in the calculation of gain. The gain from the extinguishment of the Notes was treated as a capital transaction. The Secured Note includes various features that were advantageous to the Company, including a lower interest rate compared to current market rates and a share conversion feature. There were no other negotiating parties that had similar terms or economic outcomes. As such, the exchange was considered not to be an arm’s length transaction, and therefore the resulting gain was accounted
for as a capital transaction. The net carrying amount of the extinguished Notes was $49.6 million. The estimated fair value of the Secured Note and the Warrant on August 15, 2022 was $16.0 million and $3.8 million, respectively, which resulted in a net gain of $29.8 million that was recorded to contributed capital. See Note 18, Stockholders' Equity and Note 11, Long-Term Debt Related-Party for additional information.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt Related-Party
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Long-Term Debt Related-Party
NOTE 11. LONG-TERM DEBT RELATED-PARTY

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust, a holder of the Notes. Jack Schuler, who serves as a member of the Company’s board of directors, is the sole trustee of the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a Warrant to acquire the Company’s common stock at an exercise price of $2.12 per share (the “Warrant”).

The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. See Note 10, Convertible Notes for additional information. The Secured Notes is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. To estimate the Secured Note’s fair value, the Company applied a Monte Carlo simulation which simulated the share price of the Company over the remaining term to the maturity date of the Secured Note. The simulated per-share price in a given iteration determined if the Company settled in cash or shares. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. This valuation estimated an issuance discount of $18.9 million. The effective interest rate on the Secured Note is 24.60%.

The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 

Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 
Warrant

The Warrant may be exercised from February 15, 2023 through the earlier of (i) August 15, 2029 and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in the Warrant. The Warrant is exercisable for up to 2,471,710 shares of common stock. The Warrant meets the criteria for classification in stockholders’ equity and was recorded in equity and initially measured at fair value. The Warrant was measured at fair value on a non-recurring basis using Level 3 inputs. The fair value of the warrant on August 15, 2022 was $3.8 million.

The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:

Contractual term (in years)
7.0
Volatility76.10 %
Expected dividends— 
Risk free interest rates2.86 %
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Loss Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Loss Per Share
NOTE 12. LOSS PER SHARE

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Shares issuable upon the release of RSUs4,619 2,320 4,619 2,320 
Shares issuable upon exercise of stock options5,665 7,634 5,665 7,634 
Shares issuable upon the exercise of the Warrant2,472 — 2,472 — 
12,756 9,954 12,756 9,954 

Potentially dilutive common shares would include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 10, Convertible Notes, upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock. As of September 30, 2022, no Notes were convertible pursuant to the original terms. The number of shares of common stock issuable upon conversion of the outstanding Notes based on the initial conversion rate was approximately 1,830,441 shares as of September 30, 2022. Historically the Company has engaged in privately negotiated exchanges of Notes for a substantially greater number of shares than the initial conversion rate of the Notes described above because the Company’s stock price at the time of such exchanges was significantly less than the $30.92 initial conversion price of the Notes.

In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for
corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.

Potentially dilutive common shares include common shares that would be outstanding if Series A Preferred Stock were converted into common stock. Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock. Additionally, each share of Series A Preferred Stock will automatically be converted into one share of the Company’s common stock immediately upon a sale of all outstanding stock of the Company or a merger of the Company into another corporation where the pre-merger Company’s stockholders cease to be the controlling stockholders of the post-merger corporation. The number of shares of common stock issuable upon conversion of the Series A Preferred Stock is 3,954,546 as of September 30, 2022.

As discussed in Note 18, Stockholders' Equity, the Company entered into a securities purchase agreement with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock. The closing of the transaction is expected to occur on December 30, 2022, subject to the satisfaction of customary closing conditions and is considered an equity forward agreement. The shares to be issued from this agreement were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.

As discussed in Note 11, Long-Term Debt Related-Party, the Company may, at its option, repay the Secured Note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The number of shares of common stock issuable upon conversion of the Secured Note and accrued interest was approximately 16,478,066 and 103,834 shares respectively, as of September 30, 2022. The shares issuable in connection with a repayment of the Secured Note were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Employee Equity-Based Compensation
NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION

The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:

Number of SharesWeighted Average Exercise Price per Share
Options outstanding January 1, 20227,192,540 $13.89 
Granted140,000 3.05 
Forfeited(204,232)12.49 
Exercised(6,105)1.04 
Expired(1,457,019)10.33 
Options outstanding September 30, 20225,665,184 $14.60 

No stock options were granted during the three months ended September 30, 2022 and 2021.
The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:

Options
Outstanding		Options
Exercisable
Number of options5,665,184 4,422,595 
Weighted average remaining contractual term (in years)5.545.04
Weighted average exercise price$14.60 $15.32 
Weighted average fair value$9.10 $9.44 
Aggregate intrinsic value (in thousands)$— $— 

The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 20222,090,182 $10.77 
Granted4,107,083 1.55 
Forfeited(451,703)8.68 
Released(1,127,017)3.43 
Outstanding September 30, 20224,618,545 $4.57 

The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of sales$167 $82 $570 $257 
Research and development151 266 1,052 4,340 
Sales, general and administrative911 3,281 6,557 14,461 
$1,229 $3,629 $8,179 $19,058 

The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost capitalized to inventory
$69 $77 $186 $319 

As of September 30, 2022, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $2.3 million and $7.8 million, respectively. This is expected to be recognized over the years 2022 through 2027.

Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based
options issued under the Company's equity incentive plans. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted 105,000 performance-based stock options. Of these performance-based stock options, performance obligations had been met for 90,000 options which became exercisable in a prior period. Of these performance-based stock options, 90,000 options expired during the nine months ended September 30, 2022. No performance-based stock options were outstanding as of September 30, 2022.

The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based stock option expense
$— $230 

Included in the above-noted RSU and restricted stock award outstanding amounts are performance-based RSUs which vest only upon the achievement of certain targets. Performance-based RSUs contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted performance-based RSUs of which 165,974 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.

During 2021, the Company granted performance-based RSUs of which 111,806 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.

The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based RSU expense
$— $818 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes
NOTE 14. INCOME TAXES

For the nine months ended September 30, 2022, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2022 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $47.9 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions due to the valuation allowance. At September 30, 2022, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.

The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2022, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments
NOTE 15. COMMITMENTS

During April 2022, the Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of $11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. This commitment was entered into to ensure proper material quantities to develop and commercialize our next generation AST platform.

As of September 30, 2022 the commitment remains $11.9 million as the Company has not taken delivery of any inventory.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Leases
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases
NOTE 16. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 

The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%.

The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 
The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):

Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 
Leases
NOTE 16. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 

The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%.

The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 
The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):

Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Geographic and Revenue Disaggregation
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Geographic and Revenue Disaggregation
NOTE 17. GEOGRAPHIC AND REVENUE DISAGGREGATION

The Company operates as one operating segment. Sales to customers outside the U.S. represented 14% and 8% for the three months ended September 30, 2022 and 2021, respectively, and 14% and 12% for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022 and December 31, 2021, balances due from foreign customers, in U.S. dollars, were $0.6 million and $0.7 million, respectively.

The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Domestic$2,551 $2,874 $8,390 $7,406 
Foreign409 248 1,390 1,033 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accelerate Pheno revenue
$2,933 $3,084 $9,669 $8,324 
Other revenue27 38 111 115 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Products$2,532 $2,773 $8,554 $7,474 
Services428 349 1,226 965 
$2,960 $3,122 $9,780 $8,439 
Lease revenue included in net sales was $0.2 million and $0.5 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million for each of the nine months ended September 30, 2022 and 2021.

The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20222021
Domestic$3,383 $5,014 
Foreign238 375 
$3,621 $5,389 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholders' Equity
NOTE 18. STOCKHOLDERS' EQUITY

December 2020 Securities Purchase Agreement

During December 2020, the Company entered into a securities purchase agreement (the “December 2020 Securities Purchase Agreement”) with Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips, or entities affiliated with such persons (collectively, the “Original Purchasers”), for the issuance and sale by the Company of an aggregate of 4,166,663 shares of the Company’s common stock. Each of Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips is a member of the Company’s board of directors. Mr. Phillips also serves as the Company’s President and Chief Executive Officer.

The Schuler Trust, which was the entity affiliated with Jack W. Schuler that originally entered into the December 2020 Securities Purchase Agreement for the purchase of 3,964,843 shares for an aggregate purchase price of approximately $30.5 million, subsequently entered into an assignment and assumption agreement whereby it assigned all of its rights and obligations as an Original Purchaser to three other entities under the December 2020 Securities Purchase Agreement (collectively, the “Schuler Purchasers”). These three entities are related to Jack W. Schuler but are not affiliates of his.

Pursuant to the December 2020 Securities Purchase Agreement, the Original Purchasers agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $7.68 per share, for an aggregate purchase price of approximately $32 million.

The December 2020 Securities Purchase Agreement contemplated that the closing of the purchase and sale of the shares would occur in three tranches, with the first and second tranches having closed on February 19, 2021 and April 9, 2021, respectively, whereby the Company received total proceeds of approximately $21.3 million which were recorded to contributed capital.

On September 17, 2021, the Company entered into a rescission agreement (the “Rescission Agreement”) with the Schuler Purchasers and the Schuler Trust pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 shares in the first two tranche closings and the third tranche (as discussed below) under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The 2,643,228 Shares re-acquired by the Company from the Schuler Purchasers as a result of the Rescission Agreement were treated as a reduction to contributed capital and were not outstanding for purposes of the calculation of basic and diluted earnings per share.

On September 30, 2021, the Company closed the final third tranche in connection with the December 2020 Securities Purchase Agreement and received total proceeds of approximately $0.5 million. In accordance with the Rescission Agreement, the Schuler Purchasers did not participate in the third tranche. During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement, which were recorded to contributed capital, after giving effect to the Rescission Agreement.
September 2021 Securities Purchase Agreement

During September 2021, the Company entered into a new securities purchase agreement (the “September 2021 Securities Purchase Agreement”) with the Schuler Purchasers for the issuance and sale by the Company of an aggregate of 3,954,546 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Shares”). Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock.

Pursuant to the September 2021 Securities Purchase Agreement, the Schuler Purchasers agreed to purchase the Series A Preferred Shares at a purchase price of $7.70 per share for an aggregate purchase price of approximately $30.5 million.

The September 2021 Securities Purchase Agreement contemplated the closing of the purchase and sale of the Series A Preferred Shares would occur in two tranches. The first tranche closed on the date of the execution of the September 2021 Securities Purchase Agreement whereby an aggregate of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Purchasers. The Company received total proceeds of approximately $20.3 million, which was recorded to contributed capital during the three months ended September 30, 2021.

The second tranche (the “Tranche Right”) had not closed by September 30, 2021 and was concluded to be an obligation of the Schuler Purchasers to acquire, and the Company to sell an additional 1,318,182 Series A Preferred Shares at a purchase price of $7.70 per share for proceeds of $10.2 million, subsequent to the September 30, 2021 balance sheet date. The Company concluded the Tranche Right met the definition of a freestanding financial instrument which was recorded within stockholder’s equity. The value of this Tranche Right as September 30, 2021 was $2.5 million. The estimated fair value of the Tranche Right represented a Level 3 measurement as this financial instrument has no market activity. The estimated fair value of the Tranche Right was determined as the excess value of the forward contract when compared to the underlying asset. The fair value of this forward contract can be represented by the difference between the contractual forward price of $7.70 and the prevailing exchange-traded common stock price ($5.81 at September 22, 2021 and $5.83 at September 30, 2021), multiplied by 1,318,182 Series A Preferred Shares. On October 29, 2021, the Company closed the final second tranche in connection with the September 2021 Securities Purchase Agreement whereby the Company issued and sold an aggregate of 1,318,182 Series A Preferred Shares to the Schuler Purchasers and received total proceeds of approximately $10.2 million.

2021 Exchange Transactions

During the nine months ended September 30, 2021, certain holders of the Notes exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock pursuant to their respective exchange agreement. Using the closing stock price on September 22, 2021 of $5.81, the 5,945,718 shares of the Company’s common stock were determined to have a value of $34.5 million, which was recorded to contributed capital during the nine months ended September 30, 2021. See Note 10, Convertible Notes, for additional information.

March 2022 Exchange Transaction

During the nine months ended September 30, 2022, a holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company's common stock pursuant to the March 2022 Exchange Agreement. The 10,798,482 shares of the Company’s common stock were determined to have a value of $10.2 million, which was recorded to contributed capital during the nine months ended September 30, 2022. See Note 10, Convertible Notes for additional information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.
Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, for an aggregate purchase price of $4.0 million.

On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock. The gain from the extinguishment of the Notes was treated as a capital transaction. The net gain on extinguishment was $29.8 million during the three months ended months ended September 30, 2022, and was recorded to contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

The Warrant meets the criteria for classification in stockholders’ equity and was recorded in contributed capital at fair value of $3.8 million on August 15, 2022.

August 2022 Public Offering

On August 23, 2022, the Company completed a public offering 17,500,000 shares of its common stock at a public offering price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions
NOTE 19. RELATED-PARTY TRANSACTIONS

2021 Exchange Transactions

As discussed in Note 10, Convertible Notes, the Company carries Notes. The Schuler Family Foundation (the “Foundation”) previously held an aggregate of $42.0 million of the Notes. Jack W. Schuler, a member of the Company’s board of directors, is the President of the Foundation.

During the three months ended September 30, 2021, the Foundation transferred by gift the $42.0 million aggregate principal amount of Notes held by the Foundation to the Schuler Initiative Supporting Charitable Trust (the “Supporting Organization”), a tax-exempt organization that is not an affiliate of Jack W. Schuler.

In connection with the 2021 Exchange Transactions the Supporting Organization exchanged $42.0 million in aggregate principal amount of Notes held by it for 5,428,699 shares of the Company's common stock. Using the closing stock price on September 22, 2021 of $5.81, the 5,428,699 shares of the Company's common stock were determined to have a value of $31.5 million which was recorded to contributed capital for the three months ended September 30, 2021. The Supporting Organization had the same or similar terms as the other counter parties. The Company determined the 2021 Exchange Transactions did not meet the criteria of a capital transaction and was recorded as a gain on extinguishment of debt. See Note 10, Convertible Notes and Note 18, Stockholders' Equity, for additional information.

December 2020 Securities Purchase Agreement

On December 24, 2020, the Company entered into the December 2020 Securities Purchase Agreement with the Original Purchasers for the issuance and sale by the Company of 4,166,663 shares of the Company’s common stock. The Original Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons. See Note 18, Stockholders' Equity, for further information.

On September 17, 2021, the Company entered into the Rescission Agreement with the Schuler Purchasers and the Schuler Trust, an entity affiliated with Jack W. Schuler, pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase
Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 Shares in the first two tranche closings and the third tranche under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. See Note 18, Stockholders' Equity, for further information.

During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement after giving effect to the Rescission Agreement.

September 2021 Securities Purchase Agreement

On September 22, 2021, the Company entered into the September 2021 Securities Purchase Agreement with the Schuler Purchasers for the issuance and sale by the Company of 3,954,546 Series A Preferred Shares. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his.

During the nine months ended September 30, 2021, the Company issued 2,636,364 Series A Preferred Shares and received total proceeds of approximately $20.3 million under the September 2021 Securities Purchase Agreement. See Note 18, Stockholders' Equity, for further information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into the March 2022 Securities Purchase Agreement with the Schuler Trust for the issuance and sale by the Company of 2,439,024 shares of the Company’s common stock. Jack Schuler serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust. See Note 18, Stockholders’ Equity, for further information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for the Secured Note in an aggregate principal amount of $34.9 million and a warrant to acquire the Company’s common stock. The net gain on extinguishment was $29.8 million during the nine months ended September 30, 2022, and was recorded as contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.

The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Principles of Consolidation
Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.
Use of Estimates
Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.
Estimated Fair Value of Financial Instruments
Estimated Fair Value of Financial Instruments

The Company follows ASC 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.

The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.
The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant.
Cash and Cash Equivalents
Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
Investments
Investments

The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and
the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.
Inventory
Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.
Accounts Receivable
Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.
Property and Equipment
Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.

The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.
Long-lived Assets
Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
Warranty Reserve
Warranty Reserve (As Restated)

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.
Convertible Notes
Convertible Notes

On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.
Revenue Recognition
Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.
Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.

Gross Profit and Gross Margin

Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.

The Company’s overall gross margin was 20% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 25% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.
Leases as Lessee
Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Leases as Lessee

Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.
Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.
Leases as Lessor
Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.
Leases as Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.

Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.
Nonqualified Cash Deferral Plan
Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.
Equity-Based Compensation
Equity-Based Compensation

The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

•Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.

•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.
The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.

The Company accounts for forfeitures as they occur rather than on an estimated basis.

The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.
Deferred Tax
Deferred Tax

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.
Foreign Currency Translation and Foreign Currency Transactions
Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.
Loss Per Share
Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.
Comprehensive Loss
Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
Standards that were recently adopted and standards not yet adopted
Standards that were recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.

Standards not yet adopted

In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not
expect the update to have a material effect on our condensed consolidated financial statements.
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Effect of Restatement
The effects of the correction of the prior-period misstatements on our Condensed Consolidated Balance Sheet relating to the Notes are reflected in the table below (in thousands). The Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Cash Flows, and the Condensed Consolidated Statements of Stockholders’ Equity were also corrected for the other previously identified immaterial error as reflected in the tables below (in thousands).

September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Accrued liabilities4,300 191 4,491 
Current portion of convertible notes— 56,325 56,325 
Total current liabilities9,568 56,516 66,084 
Convertible notes56,325 (56,325)— 
Total liabilities85,644 191 85,835 
Accumulated deficit ending balance(592,439)(191)(592,630)
Total stockholders’ deficit ending balance(9,797)(191)(9,988)

Three Months Ended
September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cost of sales2,190 191 2,381 
Gross profit770 (191)579 
Loss from operations(14,770)(191)(14,961)
Net loss before income taxes(15,705)(191)(15,896)
Net loss(15,705)(191)(15,896)
Comprehensive loss(15,518)(191)(15,709)

Nine Months Ended
September 30,
2022
As Previously ReportedAdjustmentsAs Restated
Cost of sales7,127 191 7,318 
Gross profit2,653 (191)2,462 
Loss from operations(48,654)(191)(48,845)
Net loss before income taxes(47,693)(191)(47,884)
Net loss(47,693)(191)(47,884)
Comprehensive loss(47,878)(191)(48,069)
Schedule of Allowance For Credit Losses
The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$150 $213 140 445 
(Reversals) provisions, net
(12)78 18 114 
Write-offs
— (77)(20)(345)
$138 $214 $138 $214 
Schedule of Warranty Reserve
Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
As Restated
As Restated
Beginning balance$255 $169 $139 $232 
Provisions (reversals), net
187 (31)325 (41)
Warranty cost incurred
(29)(17)(51)(70)
Ending balance$413 $121 $413 $121 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurement
The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,145 $— $— $5,145 
Total cash and cash equivalents5,145 — — 5,145 
Equity investments:
Mutual funds808 — — 808 
Total equity investments808 — — 808 
Debt securities available-for-sale:
Certificates of deposit— 3,382 — 3,382 
U.S. Treasury securities5,228 — — 5,228 
Commercial paper— 2,893 — 2,893 
Corporate notes and bonds— 4,096 — 4,096 
Debt securities available-for-sale5,228 10,371 — 15,599 
Total assets measured at fair value$11,181 $10,371 $— $21,552 
December 31, 2021
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,563 $— $— $5,563 
Commercial paper— 200 — 200 
Total cash and cash equivalents5,563 200 — 5,763 
Equity investments:
Mutual funds841 — — 841 
Total equity investments841 — — 841 
Debt securities available-for-sale:
Certificates of deposit— 1,351 — 1,351 
U.S. Treasury securities250 — — 250 
Commercial paper— 8,046 — 8,046 
Corporate notes and bonds— 13,232 — 13,232 
Debt securities available-for-sale250 22,629 — 22,879 
Total assets measured at fair value$6,654 $22,829 $— $29,483 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-Sale Investments
The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$3,400 $— $(18)$3,382 
U.S. Treasury securities5,266 — (38)5,228 
Commercial paper2,901 — (8)2,893 
Corporate notes and bonds4,131 — (35)4,096 
Total$15,698 $— $(99)$15,599 

December 31, 2021
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$1,351 $— $— $1,351 
U.S. Treasury securities250 — — 250 
Commercial paper8,048 — (2)8,046 
Corporate notes and bonds13,245 — (13)13,232 
Total$22,894 $— $(15)$22,879 
Schedule of Maturities of Available-for-Sale Investments
The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022December 31, 2021
Amortized
Cost		Fair ValueAmortized
Cost		Fair Value
Due in less than 1 year$15,698 $15,599 $22,663 $22,649 
Due in 1-3 years— — 231 230 
Total
$15,698 $15,599 $22,894 $22,879 
Schedule of Unrealized Losses or Gains on Equity Securities
Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Unrealized (loss) gain on equity investments$(50)$(5)$(206)$39 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Inventory (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Raw materials$1,769 $1,343 
Work in process2,133 1,625 
Finished goods1,490 2,099 
$5,392 $5,067 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Computer equipment$3,866 $3,181 
Technical equipment3,259 3,285 
Facilities3,674 3,675 
Instruments3,594 5,364 
Capital projects in progress48 683 
Total property and equipment$14,441 $16,188 
Accumulated depreciation(10,820)(10,799)
Property and equipment, net$3,621 $5,389 

Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$381 $487 $1,284 $1,540 
Schedule of Instruments at Cost and Accumulated Depreciation, Lessor Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):
September 30,December 31,
20222021
Instruments at cost under operating leases$2,452 $3,110 
Accumulated depreciation under operating leases(1,109)(1,165)
Net property and equipment under operating leases$1,343 $1,945 
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Deferred Revenue and Remaining Performance Obligations (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Deferred Revenue and Income Summary A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):
September 30,December 31,
20222021
Products and services not yet delivered$524 $451 
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):

September 30,December 31,
20222021
Loans - various interest$80 $80 
Current portion of long-term debt80 80 
Long-term debt$— $— 
Schedule of Maturities of Long-term Debt
The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):

Remainder of 2022$80 
2023— 
2024— 
2025— 
2026— 
Thereafter— 
Total$80 
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Notes (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Interest Expense
Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 
Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 
Schedule of Gain on Extinguishment
Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Gain on extinguishment$— $4,999 $3,565 $4,999 
Schedule of Carrying Value of the Notes
The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 

As of September 30, 2022 the Notes consisted of the following (in thousands):

September 30,
2022
(As Restated)
Current portion of convertible notes$56,325 
Non-current portion of convertible notes— 
Total convertible notes$56,325 
The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt Related-Party (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Carrying Value of the Secured Notes
The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 

As of September 30, 2022 the Notes consisted of the following (in thousands):

September 30,
2022
(As Restated)
Current portion of convertible notes$56,325 
Non-current portion of convertible notes— 
Total convertible notes$56,325 
The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 
Schedule of Interest Expense in Connection with the Secured Note
Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 
Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 
Summary of Inputs Used to Calculate Estimated Fair Value
The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:

Contractual term (in years)
7.0
Volatility76.10 %
Expected dividends— 
Risk free interest rates2.86 %
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Shares issuable upon the release of RSUs4,619 2,320 4,619 2,320 
Shares issuable upon exercise of stock options5,665 7,634 5,665 7,634 
Shares issuable upon the exercise of the Warrant2,472 — 2,472 — 
12,756 9,954 12,756 9,954 
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Option Activity under the Company's Equity-Based Compensation
The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:

Number of SharesWeighted Average Exercise Price per Share
Options outstanding January 1, 20227,192,540 $13.89 
Granted140,000 3.05 
Forfeited(204,232)12.49 
Exercised(6,105)1.04 
Expired(1,457,019)10.33 
Options outstanding September 30, 20225,665,184 $14.60 
Schedule of Outstanding Options and Options that are Exercisable (Vested)
The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:

Options
Outstanding		Options
Exercisable
Number of options5,665,184 4,422,595 
Weighted average remaining contractual term (in years)5.545.04
Weighted average exercise price$14.60 $15.32 
Weighted average fair value$9.10 $9.44 
Aggregate intrinsic value (in thousands)$— $— 
Schedule of Restricted Stock Activity
The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 20222,090,182 $10.77 
Granted4,107,083 1.55 
Forfeited(451,703)8.68 
Released(1,127,017)3.43 
Outstanding September 30, 20224,618,545 $4.57 
Schedule of Equity-Based Compensation Expense
The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of sales$167 $82 $570 $257 
Research and development151 266 1,052 4,340 
Sales, general and administrative911 3,281 6,557 14,461 
$1,229 $3,629 $8,179 $19,058 

The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost capitalized to inventory
$69 $77 $186 $319 
The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based stock option expense
$— $230 
The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based RSU expense
$— $818 
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Leases (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of Supplemental Lease Information
The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 
Schedule of Lease Costs
The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 
Schedule of Maturities of Operating Lease Liabilities
The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 
Schedule of Maturities of Sales-type Lease Receivables The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):
Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Geographic and Revenue Disaggregation (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Disaggregation of Revenue
The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Domestic$2,551 $2,874 $8,390 $7,406 
Foreign409 248 1,390 1,033 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accelerate Pheno revenue
$2,933 $3,084 $9,669 $8,324 
Other revenue27 38 111 115 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Products$2,532 $2,773 $8,554 $7,474 
Services428 349 1,226 965 
$2,960 $3,122 $9,780 $8,439 
Schedule of Long-lived Assets by Geographic Territory
The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20222021
Domestic$3,383 $5,014 
Foreign238 375 
$3,621 $5,389 
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Property, Plant and Equipment [Line Items]          
Convertible notes $ 0   $ 0   $ 107,984,000
Accumulated deficit (592,630,000)   (592,630,000)   (570,668,000)
Net loss (15,896,000) $ (8,986,000) (47,884,000) $ (54,899,000)  
Net cash used in operating activities     (39,178,000) $ (35,376,000)  
Cash, cash equivalents, and marketable securities 55,400,000   55,400,000    
Total current liabilities 66,084,000   66,084,000   6,945,000
Current portion of convertible notes 56,325,000   56,325,000   $ 0
Impairment charges $ 0   $ 0    
Instrument warranty term     1 year    
Kits and accessories warranty term     60 days    
Gross margin 0.20 0.32 0.25 0.35  
Lease extension 1 year   1 year    
Lessor lease term 5 years   5 years    
As Previously Reported          
Property, Plant and Equipment [Line Items]          
Convertible notes $ 56,325,000   $ 56,325,000    
Accumulated deficit (592,439,000)   (592,439,000)    
Net loss (15,705,000)   (47,693,000)    
Total current liabilities 9,568,000   9,568,000    
Current portion of convertible notes $ 0   $ 0    
Instruments          
Property, Plant and Equipment [Line Items]          
Estimated useful life of assets     5 years    
Equipment          
Property, Plant and Equipment [Line Items]          
Lease term 3 years   3 years    
Minimum          
Property, Plant and Equipment [Line Items]          
Estimated useful life of assets     1 year    
Lease term 2 years   2 years    
Maximum          
Property, Plant and Equipment [Line Items]          
Estimated useful life of assets     7 years    
Lease term 6 years   6 years    
2.50% Convertible notes due 2023 | Convertible notes          
Property, Plant and Equipment [Line Items]          
Interest rate 2.50%   2.50%    
2.50% Convertible notes due 2023 | Convertible notes | As Previously Reported          
Property, Plant and Equipment [Line Items]          
Convertible notes $ 56,300,000   $ 56,300,000    
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Effect of Restatement (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Accrued liabilities $ 4,491   $ 4,491   $ 2,853
Current portion of convertible notes 56,325   56,325   0
Total current liabilities 66,084   66,084   6,945
Convertible notes 0   0   107,984
Total liabilities 85,835   85,835   118,118
Accumulated deficit (592,630)   (592,630)   (570,668)
Total stockholders’ deficit ending balance (9,988) $ (39,747) (9,988) $ (39,747) $ (35,071)
Cost of sales 2,381 2,136 7,318 5,502  
Gross profit 579 986 2,462 2,937  
Loss from operations (14,961) (14,532) (48,845) (52,148)  
Net loss before income taxes (15,896) (8,986) (47,884) (54,899)  
Net loss 15,896 8,986 47,884 54,899  
Comprehensive loss (15,709) $ (9,016) (48,069) $ (55,007)  
As Previously Reported          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Accrued liabilities 4,300   4,300    
Current portion of convertible notes 0   0    
Total current liabilities 9,568   9,568    
Convertible notes 56,325   56,325    
Total liabilities 85,644   85,644    
Accumulated deficit (592,439)   (592,439)    
Total stockholders’ deficit ending balance (9,797)   (9,797)    
Cost of sales 2,190   7,127    
Gross profit 770   2,653    
Loss from operations (14,770)   (48,654)    
Net loss before income taxes (15,705)   (47,693)    
Net loss 15,705   47,693    
Comprehensive loss (15,518)   (47,878)    
Adjustments          
Error Corrections and Prior Period Adjustments Restatement [Line Items]          
Accrued liabilities 191   191    
Current portion of convertible notes 56,325   56,325    
Total current liabilities 56,516   56,516    
Convertible notes (56,325)   (56,325)    
Total liabilities 191   191    
Accumulated deficit (191)   (191)    
Total stockholders’ deficit ending balance (191)   (191)    
Cost of sales 191   191    
Gross profit (191)   (191)    
Loss from operations (191)   (191)    
Net loss before income taxes (191)   (191)    
Net loss 191   191    
Comprehensive loss $ (191)   $ (191)    
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]        
Beginning balance $ 150 $ 213 $ 140 $ 445
(Reversals) provisions, net (12) 78 18 114
Write-offs 0 (77) (20) (345)
Ending balance $ 138 $ 214 $ 138 $ 214
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]        
Beginning balance $ 255 $ 169 $ 139 $ 232
Provisions (reversals), net 187 (31) 325 (41)
Warranty cost incurred (29) (17) (51) (70)
Ending balance $ 413 $ 121 $ 413 $ 121
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Recently Issued Accounting Pronouncements (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Jan. 01, 2022
Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Carrying amount of convertible notes $ 56,325    
Decrease in accumulated deficit $ (592,630)   $ (570,668)
Cumulative effect of accounting changes | Accounting Standards Update 2020-06      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Carrying amount of convertible notes   $ 11,500  
Decrease in additional paid in capital   (37,400)  
Decrease in accumulated deficit   $ 25,900  
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Concentration of Credit Risk (Details)
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Cash and cash equivalents | Concentration of credit risk | Financial Institutions One    
Concentration Risk [Line Items]    
Risk concentration 74.00% 72.00%
Cash and cash equivalents | Concentration of credit risk | Financial Institutions Two    
Concentration Risk [Line Items]    
Risk concentration 12.00% 13.00%
Cash and cash equivalents | Concentration of credit risk | Financial Institutions Three    
Concentration Risk [Line Items]    
Risk concentration 13.00%  
Net accounts receivable | Customer concentration | One customer    
Concentration Risk [Line Items]    
Risk concentration 16.00% 13.00%
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: $ 800 $ 800
Debt securities available-for-sale: 15,599 22,879
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 3,382 1,351
U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 5,228 250
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 2,893 8,046
Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 4,096 13,232
Fair Value on a Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,763
Equity investments: 808 841
Debt securities available-for-sale: 15,599 22,879
Total assets measured at fair value 21,552 29,483
Fair Value on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,563
Equity investments: 808 841
Debt securities available-for-sale: 5,228 250
Total assets measured at fair value 11,181 6,654
Fair Value on a Recurring Basis | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 0 200
Equity investments: 0 0
Debt securities available-for-sale: 10,371 22,629
Total assets measured at fair value 10,371 22,829
Fair Value on a Recurring Basis | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 0 0
Equity investments: 0 0
Debt securities available-for-sale: 0 0
Total assets measured at fair value 0 0
Fair Value on a Recurring Basis | Mutual funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 808 841
Fair Value on a Recurring Basis | Mutual funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 808 841
Fair Value on a Recurring Basis | Mutual funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 0 0
Fair Value on a Recurring Basis | Mutual funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 0 0
Fair Value on a Recurring Basis | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 3,382 1,351
Fair Value on a Recurring Basis | Certificates of deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Certificates of deposit | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 3,382 1,351
Fair Value on a Recurring Basis | Certificates of deposit | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 5,228 250
Fair Value on a Recurring Basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 5,228 250
Fair Value on a Recurring Basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | U.S. Treasury securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 2,893 8,046
Fair Value on a Recurring Basis | Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Commercial paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 2,893 8,046
Fair Value on a Recurring Basis | Commercial paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 4,096 13,232
Fair Value on a Recurring Basis | Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Corporate notes and bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 4,096 13,232
Fair Value on a Recurring Basis | Corporate notes and bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,563
Fair Value on a Recurring Basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,563
Fair Value on a Recurring Basis | Money market funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 0 0
Fair Value on a Recurring Basis | Money market funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: $ 0 0
Fair Value on a Recurring Basis | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   200
Fair Value on a Recurring Basis | Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   0
Fair Value on a Recurring Basis | Commercial paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   200
Fair Value on a Recurring Basis | Commercial paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   $ 0
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Aug. 15, 2022
Dec. 31, 2021
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant      
Debt Instrument [Line Items]      
Warrants fair value   $ 3,800  
Level 3 | August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant      
Debt Instrument [Line Items]      
Warrants fair value   3,800  
Convertible notes | 2.50% Convertible notes due 2023      
Debt Instrument [Line Items]      
Outstanding principal at par $ 56,595   $ 120,500
Convertible notes | 2.50% Convertible notes due 2023 | Level 2      
Debt Instrument [Line Items]      
Fair value 51,700   $ 89,400
Senior Notes | 5.0% Secured promissory note | August 2022 Exchange Transaction | Schuler Trust      
Debt Instrument [Line Items]      
Outstanding principal at par $ 34,934    
Senior Notes | 5.0% Secured promissory note | Level 3 | Schuler Trust      
Debt Instrument [Line Items]      
Fair value   $ 16,000  
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Investments - Schedule of Available-for-sale Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost $ 15,698 $ 22,894
Gross Unrealized Gains 0 0
Gross Unrealized Losses (99) (15)
Fair Value 15,599 22,879
Certificates of deposit    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 3,400 1,351
Gross Unrealized Gains 0 0
Gross Unrealized Losses (18) 0
Fair Value 3,382 1,351
U.S. Treasury securities    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 5,266 250
Gross Unrealized Gains 0 0
Gross Unrealized Losses (38) 0
Fair Value 5,228 250
Commercial paper    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 2,901 8,048
Gross Unrealized Gains 0 0
Gross Unrealized Losses (8) (2)
Fair Value 2,893 8,046
Corporate notes and bonds    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 4,131 13,245
Gross Unrealized Gains 0 0
Gross Unrealized Losses (35) (13)
Fair Value $ 4,096 $ 13,232
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Investments - Schedule of Available-for-Sale Investment Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Amortized Cost    
Due in less than 1 year $ 15,698 $ 22,663
Due in 1-3 years 0 231
Amortized Cost 15,698 22,894
Fair Value    
Due in less than 1 year 15,599 22,649
Due in 1-3 years 0 230
Fair Value $ 15,599 $ 22,879
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Investments - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]          
Proceeds from sales of debt securities $ 0 $ 0 $ 0 $ 0  
Realized gain (loss) from debt securities 0 0 0 0  
Unrealized loss position of debt securities 0 0 0 0  
Fair value of equity securities 800,000   800,000   $ 800,000
Realized gains or losses from equity securities 0 0 0 0  
Reclassified debt securities available-for-sale balances          
Debt Securities, Available-for-sale [Line Items]          
Reclassified from out of accumulated other comprehensive income (loss) $ 0 $ 0 $ 0 $ 0  
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Investments - Unrealized Losses or Gains on Equity Securities (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]        
Unrealized (loss) gain on equity investments $ (50) $ (5) $ (206) $ 39
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 1,769 $ 1,343
Work in process 2,133 1,625
Finished goods 1,490 2,099
Inventory $ 5,392 $ 5,067
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Property and Equipment - Property and Equipment at Cost (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment [Line Items]          
Total property and equipment $ 14,441   $ 14,441   $ 16,188
Accumulated depreciation (10,820)   (10,820)   (10,799)
Property and equipment, net 3,621   3,621   5,389
Depreciation expense 381 $ 487 1,284 $ 1,540  
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,866   3,866   3,181
Technical equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,259   3,259   3,285
Facilities          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,674   3,674   3,675
Instruments          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,594   3,594   5,364
Capital projects in progress          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 48   $ 48   $ 683
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Instruments at cost under operating leases $ 2,452 $ 3,110
Accumulated depreciation under operating leases (1,109) (1,165)
Net property and equipment under operating leases $ 1,343 $ 1,945
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Deferred Revenue and Remaining Performance Obligations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Disaggregation of Revenue [Line Items]          
Products and services not yet delivered $ 524   $ 524   $ 451
Revenues recognized included in contract liabilities balances 200 $ 100 400 $ 300  
Revenue expected to be recognized from remaining performance obligations 9,000   $ 9,000    
Contact period     These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.    
Products and services not yet delivered          
Disaggregation of Revenue [Line Items]          
Products and services not yet delivered $ 524   $ 524   $ 451
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 15, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
loan
Apr. 14, 2020
USD ($)
Debt Instrument [Line Items]              
Gain on extinguishment of debt   $ 0 $ 9,840 $ 3,565 $ 9,840    
Other loans | Notes payable, other payables              
Debt Instrument [Line Items]              
Number of loan agreements | loan           2  
Number of capital asset financing companies | loan           1  
Proceeds from debt           $ 200  
Other loans | Notes payable, other payables | Minimum              
Debt Instrument [Line Items]              
Interest rate           9.80%  
Other loans | Notes payable, other payables | Maximum              
Debt Instrument [Line Items]              
Interest rate           12.40%  
Paycheck Protection Program | Unsecured obligations              
Debt Instrument [Line Items]              
Aggregate principal amount             $ 4,800
Debt forgiveness $ 4,800            
Gain on extinguishment of debt $ 4,800            
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Loans - various interest $ 80  
Current portion of long-term debt 80 $ 80
Long-term debt 0 0
Loans - various interest | Loans - various interest    
Debt Instrument [Line Items]    
Loans - various interest $ 80 $ 80
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2022 $ 80
2023 0
2024 0
2025 0
2026 0
Thereafter 0
Loans - various interest $ 80
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Notes - Narrative (Details)
 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 15, 2022
USD ($)
$ / shares
Mar. 21, 2022
USD ($)
tranche
May 18, 2022
tranche
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
day
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Debt Instrument [Line Items]              
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs           $ 49,624,000 $ 0
Gain on extinguishment of debt       $ 0 $ 9,840,000 3,565,000 9,840,000
Convertible notes value           49,624,000 0
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant              
Debt Instrument [Line Items]              
Warrants fair value $ 3,800,000            
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant | Level 3              
Debt Instrument [Line Items]              
Warrants fair value 3,800,000            
Prepaid Forward              
Debt Instrument [Line Items]              
Funded prepaid forward           $ 45,100,000  
Stock underlying the prepaid forward (in shares) | shares       1,858,500   1,858,500  
Convertible notes | 2.50% Convertible notes due 2023              
Debt Instrument [Line Items]              
Conversion ratio           0.0323428  
Initial conversion price (in usd per share) | $ / shares       $ 30.92   $ 30.92  
Interest rate       2.50%   2.50%  
Contractual term           5 years  
Effective interest rate       3.20%   3.20%  
Repurchase principal balance           100.00%  
Convertible notes | 2.50% Convertible notes due 2023 | 2021 Exchange Transaction              
Debt Instrument [Line Items]              
Notes exchanged             $ 46,000,000
Shares issued (in shares) | shares             5,945,718
Repurchase of exchanged amount         40,400,000   $ 40,400,000
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs             34,500,000
Reacquisition costs             800,000
Gain on extinguishment of debt         5,000,000   5,000,000
Convertible notes value             34,500,000
Convertible notes | 2.50% Convertible notes due 2023 | March 2022 Exchange Transaction              
Debt Instrument [Line Items]              
Conversion ratio   0.02264          
Notes exchanged   $ 14,000,000          
Number of tranches | tranche   8 8        
Conversion numerator (in usd per share)   $ 155.67          
Convertible notes | 2.50% Convertible notes due 2023 | August 2022 Exchange Transaction | Schuler Trust              
Debt Instrument [Line Items]              
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,900,000            
Convertible notes value 49,900,000            
Convertible notes | 2.50% Convertible notes due 2023 | Exchange Agreement              
Debt Instrument [Line Items]              
Gain on extinguishment of debt       $ 0 $ 4,999,000 $ 3,565,000 $ 4,999,000
Convertible notes | 2.50% Convertible notes due 2023 | Option one to convert              
Debt Instrument [Line Items]              
Stock price conversion threshold, percentage           130.00%  
Consecutive trading days | day           20  
Threshold trading days | day           30  
Convertible notes | 2.50% Convertible notes due 2023 | Option two to convert              
Debt Instrument [Line Items]              
Consecutive trading days | day           5  
Threshold trading days | day           5  
Trading price threshold, percentage           98.00%  
Convertible notes | New Notes | March 2022 Exchange Transaction              
Debt Instrument [Line Items]              
Notes exchanged           $ 14,000,000  
Shares issued (in shares) | shares           10,798,482  
Repurchase of exchanged amount       $ 14,000,000   $ 14,000,000  
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs           10,200,000  
Reacquisition costs           200,000  
Gain on extinguishment of debt           3,600,000  
Convertible notes value           10,200,000  
Convertible notes | New Notes | Exchange Agreement              
Debt Instrument [Line Items]              
Notes exchanged           $ 14,000,000  
Shares issued (in shares) | shares           10,798,482  
Senior Notes | 5.0% Secured promissory note | Schuler Trust | Level 3              
Debt Instrument [Line Items]              
Fair value $ 16,000,000            
Senior Notes | 5.0% Secured promissory note | August 2022 Exchange Transaction | Schuler Trust              
Debt Instrument [Line Items]              
Initial conversion price (in usd per share) | $ / shares $ 2.12            
Interest rate 5.00%            
Effective interest rate       24.60%   24.60%  
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs $ 34,900,000            
Convertible notes value 34,900,000            
Secured Debt | 5.0% Secured promissory note | August 2022 Exchange Transaction | Schuler Trust              
Debt Instrument [Line Items]              
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,600,000            
Convertible notes value 49,600,000            
Capital contribution from related-party in connection with exchange transaction $ 29,800,000            
XML 69 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Notes - Schedule of Interest Expense (Details) - 2.50% Convertible notes due 2023 - Convertible notes - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]        
Contractual coupon interest $ 79 $ 1,024 $ 1,528 $ 3,168
Amortization of debt issuance costs 121 185 386 539
Amortization of the debt discount 0 2,987 0 8,711
Total interest expense on convertible notes $ 200 $ 4,196 $ 1,914 $ 12,418
XML 70 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Notes - Gain on Extinguishment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]        
Gain on extinguishment of debt $ 0 $ 9,840 $ 3,565 $ 9,840
Exchange Agreement | 2.50% Convertible notes due 2023 | Convertible notes        
Debt Instrument [Line Items]        
Gain on extinguishment of debt $ 0 $ 4,999 $ 3,565 $ 4,999
XML 71 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Notes - Schedule of Notes and New Notes (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Loans - various interest $ 80  
Convertible Debt [Abstract]    
Current portion of convertible notes 56,325 $ 0
Non-current portion of convertible notes 0 107,984
Total convertible notes 56,325  
Convertible notes | 2.50% Convertible notes due 2023    
Debt Instrument [Line Items]    
Outstanding principal at par 56,595 $ 120,500
Unamortized debt issuance discount (270)  
Loans - various interest $ 56,325  
XML 72 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt Related-Party - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Aug. 15, 2022
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   $ 49,624 $ 0
2.50% Convertible notes due 2023 | Convertible notes      
Debt Instrument [Line Items]      
Initial conversion price (in usd per share)   $ 30.92  
Interest rate   2.50%  
Effective interest rate   3.20%  
5.0% Secured promissory note | Senior Notes | Schuler Trust | Level 3      
Debt Instrument [Line Items]      
Fair value $ 16,000    
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant      
Debt Instrument [Line Items]      
Warrants issued (in shares) 2,471,710    
Warrants fair value $ 3,800    
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant | Level 3      
Debt Instrument [Line Items]      
Warrants fair value 3,800    
August 2022 Exchange Transaction | 2.50% Convertible notes due 2023 | Convertible notes | Schuler Trust      
Debt Instrument [Line Items]      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,900    
August 2022 Exchange Transaction | 5.0% Secured promissory note | Senior Notes | Schuler Trust      
Debt Instrument [Line Items]      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs $ 34,900    
Initial conversion price (in usd per share) $ 2.12    
Interest rate 5.00%    
Unamortized debt issuance   $ 18,900  
Effective interest rate   24.60%  
XML 73 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Debt Instrument [Line Items]  
Loans - various interest $ 80
5.0% Secured promissory note | Senior Notes | August 2022 Exchange Transaction | Schuler Trust  
Debt Instrument [Line Items]  
Outstanding principal 34,934
Unamortized debt issuance discount (18,635)
Loans - various interest $ 16,299
XML 74 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) - Schuler Trust - August 2022 Exchange Transaction - 5.0% Secured promissory note - Senior Notes - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]        
Contractual interest $ 220 $ 0 $ 220 $ 0
Amortization of the debt discount 275 0 275 0
Total interest expense on convertible notes $ 495 $ 0 $ 495 $ 0
XML 75 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) - Embeded Warrant - Schuler Trust
Sep. 30, 2022
year
Contractual term (in years)  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 7.0
Volatility  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 0.7610
Expected dividends  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 0
Risk free interest rates  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 0.0286
XML 76 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 12,756 9,954 12,756 9,954
Shares issuable upon the release of RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 4,619 2,320 4,619 2,320
Shares issuable upon exercise of stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 5,665 7,634 5,665 7,634
Shares issuable upon the exercise of the Warrant        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 2,472 0 2,472 0
XML 77 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Loss Per Share - Narrative (Details)
 9 Months Ended
Sep. 30, 2022
instrument
$ / shares
shares
Aug. 15, 2022
$ / shares
Mar. 24, 2022
shares
Debt Instrument [Line Items]      
Common stock issuable upon conversion of the Series A Preferred Stock (in shares) 3,954,546    
Schuler Trust | August 2022 Exchange Transaction      
Debt Instrument [Line Items]      
Debt instrument, convertible, number of accrued interest | instrument 103,834    
March 2022 Securities Purchase Agreement | Affiliated Entity      
Debt Instrument [Line Items]      
Agreement to purchase shares (in shares)     2,439,024
Series A Preferred Stock      
Debt Instrument [Line Items]      
Conversion ratio (in shares) 0.01    
Sale or merger trigger conversion ratio (in shares) 0.01    
Series A Preferred Stock | March 2022 Securities Purchase Agreement | Affiliated Entity      
Debt Instrument [Line Items]      
Agreement to purchase shares (in shares)     2,439,024
Prepaid Forward      
Debt Instrument [Line Items]      
Stock underlying the prepaid forward (in shares) 1,858,500    
Convertible notes | 2.50% Convertible notes due 2023      
Debt Instrument [Line Items]      
Conversion ratio 0.0323428    
Initial conversion price (in usd per share) | $ / shares $ 30.92    
Issuable upon conversion of the notes (in shares) 1,830,441    
Senior Notes | 5.0% Secured promissory note | Schuler Trust | August 2022 Exchange Transaction      
Debt Instrument [Line Items]      
Initial conversion price (in usd per share) | $ / shares   $ 2.12  
Debt instrument, convertible, number of equity instruments | instrument 16,478,066    
XML 78 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Number of Shares      
Outstanding, beginning balance (in shares)     7,192,540
Granted (in shares) 0 0 140,000
Forfeited (in shares)     (204,232)
Exercised (in shares)     (6,105)
Expired (in shares)     (1,457,019)
Outstanding, ending balance (in shares) 5,665,184   5,665,184
Weighted Average Exercise Price per Share      
Outstanding, beginning balance (in usd per share)     $ 13.89
Granted (in usd per share)     3.05
Forfeited (in usd per share)     12.49
Exercised (in usd per share)     1.04
Expired (in usd per share)     10.33
Outstanding, ending balance (in usd per share) $ 14.60   $ 14.60
XML 79 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2020
Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Granted (in shares) 0 0 140,000    
Unrecognized equity-based compensation cost $ 2.3   $ 2.3    
Expired (in shares)     1,457,019    
Number of options (in shares) 5,665,184   5,665,184   7,192,540
RSUs          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Unrecognized equity-based compensation cost, restricted stock units $ 7.8   $ 7.8    
Performance-based stock options          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Granted (in shares)       105,000  
Contractual life     10 years    
Exercisable (in shares)       90,000  
Expired (in shares)     90,000    
Number of options (in shares) 0   0    
Performance-based stock options | Minimum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     1 year    
Expected term of award     5 years    
Performance-based stock options | Maximum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     2 years    
Expected term of award     7 years    
Performance-based RSU expense          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Contractual life     10 years    
Outstanding (in shares)       165,974 111,806
Performance-based RSU expense | Minimum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     1 year    
Performance-based RSU expense | Maximum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     3 years    
XML 80 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Options Outstanding    
Number of options (in shares) 5,665,184 7,192,540
Weighted average remaining contractual term (in years) 5 years 6 months 14 days  
Weighted average exercise price (in usd per share) $ 14.60 $ 13.89
Weighted average fair value (in usd per shares) $ 9.10  
Aggregate intrinsic value (in thousands) $ 0  
Options Exercisable    
Number of options (in shares) 4,422,595  
Weighted average remaining contractual term (in years) 5 years 14 days  
Weighted average exercise price (in usd per share) $ 15.32  
Weighted average fair value (in usd per share) $ 9.44  
Aggregate intrinsic value (in thousands) $ 0  
XML 81 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation - Restricted Stock Activity (Details) - RSUs and RSAs
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Number of Shares  
Beginning balance (in shares) | shares 2,090,182
Granted (in shares) | shares 4,107,083
Forfeited (in shares) | shares (451,703)
Released (in shares) | shares (1,127,017)
Ending balance (in shares) | shares 4,618,545
Weighted Average Grant Date Fair Value per Share  
Beginning balance (in usd per share) | $ / shares $ 10.77
Granted (in usd per share) | $ / shares 1.55
Forfeited (in usd per share) | $ / shares 8.68
Released (in usd per share) | $ / shares 3.43
Ending balance (in usd per share) | $ / shares $ 4.57
XML 82 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense $ 1,229 $ 3,629 $ 8,179 $ 19,058
Cost capitalized to inventory 69 77 186 319
Performance-based stock option expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense     0 230
Performance-based RSU expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense     0 818
Cost of sales        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense 167 82 570 257
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense 151 266 1,052 4,340
Sales, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense $ 911 $ 3,281 $ 6,557 $ 14,461
XML 83 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 0 $ 0 $ 0 $ 0
Pre-tax loss $ 15,896,000 $ 8,986,000 $ 47,884,000 $ 54,899,000
XML 84 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Apr. 30, 2022
Commitments and Contingencies Disclosure [Abstract]    
Total commitments $ 11.9 $ 11.9
XML 85 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Assets and Liabilities (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Cash paid for amounts included in lease liabilities:        
Operating cash flows from operating leases $ 219 $ 195 $ 712 $ 502
Operating cash flows from finance leases 684 0 1,109 0
ROU assets obtained in exchange for lease obligations:        
Operating leases 0 0 0 0
Finance leases 0 0 2,760 0
Lease Cost:        
Operating leases 254 257 818 816
Finance leases 240 0 462 0
Short-term leases $ 26 $ 40 $ 67 $ 99
Weighted average remaining lease term (years) 2 years 9 months 18 days   2 years 9 months 18 days  
Weighted average discount rate (%) 7.10%   7.10%  
Weighted average remaining lease term finance leases (years) 2 years 6 months   2 years 6 months  
Weighted average discount rate finance leases (%) 4.60%   4.60%  
XML 86 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Operating  
Remainder of 2022 $ 227
2023 968
2024 1,047
2025 584
2026 0
Thereafter 0
Total lease payments 2,826
Less imputed interest (278)
Lessee lease liabilities 2,548
Finance  
Remainder of 2022 180
2023 721
2024 721
2025 173
2026 0
Thereafter 0
Total lease payments 1,795
Less imputed interest (144)
Finance lease obligation $ 1,651
XML 87 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Sales-type Lease Receivable Maturity (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Leases [Abstract]  
Net investment in leases $ 3,000
Remainder of 2022 351
2023 1,154
2024 661
2025 206
2026 640
Thereafter 0
Total undiscounted cash flows 3,012
Less imputed interest 0
Present value of lease payments $ 3,012
XML 88 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Geographic and Revenue Disaggregation - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Segment Reporting [Abstract]          
Number of operating segments | segment     1    
Segment Reporting Information [Line Items]          
Trade accounts receivable, net $ 2,393   $ 2,393   $ 2,320
Lease income $ 200 $ 500 $ 1,300 $ 1,300  
Geographic concentration | Outside the U.S. | Total revenue          
Segment Reporting Information [Line Items]          
Risk concentration 14.00% 8.00% 14.00% 12.00%  
Geographic concentration | Outside the U.S. | Net accounts receivable          
Segment Reporting Information [Line Items]          
Trade accounts receivable, net $ 600   $ 600   $ 700
XML 89 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Net sales $ 2,960 $ 3,122 $ 9,780 $ 8,439
Accelerate Pheno revenue        
Disaggregation of Revenue [Line Items]        
Net sales 2,933 3,084 9,669 8,324
Other revenue        
Disaggregation of Revenue [Line Items]        
Net sales 27 38 111 115
Products        
Disaggregation of Revenue [Line Items]        
Net sales 2,532 2,773 8,554 7,474
Services        
Disaggregation of Revenue [Line Items]        
Net sales 428 349 1,226 965
Domestic        
Disaggregation of Revenue [Line Items]        
Net sales 2,551 2,874 8,390 7,406
Foreign        
Disaggregation of Revenue [Line Items]        
Net sales $ 409 $ 248 $ 1,390 $ 1,033
XML 90 R81.htm IDEA: XBRL DOCUMENT v3.22.4
Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) $ 3,621 $ 5,389
Property and equipment | Geographic concentration    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) 3,621 5,389
Property and equipment | Geographic concentration | Domestic    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) 3,383 5,014
Property and equipment | Geographic concentration | Foreign    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) $ 238 $ 375
XML 91 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 22, 2022
USD ($)
$ / shares
shares
Aug. 15, 2022
USD ($)
Mar. 21, 2022
USD ($)
Oct. 29, 2021
USD ($)
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 17, 2021
tranche
shares
Sep. 30, 2021
USD ($)
tranche
$ / shares
shares
Dec. 31, 2020
USD ($)
entity
tranche
$ / shares
shares
Apr. 09, 2021
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Mar. 24, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
$ / shares
Sep. 22, 2021
$ / shares
Class of Stock [Line Items]                                
Share price (in usd per share) | $ / shares         $ 5.83   $ 5.83       $ 5.83   $ 5.83     $ 5.81
Proceeds from issuance of common stock                       $ 32,872 $ 22,640      
Preferred Stock, par value (in usd per share) | $ / shares                   $ 0.001   $ 0.001     $ 0.001  
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                       $ 49,624 0      
August 2022 Public Offering                                
Class of Stock [Line Items]                                
Share price (in usd per share) | $ / shares $ 2.00                              
Net proceeds $ 32,900                              
Series A Preferred Stock                                
Class of Stock [Line Items]                                
Conversion ratio (in shares)                   0.01   0.01        
Common stock | August 2022 Public Offering                                
Class of Stock [Line Items]                                
Sale of stock (in shares) | shares 17,500,000                              
2.50% Convertible notes due 2023 | Convertible notes | 2021 Exchange Transaction                                
Class of Stock [Line Items]                                
Notes exchanged                         $ 46,000      
Shares issued (in shares) | shares                         5,945,718      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                         $ 34,500      
2.50% Convertible notes due 2023 | Convertible notes | March 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Notes exchanged     $ 14,000                          
New Notes | Convertible notes | March 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Notes exchanged                       $ 14,000        
Shares issued (in shares) | shares                       10,798,482        
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                       $ 10,200        
Schuler Trust | August 2022 Exchange Transaction | Embeded Warrant                                
Class of Stock [Line Items]                                
Warrants fair value   $ 3,800                            
Schuler Trust | August 2022 Exchange Transaction | Embeded Warrant | Level 3                                
Class of Stock [Line Items]                                
Warrants fair value   3,800                            
Warrant issued to related-party   3,800                            
Schuler Trust | 2.50% Convertible notes due 2023 | Convertible notes | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   49,900                            
Schuler Trust | 5.0% Secured promissory note | Senior Notes | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   34,900                            
Schuler Trust | 5.0% Secured promissory note | Secured Debt | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   49,600                            
Capital contribution from related-party in connection with exchange transaction   $ 29,800                            
Schuler Trust | Extinguished Notes | Secured Debt | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Capital contribution from related-party in connection with exchange transaction                   $ 29,800   $ 29,800        
December 2020 Securities Purchase Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Purchase price               $ 32,000                
Share price (in usd per share) | $ / shares               $ 7.68                
Number of tranches | tranche               3                
Proceeds from issuance of common stock         $ 500       $ 21,300       $ 1,500      
Sale of stock (in shares) | shares                         201,820      
December 2020 Securities Purchase Agreement | Affiliated Entity | Original Purchasers                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares               4,166,663                
Non-affiliate related entities | entity               3                
December 2020 Securities Purchase Agreement | Affiliated Entity | Schuler Trust                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares               3,964,843                
Purchase price               $ 30,500                
Non-affiliate related entities | entity               3                
September 2021 Rescission Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Number of tranches | tranche           2                    
Sale of stock (in shares) | shares           2,643,228                    
September 2021 Securities Purchase Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Number of tranches | tranche             2                  
September 2021 Securities Purchase Agreement | Affiliated Entity | Series A Preferred Stock                                
Class of Stock [Line Items]                                
Sale of stock (in shares) | shares             2,636,364           2,636,364      
Agreement to purchase preferred shares (in shares) | shares         3,954,546   3,954,546       3,954,546   3,954,546      
Preferred Stock, par value (in usd per share) | $ / shares         $ 0.001   $ 0.001       $ 0.001   $ 0.001      
Conversion ratio (in shares)         1   1       1   1      
Aggregate purchase price         $ 30,500   $ 30,500       $ 30,500   $ 30,500      
Proceeds from issuance of preferred stock                     $ 20,300          
Tranche Right | Affiliated Entity | Series A Preferred Stock                                
Class of Stock [Line Items]                                
Sale of stock (in shares) | shares       1,318,182                        
Agreement to purchase preferred shares (in shares) | shares         1,318,182   1,318,182       1,318,182   1,318,182      
Share price (in usd per share) | $ / shares         $ 7.70   $ 7.70       $ 7.70   $ 7.70      
Proceeds from issuance of preferred stock       $ 10,200     $ 10,200                  
Tranche right value         $ 2,500   $ 2,500       $ 2,500   $ 2,500      
March 2022 Securities Purchase Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares                           2,439,024    
Purchase price                           $ 4,000    
Share price (in usd per share) | $ / shares                           $ 1.64    
March 2022 Securities Purchase Agreement | Affiliated Entity | Series A Preferred Stock                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares                           2,439,024    
XML 92 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Related-Party Transactions (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 15, 2022
Sep. 30, 2021
Sep. 22, 2021
Sep. 17, 2021
Sep. 30, 2021
Apr. 09, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Mar. 24, 2022
Dec. 31, 2020
Dec. 24, 2020
Related Party Transaction [Line Items]                          
Share price (in usd per share)   $ 5.83 $ 5.81   $ 5.83     $ 5.83   $ 5.83      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                 $ 49,624 $ 0      
Proceeds from issuance of common stock                 32,872 $ 22,640      
Affiliated Entity | Convertible Note Purchases | 2021 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Shares issued (in shares)     5,428,699                    
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs               $ 31,500          
Affiliated Entity | September 2021 Rescission Agreement                          
Related Party Transaction [Line Items]                          
Sale of stock (in shares)       2,643,228                  
Affiliated Entity | December 2020 Securities Purchase Agreement                          
Related Party Transaction [Line Items]                          
Share price (in usd per share)                       $ 7.68  
Sale of stock (in shares)                   201,820      
Proceeds from issuance of common stock   $ 500       $ 21,300       $ 1,500      
Affiliated Entity | September 2021 Securities Purchase Agreement | Series A Preferred Stock                          
Related Party Transaction [Line Items]                          
Sale of stock (in shares)         2,636,364         2,636,364      
Agreement to purchase preferred shares (in shares)   3,954,546     3,954,546     3,954,546   3,954,546      
Proceeds from issuance of preferred stock               $ 20,300          
Affiliated Entity | Securities Purchase Agreement                          
Related Party Transaction [Line Items]                          
Agreement to purchase shares (in shares)                         4,166,663
Affiliated Entity | March 2022 Securities Purchase Agreement                          
Related Party Transaction [Line Items]                          
Share price (in usd per share)                     $ 1.64    
Agreement to purchase shares (in shares)                     2,439,024    
Affiliated Entity | March 2022 Securities Purchase Agreement | Series A Preferred Stock                          
Related Party Transaction [Line Items]                          
Agreement to purchase shares (in shares)                     2,439,024    
Affiliated Entity | Schuler Family Foundation | Convertible Note Purchases | 2021 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Aggregate principal amount   $ 42,000     $ 42,000     $ 42,000   $ 42,000      
Convertible notes | 2.50% Convertible notes due 2023 | 2021 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Shares issued (in shares)                   5,945,718      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                   $ 34,500      
Convertible notes | 2.50% Convertible notes due 2023 | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs $ 49,900                        
Senior Notes | 5.0% Secured promissory note | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 34,900                        
Secured Debt | 5.0% Secured promissory note | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,600                        
Capital contribution from related-party in connection with exchange transaction $ (29,800)                        
Secured Debt | Extinguished Notes | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Capital contribution from related-party in connection with exchange transaction             $ (29,800)   $ (29,800)        
XML 93 axdx-20220930_htm.xml IDEA: XBRL DOCUMENT 0000727207 2022-01-01 2022-09-30 0000727207 2022-11-10 0000727207 2022-09-30 0000727207 2021-12-31 0000727207 2022-07-01 2022-09-30 0000727207 2021-07-01 2021-09-30 0000727207 2021-01-01 2021-09-30 0000727207 2020-12-31 0000727207 2021-09-30 0000727207 us-gaap:PreferredStockMember 2022-06-30 0000727207 us-gaap:PreferredStockMember 2021-06-30 0000727207 us-gaap:PreferredStockMember 2021-12-31 0000727207 us-gaap:PreferredStockMember 2020-12-31 0000727207 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000727207 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0000727207 us-gaap:PreferredStockMember 2022-09-30 0000727207 us-gaap:PreferredStockMember 2021-09-30 0000727207 us-gaap:CommonStockMember 2022-06-30 0000727207 us-gaap:CommonStockMember 2021-06-30 0000727207 us-gaap:CommonStockMember 2021-12-31 0000727207 us-gaap:CommonStockMember 2020-12-31 0000727207 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000727207 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000727207 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000727207 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000727207 us-gaap:CommonStockMember 2022-09-30 0000727207 us-gaap:CommonStockMember 2021-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000727207 us-gaap:RetainedEarningsMember 2022-06-30 0000727207 us-gaap:RetainedEarningsMember 2021-06-30 0000727207 us-gaap:RetainedEarningsMember 2021-12-31 0000727207 us-gaap:RetainedEarningsMember 2020-12-31 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0000727207 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000727207 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000727207 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000727207 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000727207 us-gaap:RetainedEarningsMember 2022-09-30 0000727207 us-gaap:RetainedEarningsMember 2021-09-30 0000727207 us-gaap:TreasuryStockCommonMember 2022-06-30 0000727207 us-gaap:TreasuryStockCommonMember 2021-06-30 0000727207 us-gaap:TreasuryStockCommonMember 2021-12-31 0000727207 us-gaap:TreasuryStockCommonMember 2020-12-31 0000727207 us-gaap:TreasuryStockCommonMember 2022-09-30 0000727207 us-gaap:TreasuryStockCommonMember 2021-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 srt:ScenarioPreviouslyReportedMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 srt:ScenarioPreviouslyReportedMember 2022-09-30 0000727207 srt:RestatementAdjustmentMember 2022-09-30 0000727207 srt:ScenarioPreviouslyReportedMember 2022-07-01 2022-09-30 0000727207 srt:RestatementAdjustmentMember 2022-07-01 2022-09-30 0000727207 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-09-30 0000727207 srt:RestatementAdjustmentMember 2022-01-01 2022-09-30 0000727207 2022-06-30 0000727207 2021-06-30 0000727207 srt:MinimumMember 2022-01-01 2022-09-30 0000727207 srt:MaximumMember 2022-01-01 2022-09-30 0000727207 axdx:InstrumentsMember 2022-01-01 2022-09-30 0000727207 srt:MinimumMember 2022-09-30 0000727207 srt:MaximumMember 2022-09-30 0000727207 us-gaap:EquipmentMember 2022-09-30 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsOneMember 2022-01-01 2022-09-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsTwoMember 2022-01-01 2022-09-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsThreeMember 2022-01-01 2022-09-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsOneMember 2021-01-01 2021-12-31 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsTwoMember 2021-01-01 2021-12-31 0000727207 axdx:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000727207 axdx:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-12-31 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2021-12-31 0000727207 axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember us-gaap:FairValueInputsLevel3Member axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-07-01 2021-09-30 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-09-30 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-07-01 2022-09-30 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000727207 us-gaap:ComputerEquipmentMember 2022-09-30 0000727207 us-gaap:ComputerEquipmentMember 2021-12-31 0000727207 us-gaap:TechnologyEquipmentMember 2022-09-30 0000727207 us-gaap:TechnologyEquipmentMember 2021-12-31 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-09-30 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-12-31 0000727207 axdx:InstrumentsMember 2022-09-30 0000727207 axdx:InstrumentsMember 2021-12-31 0000727207 us-gaap:ConstructionInProgressMember 2022-09-30 0000727207 us-gaap:ConstructionInProgressMember 2021-12-31 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2022-09-30 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2021-12-31 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-12-31 0000727207 srt:MinimumMember axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0000727207 srt:MaximumMember axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2022-09-30 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2021-12-31 0000727207 axdx:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember 2020-04-14 0000727207 axdx:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember 2021-07-15 2021-07-15 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000727207 axdx:PrepaidForwardMember 2022-01-01 2022-09-30 0000727207 axdx:PrepaidForwardMember 2022-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-03-21 2022-03-21 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-03-21 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-03-29 2022-05-18 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroNewConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroNewConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroNewConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SecuredDebtMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-07-01 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2021-07-01 2021-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-01-01 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2021-01-01 2021-09-30 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputExpectedTermMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputPriceVolatilityMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000727207 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000727207 us-gaap:WarrantMember 2021-07-01 2021-09-30 0000727207 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000727207 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000727207 us-gaap:SeriesAPreferredStockMember 2022-09-30 0000727207 axdx:March2022SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2022-03-24 0000727207 axdx:August2022ExchangeTransactionMember axdx:JackWSchulerLivingTrustMember 2022-01-01 2022-09-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2021-12-31 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2022-01-01 2022-09-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2022-09-30 0000727207 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000727207 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000727207 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000727207 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000727207 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000727207 srt:MaximumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000727207 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000727207 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000727207 us-gaap:PerformanceSharesMember 2022-09-30 0000727207 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0000727207 srt:MinimumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0000727207 srt:MaximumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-12-31 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2021-12-31 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2021-01-01 2021-09-30 0000727207 2022-04-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-07-01 2022-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-07-01 2021-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-01-01 2021-09-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-09-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-12-31 0000727207 us-gaap:GeographicDistributionDomesticMember 2022-07-01 2022-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2021-07-01 2021-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2022-01-01 2022-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2021-01-01 2021-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2022-07-01 2022-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2021-07-01 2021-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2021-01-01 2021-09-30 0000727207 axdx:AcceleratePhenoMember 2022-07-01 2022-09-30 0000727207 axdx:AcceleratePhenoMember 2021-07-01 2021-09-30 0000727207 axdx:AcceleratePhenoMember 2022-01-01 2022-09-30 0000727207 axdx:AcceleratePhenoMember 2021-01-01 2021-09-30 0000727207 axdx:OtherRevenueMember 2022-07-01 2022-09-30 0000727207 axdx:OtherRevenueMember 2021-07-01 2021-09-30 0000727207 axdx:OtherRevenueMember 2022-01-01 2022-09-30 0000727207 axdx:OtherRevenueMember 2021-01-01 2021-09-30 0000727207 us-gaap:ProductMember 2022-07-01 2022-09-30 0000727207 us-gaap:ProductMember 2021-07-01 2021-09-30 0000727207 us-gaap:ProductMember 2022-01-01 2022-09-30 0000727207 us-gaap:ProductMember 2021-01-01 2021-09-30 0000727207 us-gaap:ServiceMember 2022-07-01 2022-09-30 0000727207 us-gaap:ServiceMember 2021-07-01 2021-09-30 0000727207 us-gaap:ServiceMember 2022-01-01 2022-09-30 0000727207 us-gaap:ServiceMember 2021-01-01 2021-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember 2022-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember 2021-12-31 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-12-31 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember 2022-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember 2021-12-31 0000727207 axdx:CertainDirectorsAndOfficersOrAffiliatesMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-31 0000727207 axdx:JackWSchulerLivingTrustMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-31 0000727207 axdx:CertainDirectorsAndOfficersOrAffiliatesMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-01 2020-12-31 0000727207 axdx:JackWSchulerLivingTrustMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-01 2020-12-31 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-31 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-01 2020-12-31 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-02-19 2021-04-09 0000727207 axdx:September2021RescissionAgreementMember srt:AffiliatedEntityMember 2021-09-17 2021-09-17 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-09-30 2021-09-30 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-01-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-09-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-01 2021-09-30 0000727207 2021-09-22 0000727207 axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-10-29 2021-10-29 0000727207 axdx:August2022ExchangeTransactionMember axdx:ExtinguishedNotesMember us-gaap:SecuredDebtMember axdx:JackWSchulerLivingTrustMember 2022-07-01 2022-09-30 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember us-gaap:FairValueInputsLevel3Member axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 us-gaap:CommonStockMember axdx:August2022PublicOfferingMember 2022-08-22 2022-08-22 0000727207 axdx:August2022PublicOfferingMember 2022-08-22 0000727207 axdx:August2022PublicOfferingMember 2022-08-22 2022-08-22 0000727207 axdx:SchulerFamilyFoundationMember axdx:A2021ExchangeTransactionMember axdx:ConvertibleNotePurchasesMember srt:AffiliatedEntityMember 2021-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:ConvertibleNotePurchasesMember srt:AffiliatedEntityMember 2021-09-22 2021-09-22 0000727207 axdx:A2021ExchangeTransactionMember axdx:ConvertibleNotePurchasesMember srt:AffiliatedEntityMember 2021-07-01 2021-09-30 0000727207 axdx:SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-24 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0000727207 axdx:March2022SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2022-03-24 0000727207 axdx:August2022ExchangeTransactionMember axdx:ExtinguishedNotesMember us-gaap:SecuredDebtMember axdx:JackWSchulerLivingTrustMember 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares pure axdx:loan axdx:day axdx:tranche axdx:year axdx:instrument axdx:segment axdx:entity 0000727207 true --12-31 Q3 2022 P1Y P2Y 0.0323428 0.02264 0.0323428 10-Q/A true 2022-09-30 false 001-31822 ACCELERATE DIAGNOSTICS, INC. DE 84-1072256 3950 South Country Club Road, Suite 470 Tucson, AZ 85714 520 365-3100 Common Stock, $0.001 par AXDX NASDAQ Yes Yes Non-accelerated Filer true false false 99099480 In this Amendment No. 1 to the Quarterly Report on Form 10-Q (this “Form 10-Q/A”), all references to “we” or “us” or “our” or “Accelerate” or the “Company” refer to Accelerate Diagnostics, Inc. and its consolidated subsidiaries.    Restatement OverviewOn February 6, 2023, the Audit Committee of the Company’s Board of Directors (the “Board”), in consultation with members of the Company’s management, determined that the Company’s previously issued interim unaudited financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022 (collectively, the “2022 Interim Financial Statements”), should no longer be relied upon due to the error in the balance sheet classification of the Company’s 2.50% Senior Convertible Notes due 2023 (the “Notes”) described below. For additional information, please refer to our Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 9, 2023.This Form 10-Q/A amends and restates certain items noted below in the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2022, as originally filed with the SEC on November 14, 2022 (the “Original Filing”). Except as described below, no other material changes have been made to the Original Filing. Unless otherwise noted, this Form 10-Q/A speaks as of the date of the Original Filing and does not reflect other events that may have occurred after the date of the Original Filing or modify or update any disclosures that may have been affected by subsequent events. Accordingly, this Form 10-Q/A should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original Filing, including any amendment to those filings.Background of RestatementIn March and April 2018, the Company issued $171.5 million aggregate principal amount of Notes, which have a maturity date of March 15, 2023, unless earlier converted or repurchased. Between September 2021 and August 2022, the Company entered into certain exchange transactions pursuant to which the Company exchanged $114.9 million aggregate principal amount of Notes for one or a combination of: shares of the Company’s common stock, a secured promissory note and/or warrants to purchase the Company’s common stock. As of the date of the filing of this Form 10-Q/A, $56.6 million aggregate principal amount of Notes remain outstanding.The balance sheets contained in each of the 2022 Interim Financial Statements classified the Notes as a non-current liability with a net carrying amount of $115.8 million, $105.8 million and $56.3 million as of March 31, 2022, June 30, 2022 and September 30, 2022, respectively. Pursuant to Accounting Standards Codification (“ASC”) 210-10-45, current classification is required for convertible debt if the settlement in cash is expected to occur within 12 months, subject to the issuer’s intent and ability to refinance the debt on a long-term basis pursuant to ASC 470-10-45. The identification of the error arose in connection with the Company’s year-end close for the year ended December 31, 2022, whereby the Company determined that, as of the respective balance sheet dates for each of the 2022 Interim Financial Statements, its intent to refinance the Notes on a long-term basis was not supported by an ability to consummate the refinancing of all or a portion of the Notes in accordance with ASC 470-10-45. Accordingly, the Notes (or a portion thereof, as applicable in the specific period) should have been classified as a current liability in the balance sheets contained in each of the 2022 Interim Financial Statements.The “as restated” classification of the Notes is further described and the impact of the restatement is included in Note 1 and Note 10 of the “Notes to the Condensed Consolidated Financial Statements” included in Part I, Item 1. “Financial Statements” of this Form 10-Q/A.Control ConsiderationsIn connection with the restatement, management concluded that there was a deficiency in our internal control over financial reporting that constituted a material weakness as of September 30, 2022. For a discussion of management's consideration of our disclosure controls and procedures and the material weakness identified, see Part I, Item 4, Controls and Procedures of this Form 10-Q/A.Items Amended in this FilingFor the convenience of the reader, this Form 10-Q/A sets forth the Original Filing, as amended, in its entirety; however, this Form 10-Q/A amends and restates only the following Items of the Original Filing to the extent necessary to reflect the adjustments discussed above and to make corresponding adjustments to the Company’s financial data and disclosures cited elsewhere in this Form 10-Q/A:-Part I, Item 1 - Financial Statements-Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations-Part I, Item 4 - Controls and Procedures-Part II, Item 6 - ExhibitsIn addition, in connection with the preparation of this Form 10-Q/A, the Company has evaluated its financial condition as of the date of filing this Form 10-Q/A. Based on this evaluation, the Company has determined that there is substantial doubt about its ability to continue as a going concern as of the date of the filing of this Form 10-Q/A, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A. The assessment of going concern is further discussed in Note 1 of the “Notes to the Condensed Consolidated Financial Statements” included in Part I, Item 1. “Financial Statements” of this Form 10-Q/A.Further, the Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing (Exhibits 31.1, 31.2 and 32), and the Company has provided its restated condensed consolidated financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibit 101.Restatement of Other Financial StatementsIn addition to the restated financial information for the quarter ended September 30, 2022 included in this Form 10-Q/A, we are also restating our interim condensed consolidated financial statements and related disclosures for the quarters ended March 31, 2022 and June 30, 2022. Concurrently with the filing of this Form 10-Q/A, we are filing amended Quarterly Reports on Form 10-Q with the SEC with respect to these periods to address the error in the balance sheet classification of the Notes described above. 38987000 39898000 16407000 23720000 2393000 2320000 5392000 5067000 1119000 768000 1974000 1558000 66272000 73331000 3621000 5389000 2319000 0 2012000 2510000 1623000 1817000 75847000 83047000 2819000 1983000 4491000 2853000 118000 909000 524000 451000 56325000 0 80000 80000 953000 0 774000 669000 66084000 6945000 698000 0 1775000 2381000 759000 808000 220000 0 16299000 0 0 107984000 85835000 118118000 0.001 0.001 5000000 5000000 3954546 3954546 4000 4000 0.001 0.001 200000000 97240983 97240983 100000000 67649018 67649018 97000 68000 627853000 580652000 45067000 45067000 -592630000 -570668000 -245000 -60000 -9988000 -35071000 75847000 83047000 2960000 3122000 9780000 8439000 2381000 2136000 7318000 5502000 579000 986000 2462000 2937000 7285000 4712000 20885000 17341000 8255000 10806000 30422000 37744000 15540000 15518000 51307000 55085000 -14961000 -14532000 -48845000 -52148000 203000 4211000 1833000 12477000 495000 0 495000 0 0 9840000 3565000 9840000 -261000 -78000 -221000 -238000 73000 0 151000 55000 -49000 -5000 -206000 69000 -935000 5546000 961000 -2751000 -15896000 -8986000 -47884000 -54899000 0 0 0 0 -15896000 -8986000 -47884000 -54899000 -0.18 -0.18 -0.15 -0.15 -0.62 -0.62 -0.91 -0.91 87011000 87011000 61146000 61146000 77049000 77049000 60250000 60250000 -15896000 -8986000 -47884000 -54899000 48000 -3000 -84000 -21000 139000 -27000 -101000 -87000 -15709000 -9016000 -48069000 -55007000 -47884000 -54899000 2207000 1875000 -94000 -153000 8179000 19058000 386000 9250000 275000 0 -74000 202000 -206000 39000 3565000 9840000 174000 304000 73000 719000 245000 527000 491000 -860000 1221000 1017000 1153000 -436000 -785000 -1059000 220000 0 73000 93000 -49000 343000 -39178000 -35376000 446000 202000 27506000 22345000 34527000 33601000 6575000 11054000 32872000 22640000 1109000 0 7000 1456000 184000 245000 192000 0 6000 6000 31756000 24335000 -64000 -69000 -911000 -56000 39898000 35781000 38987000 35725000 -78000 508000 10180000 34545000 49624000 0 16024000 0 3753000 0 29847000 0 2214000 4288000 3955000 0 3955000 0 2636000 2636000 3955000 2636000 3955000 2636000 4000 0 4000 0 3000 3000 4000 3000 4000 3000 79701000 61489000 67649000 57608000 17500000 67000 17500000 2937000 6000 62000 1134000 1052000 34000 16000 159000 37000 2643000 2643000 5946000 10799000 5946000 97241000 64937000 97241000 64937000 80000 61000 68000 58000 17000 1000 17000 3000 1000 1000 3000 3000 6000 11000 6000 97000 65000 97000 65000 560185000 514122000 580652000 475072000 -37438000 32855000 517000 32855000 22637000 234000 6000 1455000 47000 84000 184000 245000 34539000 10169000 34539000 29847000 29847000 3753000 3753000 1166000 3638000 7825000 19186000 627853000 553134000 627853000 553134000 -576734000 -538879000 -570668000 -492966000 25922000 -15896000 -8986000 -47884000 -54899000 -592630000 -547865000 -592630000 -547865000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -432000 13000 -60000 91000 48000 -3000 -84000 -21000 139000 -27000 -101000 -87000 -245000 -17000 -245000 -17000 -9988000 -39747000 -9988000 -39747000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restatement of Previously Issued Financial Statements</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on the restatement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s previously issued interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2022 classified its 2.50% Senior Convertible Notes due 2023 (the “Notes”) as a non-current liability with a net carrying amount of $56.3 million as of September 30, 2022. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Accounting Standards Codification (“ASC”) 210-10-45, Balance Sheet, the Notes should have been classified as a current liability in the balance sheet as of September 30, 2022. In addition, the Company recorded an adjustment to correct a previously identified immaterial error related to the Company’s warranty obligations as of and for the three and nine months ended September 30, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of the restatement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The effects of the correction of the prior-period misstatements on our Condensed Consolidated Balance Sheet relating to the Notes are reflected in the table below (in thousands).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Cash Flows, and the Condensed Consolidated Statements of Stockholders’ Equity were also corrected for the other previously identified immaterial error as reflected in the tables below (in thousands).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit ending balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(592,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(592,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders’ deficit ending balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,318 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total net cash used in operating activities was not impacted by the error corrections.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to correcting the consolidated financial statements, related revisions and updates have been made to “Liquidity &amp; Going Concern (As Restated)”, Warranty Reserve (As Restated) and Note 10, Convertible Notes (As Restated).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity &amp; Going Concern (As Restated)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company’s accumulated deficit totaled $592.6 million as of September 30, 2022. For the three and nine months ended September 30, 2022, the Company had net losses of approximately $15.9 million and $47.9 million, respectively, and had negative cash flows from operations of approximately $39.2 million for the nine months ended September 30, 2022. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises and the issuance of debt (see Note 9, Long-Term Debt, Note 10, Convertible Notes and Note 18, Stockholders' Equity for additional details).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At September 30, 2022, the Company held cash, cash equivalents, and marketable securities of $55.4 million and current liabilities of $66.1 million, including $56.3 million of Notes due on March 15, 2023. Based on its evaluation pursuant to ASC 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, the Company has determined that, as of the date of this Form 10-Q/A filing, there is substantial doubt about its ability to continue as a going concern, as the Company does not currently have adequate financial resources to pay its outstanding debt obligation under the Notes and to fund its forecasted operating costs for at least twelve months from the filing of this Form 10-Q/A.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company continues to explore additional funding in the form of potential equity and/or debt financing arrangements or similar transactions, as well as non-cash means to settle or refinance the Notes, there can be no assurance the necessary financing will be available on terms acceptable to the Company, or at all. If the Company raises funds by issuing equity securities, dilution to stockholders may result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of common stock. If the Company raises funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of preferred and common stockholders. The terms of debt securities or borrowings could impose significant restrictions on our operations. Similarly, there can be no assurance that market conditions and refinancing alternatives will be sufficient to settle or refinance the Notes on or prior to their maturity on March 15, 2023. The capital markets have in the past, and may in the future, experience periods of upheaval that could impact the availability and cost of equity and debt financing. In addition, recent and anticipated future increases in federal fund rates set by the Federal Reserve, which serve as benchmark rates on borrowing, and other general economic conditions may impact the cost of debt financing or refinancing existing debt.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are actively considering all available strategic alternatives to maximize value, if we are unable to obtain adequate capital resources to fund operations and address the upcoming maturity of the Notes, we would not be able to continue to operate our business pursuant to our current plans. This may require us to, among other things, materially modify our operations to reduce spending; sell assets or operations; delay the implementation of, or revising certain aspects of, our business strategy; file a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring; or discontinue our operations entirely.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, Inventory, for further information and related disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Reversals) provisions, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-offs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The write-offs recorded during the nine months ended September 30, 2021 were in connection with a one-time restructuring activity of the Company's Europe, Middle East and Africa (“EMEA”) business. These credit losses were incurred as part of the Company terminating agreements with select distributors in geographies it exited and did not pursue collection of these accounts receivables.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5ZGM3NTExOTI1MDQ5ZWM5MWUyMjc5NzhhYzQ5ZWJhL3NlYzoyOWRjNzUxMTkyNTA0OWVjOTFlMjI3OTc4YWM0OWViYV8zMS9mcmFnOjY3ZjE0OTNlODkxYzQwNzJiYTBmMDllYWU0NjMzOWIxL3RleHRyZWdpb246NjdmMTQ5M2U4OTFjNDA3MmJhMGYwOWVhZTQ2MzM5YjFfMTYxNTE_edcfe848-014b-4720-b159-84262d7b565e">one</span> to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments Classified as Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7, Property and Equipment, for further information and related disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Reserve (As Restated)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions (reversals), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty cost incurred</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Recently Issued Accounting Pronouncements and Note 10, Convertible Notes, for further information and related disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue as we satisfy a performance obligation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s overall gross margin was 20% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 25% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessee</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5ZGM3NTExOTI1MDQ5ZWM5MWUyMjc5NzhhYzQ5ZWJhL3NlYzoyOWRjNzUxMTkyNTA0OWVjOTFlMjI3OTc4YWM0OWViYV8zMS9mcmFnOjY3ZjE0OTNlODkxYzQwNzJiYTBmMDllYWU0NjMzOWIxL3RleHRyZWdpb246NjdmMTQ5M2U4OTFjNDA3MmJhMGYwOWVhZTQ2MzM5YjFfMjY3OTU_6e540bbd-123f-4107-ac14-8b50eac9673f">two</span> and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessor</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur rather than on an estimated basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13, Employee Equity-Based Compensation for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Foreign Currency Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12, Loss Per Share, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.</span></div> 0.0250 56300000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The effects of the correction of the prior-period misstatements on our Condensed Consolidated Balance Sheet relating to the Notes are reflected in the table below (in thousands).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Cash Flows, and the Condensed Consolidated Statements of Stockholders’ Equity were also corrected for the other previously identified immaterial error as reflected in the tables below (in thousands).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit ending balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(592,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(592,630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders’ deficit ending balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,318 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,884)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4300000 191000 4491000 0 56325000 56325000 9568000 56516000 66084000 56325000 -56325000 0 85644000 191000 85835000 -592439000 -191000 -592630000 -9797000 -191000 -9988000 2190000 191000 2381000 770000 -191000 579000 -14770000 -191000 -14961000 -15705000 -191000 -15896000 -15705000 -191000 -15896000 -15518000 -191000 -15709000 7127000 191000 7318000 2653000 -191000 2462000 -48654000 -191000 -48845000 -47693000 -191000 -47884000 -47693000 -191000 -47884000 -47878000 -191000 -48069000 -592600000 -15900000 -47900000 -39200000 55400000 66100000 56300000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.</span></div>The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and </span></div>the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Reversals) provisions, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-offs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 150000 213000 140000 445000 -12000 78000 18000 114000 0 77000 20000 345000 138000 214000 138000 214000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5ZGM3NTExOTI1MDQ5ZWM5MWUyMjc5NzhhYzQ5ZWJhL3NlYzoyOWRjNzUxMTkyNTA0OWVjOTFlMjI3OTc4YWM0OWViYV8zMS9mcmFnOjY3ZjE0OTNlODkxYzQwNzJiYTBmMDllYWU0NjMzOWIxL3RleHRyZWdpb246NjdmMTQ5M2U4OTFjNDA3MmJhMGYwOWVhZTQ2MzM5YjFfMTYxNTE_edcfe848-014b-4720-b159-84262d7b565e">one</span> to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments Classified as Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.</span></div> P7Y P5Y 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Reserve (As Restated)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.</span></div> P1Y P60D <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions (reversals), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty cost incurred</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 255000 169000 139000 232000 187000 -31000 325000 -41000 29000 17000 51000 70000 413000 121000 413000 121000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue as we satisfy a performance obligation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s overall gross margin was 20% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 25% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.</span></div> 0.20 0.32 0.25 0.35 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessee</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.</span></div>Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI5ZGM3NTExOTI1MDQ5ZWM5MWUyMjc5NzhhYzQ5ZWJhL3NlYzoyOWRjNzUxMTkyNTA0OWVjOTFlMjI3OTc4YWM0OWViYV8zMS9mcmFnOjY3ZjE0OTNlODkxYzQwNzJiYTBmMDllYWU0NjMzOWIxL3RleHRyZWdpb246NjdmMTQ5M2U4OTFjNDA3MmJhMGYwOWVhZTQ2MzM5YjFfMjY3OTU_6e540bbd-123f-4107-ac14-8b50eac9673f">two</span> and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessor</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.</span></div> P1Y P6Y P3Y P5Y <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur rather than on an estimated basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Foreign Currency Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards that were recently adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards not yet adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not </span></div>expect the update to have a material effect on our condensed consolidated financial statements. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards that were recently adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards not yet adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not </span></div>expect the update to have a material effect on our condensed consolidated financial statements. 11500000 -37400000 25900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. CONCENTRATION OF CREDIT RISK</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2022, three of the Company's financial institutions held 74%, 12% and 13% of the Company’s cash and cash equivalents. As of December 31, 2021, two of the Company's financial institutions held 72% and 13% of the Company’s cash and cash equivalents.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company had one customer that accounted for 16% and 13% of the Company’s net accounts receivable balance as of September 30, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any customers that represented 10% or more of the Company’s total revenue for the three and nine months ended September 30, 2022 and 2021.</span></div> 0.74 0.12 0.13 0.72 0.13 0.16 0.13 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,552 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,654 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the Notes had an outstanding principal amount of $56.6 million with a fair value of $51.7 million. At December 31, 2021, the Notes had an outstanding principal amount of $120.5 million with a fair value of $89.4 million. The fair value of the Notes represents a Level 2 measurement. The fair value of the Notes is typically correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. See Note 10, Convertible Notes for further detail on the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Secured Note is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the warrant on August 15, 2022 was $3.8 million. See Note 11, Long-Term Debt Related-Party for further detail on the Company’s warrant with a related-party.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,552 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,654 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5145000 0 0 5145000 5145000 0 0 5145000 808000 0 0 808000 808000 0 0 808000 0 3382000 0 3382000 5228000 0 0 5228000 0 2893000 0 2893000 0 4096000 0 4096000 5228000 10371000 0 15599000 11181000 10371000 0 21552000 5563000 0 0 5563000 0 200000 0 200000 5563000 200000 0 5763000 841000 0 0 841000 841000 0 0 841000 0 1351000 0 1351000 250000 0 0 250000 0 8046000 0 8046000 0 13232000 0 13232000 250000 22629000 0 22879000 6654000 22829000 0 29483000 56600000 51700000 120500000 89400000 16000000 3800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. INVESTMENTS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1-3 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three and nine months ended September 30, 2022 and 2021. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2022 and 2021. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021. No unrealized losses on debt securities available-for-sale have been recognized in income for the three and nine months ended September 30, 2022 and 2021, as the issuers of such securities held by us were of high credit quality.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 the Company did not carry any debt securities available-for-sale that were below the Company's minimum credit rating. All debt securities available-for-sale had a credit rating of A- or better as of September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are comprised of investments in mutual funds. The fair value of equity securities for each of the periods ended September 30, 2022 and December 31, 2021 was $0.8 million.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (loss) gain on equity investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for each of the three and nine months ended September 30, 2022 and 2021.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3400000 0 18000 3382000 5266000 0 38000 5228000 2901000 0 8000 2893000 4131000 0 35000 4096000 15698000 0 99000 15599000 1351000 0 0 1351000 250000 0 0 250000 8048000 0 2000 8046000 13245000 0 13000 13232000 22894000 0 15000 22879000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1-3 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15698000 15599000 22663000 22649000 0 0 231000 230000 15698000 15599000 22894000 22879000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800000 800000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (loss) gain on equity investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -50000 -5000 -206000 39000 0 0 0 0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. INVENTORY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,067 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,067 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1769000 1343000 2133000 1625000 1490000 2099000 5392000 5067000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. PROPERTY AND EQUIPMENT</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost under operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation under operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net property and equipment under operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,945 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3866000 3181000 3259000 3285000 3674000 3675000 3594000 5364000 48000 683000 14441000 16188000 10820000 10799000 3621000 5389000 381000 487000 1284000 1540000 Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost under operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation under operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net property and equipment under operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,945 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2452000 3110000 1109000 1165000 1343000 1945000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services not yet delivered</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0.2 million and $0.4 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2021, respectively. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price Allocated to Remaining Performance Obligations</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, $9.0 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div> A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services not yet delivered</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 524000 451000 200000 400000 100000 300000 9000000 These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. LONG-TERM DEBT</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into two loan agreements with one financing company in 2020. Loan proceeds were $0.2 million, with interest rates ranging from 9.8% to 12.4% and maturities becoming due through 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans - various interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program (PPP) Loan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million made to the Company under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Small Business Administration (“SBA”) informed the Company of its full forgiveness for the entire PPP Note amount plus accrued interest, which was $4.8 million as of the date of forgiveness. The SBA’s determination of loan forgiveness does not preclude further investigation by the SBA according to its rules and regulations. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of the entire PPP Note amount of $4.8 million during the three and nine months ended September 30, 2021.</span></div> 2 1 200000 0.098 0.124 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans - various interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 80000 80000 80000 80000 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 80000 0 0 0 0 0 80000 4800000 4800000 4800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. CONVERTIBLE NOTES (As Restated) </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are the Company’s senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, pursuant to the terms and conditions of the Notes. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The Company’s Notes have a fixed coupon rate of 2.5% per annum on the principal amount.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred issuance costs related to the issuance of the Notes which is amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par was 3.2%.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of certain corporate events, such as a change of control, merger or liquidation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of September 30, 2022 and December 31, 2021, no Notes were convertible pursuant to their original terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal at par</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 the Notes consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counterparty to a major financial institution.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Exchange Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by them for shares of the Company’s common stock (the “2021 Exchange Transactions”). During the nine months ended September 30, 2021, such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock. The net carrying value of the Notes exchanged was $40.4 million which the Company repurchased for $34.5 million of common stock. The Company also incurred $0.8 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. The 2021 Exchange Transaction resulted in a net gain of $5.0 million reflected in other income (expense), net for the three and nine months ended September 30, 2021. See Note 18, Stockholders' Equity for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, the Company entered into a privately negotiated exchange agreement (the “March 2022 Exchange Agreement”) with a holder of the Notes. Under the terms of the March 2022 Exchange Agreement, the note holder agreed to exchange with the Company $14.0 million in aggregate principal amount of Notes held by it in eight equal tranches as follows for each tranche: (a) 22.64 shares per $1,000 principal amount of Notes exchanged, plus (b) an additional number of shares of the Company’s common stock per $1,000 principal amount of Notes exchanged equal to the sum, for each of the trading days during a separate agreed upon reference period for each tranche commencing on March 21, 2022 for the first tranche, of the quotient of (i) $155.67 divided by (ii) the daily volume-weighted average price for such trading day (collectively, the “March 2022 Exchange Transaction”). The closing of the March 2022 Exchange Transaction occurred in eight tranches (“Obligation to Exchange”), with the first closing occurring on March 29, 2022 and the last closing on May 18, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022 the Obligation to Exchange the $14.0 million of Notes in the March 2022 Exchange Transaction was accounted for as an extinguishment and was replaced by new notes with an embedded feature (the “New Notes”). The New Notes were elected to be carried using the fair value option. The New Notes were recorded at fair value on initial measurement and remeasured at fair value (“mark to market”) at each reporting period with changes in fair value reported in other income and expense, net. This fair value election was exclusive to the New Notes and did not extend to other Notes. The embedded feature was no longer outstanding on September 30, 2022 as the New Notes were exchanged and the Obligation to Exchange retired on May 18, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 the holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company’s common stock pursuant to the March 2022 Exchange Agreement. The net carrying value of the Notes exchanged was $14.0 million which the Company repurchased for $10.2 million of common stock. The Company also incurred $0.2 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. This exchange transaction resulted in a net gain of $3.6 million reflected in other income (expense), net for the nine months ended September 30, 2022. See Note 18, Stockholders' Equity for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”), as discussed in Note 11, Long-Term Debt Related-Party. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. The difference between the fair values of the new instruments and the net carrying amount of the Notes being extinguished was included in the calculation of gain. The gain from the extinguishment of the Notes was treated as a capital transaction. The Secured Note includes various features that were advantageous to the Company, including a lower interest rate compared to current market rates and a share conversion feature. There were no other negotiating parties that had similar terms or economic outcomes. As such, the exchange was considered not to be an arm’s length transaction, and therefore the resulting gain was accounted </span></div>for as a capital transaction. The net carrying amount of the extinguished Notes was $49.6 million. The estimated fair value of the Secured Note and the Warrant on August 15, 2022 was $16.0 million and $3.8 million, respectively, which resulted in a net gain of $29.8 million that was recorded to contributed capital. See Note 18, Stockholders' Equity and Note 11, Long-Term Debt Related-Party for additional information. 30.92 0.025 P5Y 0.032 1.30 20 30 5 5 0.98 1 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 79000 1024000 1528000 3168000 121000 185000 386000 539000 0 2987000 0 8711000 200000 4196000 1914000 12418000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 4999000 3565000 4999000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal at par</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 the Notes consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,299 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 56595000 270000 56325000 56325000 0 56325000 45100000 1858500 46000000 5945718 40400000 34500000 800000 5000000 5000000 14000000 8 155.67 8 14000000 14000000 10798482 14000000 10200000 200000 3600000 49900000 34900000 49600000 16000000 3800000 29800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. LONG-TERM DEBT RELATED-PARTY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust, a holder of the Notes. Jack Schuler, who serves as a member of the Company’s board of directors, is the sole trustee of the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a Warrant to acquire the Company’s common stock at an exercise price of $2.12 per share (the “Warrant”).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. See Note 10, Convertible Notes for additional information. The Secured Notes is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. To estimate the Secured Note’s fair value, the Company applied a Monte Carlo simulation which simulated the share price of the Company over the remaining term to the maturity date of the Secured Note. The simulated per-share price in a given iteration determined if the Company settled in cash or shares. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. This valuation estimated an issuance discount of $18.9 million. The effective interest rate on the Secured Note is 24.60%.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,299 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant may be exercised from February 15, 2023 through the earlier of (i) August 15, 2029 and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in the Warrant. The Warrant is exercisable for up to 2,471,710 shares of common stock. The Warrant meets the criteria for classification in stockholders’ equity and was recorded in equity and initially measured at fair value. The Warrant was measured at fair value on a non-recurring basis using Level 3 inputs. The fair value of the warrant on August 15, 2022 was $3.8 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:84.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 49900000 34900000 2.12 2.12 0.050 16000000 18900000 0.2460 34934000 18635000 16299000 220000 0 220000 0 275000 0 275000 0 495000 0 495000 0 2471710 3800000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:84.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 7.0 0.7610 0 0.0286 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. LOSS PER SHARE</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the release of RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the exercise of the Warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares would include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 10, Convertible Notes, upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock. As of September 30, 2022, no Notes were convertible pursuant to the original terms. The number of shares of common stock issuable upon conversion of the outstanding Notes based on the initial conversion rate was approximately 1,830,441 shares as of September 30, 2022. Historically the Company has engaged in privately negotiated exchanges of Notes for a substantially greater number of shares than the initial conversion rate of the Notes described above because the Company’s stock price at the time of such exchanges was significantly less than the $30.92 initial conversion price of the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares include common shares that would be outstanding if Series A Preferred Stock were converted into common stock. Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock. Additionally, each share of Series A Preferred Stock will automatically be converted into one share of the Company’s common stock immediately upon a sale of all outstanding stock of the Company or a merger of the Company into another corporation where the pre-merger Company’s stockholders cease to be the controlling stockholders of the post-merger corporation. The number of shares of common stock issuable upon conversion of the Series A Preferred Stock is 3,954,546 as of September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 18, Stockholders' Equity, the Company entered into a securities purchase agreement with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock. The closing of the transaction is expected to occur on December 30, 2022, subject to the satisfaction of customary closing conditions and is considered an equity forward agreement. The shares to be issued from this agreement were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 11, Long-Term Debt Related-Party, the Company may, at its option, repay the Secured Note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The number of shares of common stock issuable upon conversion of the Secured Note and accrued interest was approximately 16,478,066 and 103,834 shares respectively, as of September 30, 2022. The shares issuable in connection with a repayment of the Secured Note were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the release of RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the exercise of the Warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4619000 2320000 4619000 2320000 5665000 7634000 5665000 7634000 2472000 0 2472000 0 12756000 9954000 12756000 9954000 30.92 1830441 30.92 1858500 0.01 0.01 3954546 2439024 2.12 16478066 103834 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,192,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,457,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock options were granted during the three months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,422,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.54</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.04</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value (in thousands)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,090,182 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,107,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(451,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,127,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,618,545 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.57 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost capitalized to inventory</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $2.3 million and $7.8 million, respectively. This is expected to be recognized over the years 2022 through 2027.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options issued under the Company's equity incentive plans. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company granted 105,000 performance-based stock options. Of these performance-based stock options, performance obligations had been met for 90,000 options which became exercisable in a prior period. Of these performance-based stock options, 90,000 options expired during the nine months ended September 30, 2022. No performance-based stock options were outstanding as of September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based stock option expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the above-noted RSU and restricted stock award outstanding amounts are performance-based RSUs which vest only upon the achievement of certain targets. Performance-based RSUs contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company granted performance-based RSUs of which 165,974 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted performance-based RSUs of which 111,806 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSU expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,192,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,457,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7192540 13.89 140000 3.05 204232 12.49 6105 1.04 1457019 10.33 5665184 14.60 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,422,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.54</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.04</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value (in thousands)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5665184 4422595 P5Y6M14D P5Y14D 14.60 15.32 9.10 9.44 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,090,182 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,107,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(451,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,127,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,618,545 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.57 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2090182 10.77 4107083 1.55 451703 8.68 1127017 3.43 4618545 4.57 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost capitalized to inventory</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based stock option expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSU expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 167000 82000 570000 257000 151000 266000 1052000 4340000 911000 3281000 6557000 14461000 1229000 3629000 8179000 19058000 69000 77000 186000 319000 2300000 7800000 P1Y P2Y P10Y P5Y P7Y 105000 90000 90000 0 0 230000 P1Y P3Y P10Y 165974 111806 0 818000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. INCOME TAXES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2022 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$47.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions due to the valuation allowance. At September 30, 2022, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2022, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.</span></div> 0 -47900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. COMMITMENTS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2022, the Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. This commitment was entered into to ensure proper material quantities to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop and commercialize our next generation AST platform.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 the commitment remains </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the Company has not taken delivery of any inventory.</span></div> 11900000 11900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. LEASES</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. LEASES</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 219000 195000 712000 502000 684000 0 1109000 0 0 0 0 0 0 0 2760000 0 254000 257000 818000 816000 240000 0 462000 0 26000 40000 67000 99000 P2Y9M18D 0.071 P2Y6M 0.046 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 227000 180000 968000 721000 1047000 721000 584000 173000 0 0 0 0 2826000 1795000 278000 144000 2548000 1651000 3000000 The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 351000 1154000 661000 206000 640000 0 3012000 0 3012000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. GEOGRAPHIC AND REVENUE DISAGGREGATION</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment. Sales to customers outside the U.S. represented 14% and 8% for the three months ended September 30, 2022 and 2021, respectively, and 14% and 12% for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, balances due from foreign customers, in U.S. dollars, were $0.6 million and $0.7 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Pheno revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease revenue included in net sales was $0.2 million and $0.5 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million for each of the nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents property and equipment, net by geographic territory (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 0.14 0.08 0.14 0.12 600000 700000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Pheno revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2551000 2874000 8390000 7406000 409000 248000 1390000 1033000 2960000 3122000 9780000 8439000 2933000 3084000 9669000 8324000 27000 38000 111000 115000 2960000 3122000 9780000 8439000 2532000 2773000 8554000 7474000 428000 349000 1226000 965000 2960000 3122000 9780000 8439000 200000 500000 1300000 1300000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents property and equipment, net by geographic territory (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3383000 5014000 238000 375000 3621000 5389000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18. STOCKHOLDERS' EQUITY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2020 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2020, the Company entered into a securities purchase agreement (the “December 2020 Securities Purchase Agreement”) with Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips, or entities affiliated with such persons (collectively, the “Original Purchasers”), for the issuance and sale by the Company of an aggregate of 4,166,663 shares of the Company’s common stock. Each of Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips is a member of the Company’s board of directors. Mr. Phillips also serves as the Company’s President and Chief Executive Officer.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Schuler Trust, which was the entity affiliated with Jack W. Schuler that originally entered into the December 2020 Securities Purchase Agreement for the purchase of 3,964,843 shares for an aggregate purchase price of approximately $30.5 million, subsequently entered into an assignment and assumption agreement whereby it assigned all of its rights and obligations as an Original Purchaser to three other entities under the December 2020 Securities Purchase Agreement (collectively, the “Schuler Purchasers”). These three entities are related to Jack W. Schuler but are not affiliates of his.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the December 2020 Securities Purchase Agreement, the Original Purchasers agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $7.68 per share, for an aggregate purchase price of approximately $32 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2020 Securities Purchase Agreement contemplated that the closing of the purchase and sale of the shares would occur in three tranches, with the first and second tranches having closed on February 19, 2021 and April 9, 2021, respectively, whereby the Company received total proceeds of approximately $21.3 million which were recorded to contributed capital.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, the Company entered into a rescission agreement (the “Rescission Agreement”) with the Schuler Purchasers and the Schuler Trust pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 shares in the first two tranche closings and the third tranche (as discussed below) under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The 2,643,228 Shares re-acquired by the Company from the Schuler Purchasers as a result of the Rescission Agreement were treated as a reduction to contributed capital and were not outstanding for purposes of the calculation of basic and diluted earnings per share.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, the Company closed the final third tranche in connection with the December 2020 Securities Purchase Agreement and received total proceeds of approximately $0.5 million. In accordance with the Rescission Agreement, the Schuler Purchasers did not participate in the third tranche. During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement, which were recorded to contributed capital, after giving effect to the Rescission Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2021 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2021, the Company entered into a new securities purchase agreement (the “September 2021 Securities Purchase Agreement”) with the Schuler Purchasers for the issuance and sale by the Company of an aggregate of 3,954,546 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Shares”). Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the September 2021 Securities Purchase Agreement, the Schuler Purchasers agreed to purchase the Series A Preferred Shares at a purchase price of $7.70 per share for an aggregate purchase price of approximately $30.5 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The September 2021 Securities Purchase Agreement contemplated the closing of the purchase and sale of the Series A Preferred Shares would occur in two tranches. The first tranche closed on the date of the execution of the September 2021 Securities Purchase Agreement whereby an aggregate of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Purchasers. The Company received total proceeds of approximately $20.3 million, which was recorded to contributed capital during the three months ended September 30, 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second tranche (the “Tranche Right”) had not closed by September 30, 2021 and was concluded to be an obligation of the Schuler Purchasers to acquire, and the Company to sell an additional 1,318,182 Series A Preferred Shares at a purchase price of $7.70 per share for proceeds of $10.2 million, subsequent to the September 30, 2021 balance sheet date. The Company concluded the Tranche Right met the definition of a freestanding financial instrument which was recorded within stockholder’s equity. The value of this Tranche Right as September 30, 2021 was $2.5 million. The estimated fair value of the Tranche Right represented a Level 3 measurement as this financial instrument has no market activity. The estimated fair value of the Tranche Right was determined as the excess value of the forward contract when compared to the underlying asset. The fair value of this forward contract can be represented by the difference between the contractual forward price of $7.70 and the prevailing exchange-traded common stock price ($5.81 at September 22, 2021 and $5.83 at September 30, 2021), multiplied by 1,318,182 Series A Preferred Shares. On October 29, 2021, the Company closed the final second tranche in connection with the September 2021 Securities Purchase Agreement whereby the Company issued and sold an aggregate of 1,318,182 Series A Preferred Shares to the Schuler Purchasers and received total proceeds of approximately $10.2 million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Exchange Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, certain holders of the Notes exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock pursuant to their respective exchange agreement. Using the closing stock price on September 22, 2021 of $5.81, the 5,945,718 shares of the Company’s common stock were determined to have a value of $34.5 million, which was recorded to contributed capital during the nine months ended September 30, 2021. See Note 10, Convertible Notes, for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, a holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company's common stock pursuant to the March 2022 Exchange Agreement. The 10,798,482 shares of the Company’s common stock were determined to have a value of $10.2 million, which was recorded to contributed capital during the nine months ended September 30, 2022. See Note 10, Convertible Notes for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, for an aggregate purchase price of $4.0 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock. The gain from the extinguishment of the Notes was treated as a capital transaction. The net gain on extinguishment was $29.8 million during the three months ended months ended September 30, 2022, and was recorded to contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Warrant meets the criteria for classification in stockholders’ equity and was recorded in contributed capital at fair value of $3.8 million on August 15, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Public Offering</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2022, the Company completed a public offering 17,500,000 shares of its common stock at a public offering price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.</span></div> 4166663 3964843 30500000 3 3 7.68 32000000 3 21300000 2643228 2 2643228 500000 201820 1500000 3954546 0.001 1 7.70 30500000 2 2636364 20300000 1318182 7.70 10200000 2500000 7.70 5.81 5.83 1318182 1318182 10200000 46000000 5945718 5.81 5945718 34500000 14000000 10798482 10798482 10200000 2439024 1.64 4000000 49900000 34900000 29800000 3800000 17500000 2.00 32900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 19. RELATED-PARTY TRANSACTIONS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Exchange Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, Convertible Notes, the Company carries Notes. The Schuler Family Foundation (the “Foundation”) previously held an aggregate of $42.0 million of the Notes. Jack W. Schuler, a member of the Company’s board of directors, is the President of the Foundation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, the Foundation transferred by gift the $42.0 million aggregate principal amount of Notes held by the Foundation to the Schuler Initiative Supporting Charitable Trust (the “Supporting Organization”), a tax-exempt organization that is not an affiliate of Jack W. Schuler.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 Exchange Transactions the Supporting Organization exchanged $42.0 million in aggregate principal amount of Notes held by it for 5,428,699 shares of the Company's common stock. Using the closing stock price on September 22, 2021 of $5.81, the 5,428,699 shares of the Company's common stock were determined to have a value of $31.5 million which was recorded to contributed capital for the three months ended September 30, 2021. The Supporting Organization had the same or similar terms as the other counter parties. The Company determined the 2021 Exchange Transactions did not meet the criteria of a capital transaction and was recorded as a gain on extinguishment of debt. See Note 10, Convertible Notes and Note 18, Stockholders' Equity, for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2020 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 24, 2020, the Company entered into the December 2020 Securities Purchase Agreement with the Original Purchasers for the issuance and sale by the Company of 4,166,663 shares of the Company’s common stock. The Original Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons. See Note 18, Stockholders' Equity, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, the Company entered into the Rescission Agreement with the Schuler Purchasers and the Schuler Trust, an entity affiliated with Jack W. Schuler, pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 Shares in the first two tranche closings and the third tranche under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. See Note 18, Stockholders' Equity, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement after giving effect to the Rescission Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2021 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the Company entered into the September 2021 Securities Purchase Agreement with the Schuler Purchasers for the issuance and sale by the Company of 3,954,546 Series A Preferred Shares. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company issued 2,636,364 Series A Preferred Shares and received total proceeds of approximately $20.3 million under the September 2021 Securities Purchase Agreement. See Note 18, Stockholders' Equity, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 24, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2022 Securities Purchase Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schuler Trust</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the issuance and sale by the Company of 2,439,024 shares of the Company’s common stock. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jack Schuler serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust. See Note 18, Stockholders’ Equity, for further information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for the Secured Note in an aggregate principal amount of $34.9 million and a warrant to acquire the Company’s common stock. The net gain on extinguishment was $29.8 million during the nine months ended September 30, 2022, and was recorded as contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.</span></div> 42000000 42000000 42000000 5428699 5.81 5428699 31500000 4166663 2643228 201820 1500000 3954546 2636364 20300000 2439024 49900000 34900000 29800000 EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 331 406 1 false 96 0 false 11 false false R1.htm 0000001 - Document - Cover Page Sheet http://acceleratediagnostics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Notes 7 false false R8.htm 0000008 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements Notes 8 false false R9.htm 0000009 - Disclosure - Concentration of Credit Risk Sheet http://acceleratediagnostics.com/role/ConcentrationofCreditRisk Concentration of Credit Risk Notes 9 false false R10.htm 0000010 - Disclosure - Fair Value of Financial Instruments Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 0000011 - Disclosure - Investments Sheet http://acceleratediagnostics.com/role/Investments Investments Notes 11 false false R12.htm 0000012 - Disclosure - Inventory Sheet http://acceleratediagnostics.com/role/Inventory Inventory Notes 12 false false R13.htm 0000013 - Disclosure - Property and Equipment Sheet http://acceleratediagnostics.com/role/PropertyandEquipment Property and Equipment Notes 13 false false R14.htm 0000014 - Disclosure - Deferred Revenue and Remaining Performance Obligations Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations Deferred Revenue and Remaining Performance Obligations Notes 14 false false R15.htm 0000015 - Disclosure - Long-Term Debt Sheet http://acceleratediagnostics.com/role/LongTermDebt Long-Term Debt Notes 15 false false R16.htm 0000016 - Disclosure - Convertible Notes Notes http://acceleratediagnostics.com/role/ConvertibleNotes Convertible Notes Notes 16 false false R17.htm 0000017 - Disclosure - Long-Term Debt Related-Party Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedParty Long-Term Debt Related-Party Notes 17 false false R18.htm 0000018 - Disclosure - Loss Per Share Sheet http://acceleratediagnostics.com/role/LossPerShare Loss Per Share Notes 18 false false R19.htm 0000019 - Disclosure - Employee Equity-Based Compensation Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation Employee Equity-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Income Taxes Sheet http://acceleratediagnostics.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 0000021 - Disclosure - Commitments Sheet http://acceleratediagnostics.com/role/Commitments Commitments Notes 21 false false R22.htm 0000022 - Disclosure - Leases Sheet http://acceleratediagnostics.com/role/Leases Leases Notes 22 false false R23.htm 0000023 - Disclosure - Geographic and Revenue Disaggregation Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation Geographic and Revenue Disaggregation Notes 23 false false R24.htm 0000024 - Disclosure - Stockholders' Equity Sheet http://acceleratediagnostics.com/role/StockholdersEquity Stockholders' Equity Notes 24 false false R25.htm 0000025 - Disclosure - Related-Party Transactions Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactions Related-Party Transactions Notes 25 false false R26.htm 0000026 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Policies http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies 26 false false R27.htm 0000027 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) Tables http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies 27 false false R28.htm 0000028 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://acceleratediagnostics.com/role/FairValueofFinancialInstruments 28 false false R29.htm 0000029 - Disclosure - Investments (Tables) Sheet http://acceleratediagnostics.com/role/InvestmentsTables Investments (Tables) Tables http://acceleratediagnostics.com/role/Investments 29 false false R30.htm 0000030 - Disclosure - Inventory (Tables) Sheet http://acceleratediagnostics.com/role/InventoryTables Inventory (Tables) Tables http://acceleratediagnostics.com/role/Inventory 30 false false R31.htm 0000031 - Disclosure - Property and Equipment (Tables) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://acceleratediagnostics.com/role/PropertyandEquipment 31 false false R32.htm 0000032 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables) Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables Deferred Revenue and Remaining Performance Obligations (Tables) Tables http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations 32 false false R33.htm 0000033 - Disclosure - Long-Term Debt (Tables) Sheet http://acceleratediagnostics.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://acceleratediagnostics.com/role/LongTermDebt 33 false false R34.htm 0000034 - Disclosure - Convertible Notes (Tables) Notes http://acceleratediagnostics.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://acceleratediagnostics.com/role/ConvertibleNotes 34 false false R35.htm 0000035 - Disclosure - Long-Term Debt Related-Party (Tables) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables Long-Term Debt Related-Party (Tables) Tables http://acceleratediagnostics.com/role/LongTermDebtRelatedParty 35 false false R36.htm 0000036 - Disclosure - Loss Per Share (Tables) Sheet http://acceleratediagnostics.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://acceleratediagnostics.com/role/LossPerShare 36 false false R37.htm 0000037 - Disclosure - Employee Equity-Based Compensation (Tables) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables Employee Equity-Based Compensation (Tables) Tables http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation 37 false false R38.htm 0000038 - Disclosure - Leases (Tables) Sheet http://acceleratediagnostics.com/role/LeasesTables Leases (Tables) Tables http://acceleratediagnostics.com/role/Leases 38 false false R39.htm 0000039 - Disclosure - Geographic and Revenue Disaggregation (Tables) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables Geographic and Revenue Disaggregation (Tables) Tables http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation 39 false false R40.htm 0000040 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) Details http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables 40 false false R41.htm 0000041 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Effect of Restatement (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Effect of Restatement (Details) Details 41 false false R42.htm 0000042 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) Details 42 false false R43.htm 0000043 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) Details 43 false false R44.htm 0000044 - Disclosure - Recently Issued Accounting Pronouncements (Details) Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails Recently Issued Accounting Pronouncements (Details) Details http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements 44 false false R45.htm 0000045 - Disclosure - Concentration of Credit Risk (Details) Sheet http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails Concentration of Credit Risk (Details) Details http://acceleratediagnostics.com/role/ConcentrationofCreditRisk 45 false false R46.htm 0000046 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) Details 46 false false R47.htm 0000047 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 47 false false R48.htm 0000048 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails Investments - Schedule of Available-for-sale Securities (Details) Details 48 false false R49.htm 0000049 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails Investments - Schedule of Available-for-Sale Investment Maturities (Details) Details 49 false false R50.htm 0000050 - Disclosure - Investments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 50 false false R51.htm 0000051 - Disclosure - Investments - Unrealized Losses or Gains on Equity Securities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsUnrealizedLossesorGainsonEquitySecuritiesDetails Investments - Unrealized Losses or Gains on Equity Securities (Details) Details 51 false false R52.htm 0000052 - Disclosure - Inventory (Details) Sheet http://acceleratediagnostics.com/role/InventoryDetails Inventory (Details) Details http://acceleratediagnostics.com/role/InventoryTables 52 false false R53.htm 0000053 - Disclosure - Property and Equipment - Property and Equipment at Cost (Details) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails Property and Equipment - Property and Equipment at Cost (Details) Details 53 false false R54.htm 0000054 - Disclosure - Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) Details 54 false false R55.htm 0000055 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details) Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails Deferred Revenue and Remaining Performance Obligations (Details) Details http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables 55 false false R56.htm 0000056 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 56 false false R57.htm 0000057 - Disclosure - Long-Term Debt - Schedule of Long-term Debt (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails Long-Term Debt - Schedule of Long-term Debt (Details) Details 57 false false R58.htm 0000058 - Disclosure - Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details) Details 58 false false R59.htm 0000059 - Disclosure - Convertible Notes - Narrative (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails Convertible Notes - Narrative (Details) Details 59 false false R60.htm 0000060 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails Convertible Notes - Schedule of Interest Expense (Details) Details 60 false false R61.htm 0000061 - Disclosure - Convertible Notes - Gain on Extinguishment (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails Convertible Notes - Gain on Extinguishment (Details) Details 61 false false R62.htm 0000062 - Disclosure - Convertible Notes - Schedule of Notes and New Notes (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails Convertible Notes - Schedule of Notes and New Notes (Details) Details 62 false false R63.htm 0000063 - Disclosure - Long-Term Debt Related-Party - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails Long-Term Debt Related-Party - Narrative (Details) Details 63 false false R64.htm 0000064 - Disclosure - Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details) Notes http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details) Details 64 false false R65.htm 0000065 - Disclosure - Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) Details 65 false false R66.htm 0000066 - Disclosure - Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) Details 66 false false R67.htm 0000067 - Disclosure - Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) Sheet http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) Details 67 false false R68.htm 0000068 - Disclosure - Loss Per Share - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails Loss Per Share - Narrative (Details) Details 68 false false R69.htm 0000069 - Disclosure - Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) Details 69 false false R70.htm 0000070 - Disclosure - Employee Equity-Based Compensation - Narrative (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails Employee Equity-Based Compensation - Narrative (Details) Details 70 false false R71.htm 0000071 - Disclosure - Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) Details 71 false false R72.htm 0000072 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails Employee Equity-Based Compensation - Restricted Stock Activity (Details) Details 72 false false R73.htm 0000073 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) Details 73 false false R74.htm 0000074 - Disclosure - Income Taxes (Details) Sheet http://acceleratediagnostics.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://acceleratediagnostics.com/role/IncomeTaxes 74 false false R75.htm 0000075 - Disclosure - Commitments (Details) Sheet http://acceleratediagnostics.com/role/CommitmentsDetails Commitments (Details) Details http://acceleratediagnostics.com/role/Commitments 75 false false R76.htm 0000076 - Disclosure - Leases - Assets and Liabilities (Details) Sheet http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails Leases - Assets and Liabilities (Details) Details 76 false false R77.htm 0000077 - Disclosure - Leases - Maturities of Lease Liabilities (Details) Sheet http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails Leases - Maturities of Lease Liabilities (Details) Details 77 false false R78.htm 0000078 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) Sheet http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails Leases - Sales-type Lease Receivable Maturity (Details) Details 78 false false R79.htm 0000079 - Disclosure - Geographic and Revenue Disaggregation - Narrative (Details) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails Geographic and Revenue Disaggregation - Narrative (Details) Details 79 false false R80.htm 0000080 - Disclosure - Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) Details 80 false false R81.htm 0000081 - Disclosure - Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) Details 81 false false R82.htm 0000082 - Disclosure - Stockholders' Equity (Details) Sheet http://acceleratediagnostics.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://acceleratediagnostics.com/role/StockholdersEquity 82 false false R83.htm 0000083 - Disclosure - Related-Party Transactions (Details) Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://acceleratediagnostics.com/role/RelatedPartyTransactions 83 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:PropertyPlantAndEquipmentUsefulLife - axdx-20220930.htm 4 axdx-20220930.htm a09302022-exh311a.htm a09302022-exh312a.htm a09302022-exh32a.htm axdx-20220930.xsd axdx-20220930_cal.xml axdx-20220930_def.xml axdx-20220930_lab.xml axdx-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "axdx-20220930.htm": { "axisCustom": 0, "axisStandard": 31, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 1149, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 331, "dts": { "calculationLink": { "local": [ "axdx-20220930_cal.xml" ] }, "definitionLink": { "local": [ "axdx-20220930_def.xml" ] }, "inline": { "local": [ "axdx-20220930.htm" ] }, "labelLink": { "local": [ "axdx-20220930_lab.xml" ] }, "presentationLink": { "local": [ "axdx-20220930_pre.xml" ] }, "schema": { "local": [ "axdx-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 652, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://xbrl.sec.gov/dei/2022": 5, "total": 10 }, "keyCustom": 37, "keyStandard": 369, "memberCustom": 33, "memberStandard": 60, "nsprefix": "axdx", "nsuri": "http://acceleratediagnostics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://acceleratediagnostics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Fair Value of Financial Instruments", "menuCat": "Notes", "order": "10", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Investments", "menuCat": "Notes", "order": "11", "role": "http://acceleratediagnostics.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Inventory", "menuCat": "Notes", "order": "12", "role": "http://acceleratediagnostics.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "13", "role": "http://acceleratediagnostics.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Deferred Revenue and Remaining Performance Obligations", "menuCat": "Notes", "order": "14", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations", "shortName": "Deferred Revenue and Remaining Performance Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Long-Term Debt", "menuCat": "Notes", "order": "15", "role": "http://acceleratediagnostics.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Convertible Notes", "menuCat": "Notes", "order": "16", "role": "http://acceleratediagnostics.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:LongTermDebtRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Long-Term Debt Related-Party", "menuCat": "Notes", "order": "17", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedParty", "shortName": "Long-Term Debt Related-Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:LongTermDebtRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Loss Per Share", "menuCat": "Notes", "order": "18", "role": "http://acceleratediagnostics.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Employee Equity-Based Compensation", "menuCat": "Notes", "order": "19", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation", "shortName": "Employee Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://acceleratediagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Commitments", "menuCat": "Notes", "order": "21", "role": "http://acceleratediagnostics.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Leases", "menuCat": "Notes", "order": "22", "role": "http://acceleratediagnostics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Geographic and Revenue Disaggregation", "menuCat": "Notes", "order": "23", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation", "shortName": "Geographic and Revenue Disaggregation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "24", "role": "http://acceleratediagnostics.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Related-Party Transactions", "menuCat": "Notes", "order": "25", "role": "http://acceleratediagnostics.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "26", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "27", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Fair Value of Financial Instruments (Tables)", "menuCat": "Tables", "order": "28", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "29", "role": "http://acceleratediagnostics.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "30", "role": "http://acceleratediagnostics.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "31", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables)", "menuCat": "Tables", "order": "32", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables", "shortName": "Deferred Revenue and Remaining Performance Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Long-Term Debt (Tables)", "menuCat": "Tables", "order": "33", "role": "http://acceleratediagnostics.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Convertible Notes (Tables)", "menuCat": "Tables", "order": "34", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "shortName": "Convertible Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Long-Term Debt Related-Party (Tables)", "menuCat": "Tables", "order": "35", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables", "shortName": "Long-Term Debt Related-Party (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Loss Per Share (Tables)", "menuCat": "Tables", "order": "36", "role": "http://acceleratediagnostics.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Employee Equity-Based Compensation (Tables)", "menuCat": "Tables", "order": "37", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables", "shortName": "Employee Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:LeaseCostTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "38", "role": "http://acceleratediagnostics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeaseCostTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Geographic and Revenue Disaggregation (Tables)", "menuCat": "Tables", "order": "39", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables", "shortName": "Geographic and Revenue Disaggregation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "40", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AssetImpairmentCharges", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Effect of Restatement (Details)", "menuCat": "Details", "order": "41", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Effect of Restatement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ibc6a6e5800b846ca8b89547bcbd77f04_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ibd78accb381c4b52ae3acfa1830b606d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details)", "menuCat": "Details", "order": "42", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ibd78accb381c4b52ae3acfa1830b606d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ibd78accb381c4b52ae3acfa1830b606d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details)", "menuCat": "Details", "order": "43", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ibd78accb381c4b52ae3acfa1830b606d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Recently Issued Accounting Pronouncements (Details)", "menuCat": "Details", "order": "44", "role": "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails", "shortName": "Recently Issued Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i1cb4feaf6f5d4520a32c40c9b13c6c3b_I20220101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i686e4fb6b52844a890f814a7c581ba80_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Concentration of Credit Risk (Details)", "menuCat": "Details", "order": "45", "role": "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "shortName": "Concentration of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i686e4fb6b52844a890f814a7c581ba80_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details)", "menuCat": "Details", "order": "46", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i45fd959444034ea5a842279b1183395b_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ifb6bfab29a134349b5e32b5ca25b48ce_I20220815", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "menuCat": "Details", "order": "47", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iaee81d73dea94fee9c35227fdd0a19af_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details)", "menuCat": "Details", "order": "48", "role": "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails", "shortName": "Investments - Schedule of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details)", "menuCat": "Details", "order": "49", "role": "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "shortName": "Investments - Schedule of Available-for-Sale Investment Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "span", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Investments - Narrative (Details)", "menuCat": "Details", "order": "50", "role": "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "span", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Investments - Unrealized Losses or Gains on Equity Securities (Details)", "menuCat": "Details", "order": "51", "role": "http://acceleratediagnostics.com/role/InvestmentsUnrealizedLossesorGainsonEquitySecuritiesDetails", "shortName": "Investments - Unrealized Losses or Gains on Equity Securities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Inventory (Details)", "menuCat": "Details", "order": "52", "role": "http://acceleratediagnostics.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Property and Equipment - Property and Equipment at Cost (Details)", "menuCat": "Details", "order": "53", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails", "shortName": "Property and Equipment - Property and Equipment at Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i3320c33a97844ca9a3ea95a5e3f9abf0_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details)", "menuCat": "Details", "order": "54", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails", "shortName": "Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details)", "menuCat": "Details", "order": "55", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "shortName": "Deferred Revenue and Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Long-Term Debt - Narrative (Details)", "menuCat": "Details", "order": "56", "role": "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i749673efb16c442386a7dcc00f0ad3e4_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "axdx:NumberOfDebtInstruments", "reportCount": 1, "unique": true, "unitRef": "loan", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Long-Term Debt - Schedule of Long-term Debt (Details)", "menuCat": "Details", "order": "57", "role": "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "shortName": "Long-Term Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details)", "menuCat": "Details", "order": "58", "role": "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails", "shortName": "Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Convertible Notes - Narrative (Details)", "menuCat": "Details", "order": "59", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "shortName": "Convertible Notes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i37630a0c960045d0beffbbe735cb2999_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "axdx:PaymentsToFundPrepaidForwardStockRepurchase", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i7f20beea7b0b400e91629dbe17e7b986_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i7f20beea7b0b400e91629dbe17e7b986_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "idec225055a2742429b76518a77822ff7_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details)", "menuCat": "Details", "order": "60", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "shortName": "Convertible Notes - Schedule of Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "idec225055a2742429b76518a77822ff7_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Convertible Notes - Gain on Extinguishment (Details)", "menuCat": "Details", "order": "61", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "shortName": "Convertible Notes - Gain on Extinguishment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Convertible Notes - Schedule of Notes and New Notes (Details)", "menuCat": "Details", "order": "62", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "shortName": "Convertible Notes - Schedule of Notes and New Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ic5273a30a655468784311f9bb2a3d3b0_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Long-Term Debt Related-Party - Narrative (Details)", "menuCat": "Details", "order": "63", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "shortName": "Long-Term Debt Related-Party - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ida8f0ede10e640ceb2332931bf5bb18b_D20220815-20220815", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details)", "menuCat": "Details", "order": "64", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "shortName": "Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "axdx:LongTermDebtRelatedPartyTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i017285ae73964fdf97b64dc282695040_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "axdx:LongTermDebtRelatedPartyTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i438582b5c8cf4217b25961b2f97a37fa_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details)", "menuCat": "Details", "order": "65", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "shortName": "Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "axdx:LongTermDebtRelatedPartyTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i438582b5c8cf4217b25961b2f97a37fa_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i83f88cd9c1f043a0bf022c9a17be5e5c_I20220930", "decimals": "1", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "year", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details)", "menuCat": "Details", "order": "66", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "shortName": "Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i83f88cd9c1f043a0bf022c9a17be5e5c_I20220930", "decimals": "1", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "year", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details)", "menuCat": "Details", "order": "67", "role": "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails", "shortName": "Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Loss Per Share - Narrative (Details)", "menuCat": "Details", "order": "68", "role": "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "shortName": "Loss Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i3320c33a97844ca9a3ea95a5e3f9abf0_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details)", "menuCat": "Details", "order": "69", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails", "shortName": "Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies", "menuCat": "Notes", "order": "7", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Employee Equity-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "70", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "shortName": "Employee Equity-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ide5e02f1e61949748be2600540e39e72_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details)", "menuCat": "Details", "order": "71", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails", "shortName": "Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i89418d31d0354785a19c661fe4acf17d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details)", "menuCat": "Details", "order": "72", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails", "shortName": "Employee Equity-Based Compensation - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i89418d31d0354785a19c661fe4acf17d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details)", "menuCat": "Details", "order": "73", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "shortName": "Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "74", "role": "http://acceleratediagnostics.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Commitments (Details)", "menuCat": "Details", "order": "75", "role": "http://acceleratediagnostics.com/role/CommitmentsDetails", "shortName": "Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Leases - Assets and Liabilities (Details)", "menuCat": "Details", "order": "76", "role": "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails", "shortName": "Leases - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Leases - Maturities of Lease Liabilities (Details)", "menuCat": "Details", "order": "77", "role": "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetInvestmentInLease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details)", "menuCat": "Details", "order": "78", "role": "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails", "shortName": "Leases - Sales-type Lease Receivable Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetInvestmentInLease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Geographic and Revenue Disaggregation - Narrative (Details)", "menuCat": "Details", "order": "79", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails", "shortName": "Geographic and Revenue Disaggregation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Recently Issued Accounting Pronouncements", "menuCat": "Notes", "order": "8", "role": "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements", "shortName": "Recently Issued Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie1c175b8da8445eebd954397f321df08_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "80", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "shortName": "Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i8892f278f74440b881f4578bb47be0e2_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i32c4f274535d4c06a5c34340ebbbb670_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details)", "menuCat": "Details", "order": "81", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "shortName": "Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i83b393ecc4ce47bb8a41af8efab67a6c_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i55e68df655a845cfa68f6ad82795fdc4_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "82", "role": "http://acceleratediagnostics.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "if766385044fa487f94b7a44e0b0bee2e_I20220822", "decimals": "2", "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i55e68df655a845cfa68f6ad82795fdc4_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Related-Party Transactions (Details)", "menuCat": "Details", "order": "83", "role": "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i6c69b3355a7c404682dd4f8f459eece5_D20210922-20210922", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Concentration of Credit Risk", "menuCat": "Notes", "order": "9", "role": "http://acceleratediagnostics.com/role/ConcentrationofCreditRisk", "shortName": "Concentration of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iacd4f3539392457c818dd74b6f74c1a3_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 96, "tag": { "axdx_A2021ExchangeTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Exchange Transaction [Member]", "label": "2021 Exchange Transaction [Member]", "terseLabel": "2021 Exchange Transaction" } } }, "localname": "A2021ExchangeTransactionMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_AcceleratePhenoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerate Pheno [Member]", "label": "Accelerate Pheno [Member]", "terseLabel": "Accelerate Pheno revenue" } } }, "localname": "AcceleratePhenoMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "axdx_AmortizationOfDebtIssuanceCostsRelatedParty": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Debt Issuance Costs, Related Party", "label": "Amortization of Debt Issuance Costs, Related Party", "terseLabel": "Amortization of debt discount related-party" } } }, "localname": "AmortizationOfDebtIssuanceCostsRelatedParty", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Supplemental Lease Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "axdx_August2022ExchangeTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2022 Exchange With Related Party [Member]", "label": "August 2022 Exchange Transaction [Member]", "terseLabel": "August 2022 Exchange Transaction" } } }, "localname": "August2022ExchangeTransactionMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_August2022PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2022 Public Offering", "label": "August 2022 Public Offering [Member]", "terseLabel": "August 2022 Public Offering" } } }, "localname": "August2022PublicOfferingMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_CertainDirectorsAndOfficersOrAffiliatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain Directors And Officers Or Affiliates [Member]", "label": "Certain Directors And Officers Or Affiliates [Member]", "terseLabel": "Original Purchasers" } } }, "localname": "CertainDirectorsAndOfficersOrAffiliatesMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_ConvertibleNotePurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Note Purchases [Member]", "label": "Convertible Note Purchases [Member]", "terseLabel": "Convertible Note Purchases" } } }, "localname": "ConvertibleNotePurchasesMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "axdx_ConvertibleNotesExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Exchange Agreement", "label": "Convertible Notes Exchange Agreement [Member]", "terseLabel": "Exchange Agreement" } } }, "localname": "ConvertibleNotesExchangeAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_ConvertiblePreferredStockSaleOrMergerTriggerSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion", "label": "Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion", "terseLabel": "Sale or merger trigger conversion ratio (in shares)" } } }, "localname": "ConvertiblePreferredStockSaleOrMergerTriggerSharesIssuedUponConversion", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "pureItemType" }, "axdx_DebtConversionConversionNumerator": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Conversion Numerator", "label": "Debt Conversion, Conversion Numerator", "terseLabel": "Conversion numerator (in usd per share)" } } }, "localname": "DebtConversionConversionNumerator", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtConversionConvertedInstrumentRelatedPartyContributedCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Converted Instrument, Related Party Contributed Capital", "label": "Debt Conversion, Converted Instrument, Related Party Contributed Capital", "terseLabel": "Capital contribution from related-party in connection with the exchange transaction" } } }, "localname": "DebtConversionConvertedInstrumentRelatedPartyContributedCapital", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_DebtConversionCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Cost", "label": "Debt Conversion, Cost", "terseLabel": "Reacquisition costs" } } }, "localname": "DebtConversionCost", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtConversionNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Number Of Tranches", "label": "Debt Conversion, Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "DebtConversionNumberOfTranches", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_DebtInstrumentConvertibleNumberOfEquityInstrumentAccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest", "label": "Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest", "terseLabel": "Debt instrument, convertible, number of accrued interest" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstrumentAccruedInterest", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_DebtInstrumentConvertibleThresholdPercentageofNotesTradingPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger", "terseLabel": "Trading price threshold, percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageofNotesTradingPriceTrigger", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "axdx_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "terseLabel": "Due in 1-3 years" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "terseLabel": "Due in 1-3 years" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_December2020SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2020 Securities Purchase Agreement [Member]", "label": "December 2020 Securities Purchase Agreement [Member]", "terseLabel": "December 2020 Securities Purchase Agreement" } } }, "localname": "December2020SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_EmbededWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Embeded Warrant [Member]", "label": "Embeded Warrant [Member]", "terseLabel": "Embeded Warrant" } } }, "localname": "EmbededWarrantMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_ExerciseOfOptionsAndRestrictedStockAwardsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Of Options And Restricted Stock Awards Issued", "label": "Exercise Of Options And Restricted Stock Awards Issued", "terseLabel": "Restricted stock awards released and exercise of options (in shares)" } } }, "localname": "ExerciseOfOptionsAndRestrictedStockAwardsIssued", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "axdx_ExtinguishedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extinguished Notes", "label": "Extinguished Notes [Member]", "terseLabel": "Extinguished Notes" } } }, "localname": "ExtinguishedNotesMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_FinanceLeaseCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, to be Paid, after Year Four", "label": "Finance Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_FinancialInstitutionsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Institutions One", "label": "Financial Institutions One [Member]", "terseLabel": "Financial Institutions One" } } }, "localname": "FinancialInstitutionsOneMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Institutions Three", "label": "Financial Institutions Three [Member]", "terseLabel": "Financial Institutions Three" } } }, "localname": "FinancialInstitutionsThreeMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Institutions Two", "label": "Financial Institutions Two [Member]", "terseLabel": "Financial Institutions Two" } } }, "localname": "FinancialInstitutionsTwoMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FivePointZeroPercentSecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Zero Percent Secured Promissory Note", "label": "Five Point Zero Percent Secured Promissory Note [Member]", "terseLabel": "5.0% Secured promissory note" } } }, "localname": "FivePointZeroPercentSecuredPromissoryNoteMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_GrossMarginPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Margin Percentage", "label": "Gross Margin Percentage", "terseLabel": "Gross margin" } } }, "localname": "GrossMarginPercentage", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "pureItemType" }, "axdx_IncreaseDecreaseRelatedPartyAccruedInterest": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Related Party Accrued Interest", "label": "Increase (Decrease) Related Party Accrued Interest", "terseLabel": "Accrued interest from related-party" } } }, "localname": "IncreaseDecreaseRelatedPartyAccruedInterest", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_InstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments [Member]", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "localname": "InstrumentsMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "axdx_InterestPayableRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Payable, Related Party, Noncurrent", "label": "Interest Payable, Related Party, Noncurrent", "terseLabel": "Accrued interest related-party" } } }, "localname": "InterestPayableRelatedPartyNoncurrent", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "axdx_InventoryTransferredtoFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory Transferred to Fixed Assets", "label": "Inventory Transferred to Fixed Assets", "terseLabel": "Net transfer of instruments (to) from inventory to property and equipment" } } }, "localname": "InventoryTransferredtoFixedAssets", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_IssuanceOfCommonStockNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock, Number of Tranches", "label": "Issuance of Common Stock, Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "IssuanceOfCommonStockNumberOfTranches", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "axdx_JackWSchulerLivingTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jack W. Schuler Living Trust", "label": "Jack W. Schuler Living Trust [Member]", "terseLabel": "Schuler Trust" } } }, "localname": "JackWSchulerLivingTrustMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, after Year Four", "label": "Long-Term Debt, Maturity, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "axdx_LongTermDebtRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Debt Related Party [Text Block]", "label": "Long Term Debt Related Party [Text Block]", "terseLabel": "Long-Term Debt Related-Party" } } }, "localname": "LongTermDebtRelatedPartyTextBlock", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedParty" ], "xbrltype": "textBlockItemType" }, "axdx_March2022ExchangeTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2022 Exchange Transaction [Member]", "label": "March 2022 Exchange Transaction [Member]", "terseLabel": "March 2022 Exchange Transaction" } } }, "localname": "March2022ExchangeTransactionMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_March2022SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2022 Securities Purchase Agreement", "label": "March 2022 Securities Purchase Agreement [Member]", "terseLabel": "March 2022 Securities Purchase Agreement" } } }, "localname": "March2022SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_NumberOfCapitalAssetFinancingCompanies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Capital Asset Financing Companies", "label": "Number of Capital Asset Financing Companies", "terseLabel": "Number of capital asset financing companies" } } }, "localname": "NumberOfCapitalAssetFinancingCompanies", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_NumberOfDebtInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Debt Instruments", "label": "Number of Debt Instruments", "terseLabel": "Number of loan agreements" } } }, "localname": "NumberOfDebtInstruments", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Customer", "label": "One Customer [Member]", "terseLabel": "One customer" } } }, "localname": "OneCustomerMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_OtherLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Loans", "label": "Other Loans [Member]", "terseLabel": "Loans - various interest", "verboseLabel": "Other loans" } } }, "localname": "OtherLoansMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "axdx_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "axdx_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program", "label": "Paycheck Protection Program [Member]", "terseLabel": "Paycheck Protection Program" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_PaymentsOfDebtConversionCosts": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Of Debt Conversion Costs", "label": "Payments Of Debt Conversion Costs", "negatedTerseLabel": "Transaction costs related to debt exchange" } } }, "localname": "PaymentsOfDebtConversionCosts", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_PaymentsToFundPrepaidForwardStockRepurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Fund Prepaid Forward Stock Repurchase", "label": "Payments To Fund Prepaid Forward Stock Repurchase", "terseLabel": "Funded prepaid forward" } } }, "localname": "PaymentsToFundPrepaidForwardStockRepurchase", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units", "label": "Performance-based Restricted Stock Units [Member]", "terseLabel": "Performance-based RSU expense" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_PrepaidForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Forward", "label": "Prepaid Forward [Member]", "terseLabel": "Prepaid Forward" } } }, "localname": "PrepaidForwardMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_ProductsandServicesnotYetDeliveredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Products and Services not Yet Delivered [Member]", "label": "Products and Services not Yet Delivered [Member]", "terseLabel": "Products and services not yet delivered" } } }, "localname": "ProductsandServicesnotYetDeliveredMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "axdx_RelatedPartyNumberOfRelatedEntities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party, Number of Related Entities", "label": "Related Party, Number of Related Entities", "terseLabel": "Non-affiliate related entities" } } }, "localname": "RelatedPartyNumberOfRelatedEntities", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "axdx_RestrictedStockUnitsAndRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units And Restricted Stock Awards [Member]", "label": "Restricted Stock Units And Restricted Stock Awards [Member]", "terseLabel": "RSUs and RSAs" } } }, "localname": "RestrictedStockUnitsAndRestrictedStockAwardsMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "axdx_SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_SchulerFamilyFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schuler Family Foundation [Member]", "label": "Schuler Family Foundation [Member]", "terseLabel": "Schuler Family Foundation" } } }, "localname": "SchulerFamilyFoundationMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "axdx_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "axdx_September2021RescissionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 Rescission Agreement", "label": "September 2021 Rescission Agreement [Member]", "terseLabel": "September 2021 Rescission Agreement" } } }, "localname": "September2021RescissionAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_September2021SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 Securities Purchase Agreement", "label": "September 2021 Securities Purchase Agreement [Member]", "terseLabel": "September 2021 Securities Purchase Agreement" } } }, "localname": "September2021SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_September2021SecuritiesPurchaseAgreementSecondTrancheRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 Securities Purchase Agreement, Second Tranche Right", "label": "September 2021 Securities Purchase Agreement, Second Tranche Right [Member]", "terseLabel": "Tranche Right" } } }, "localname": "September2021SecuritiesPurchaseAgreementSecondTrancheRightMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTermOfAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award", "terseLabel": "Expected term of award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTermOfAward", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value (in usd per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value", "terseLabel": "Weighted average fair value (in usd per shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "axdx_StandardProductWarrantyAccrualIncreaseDecreaseForWarrantiesIssuedAndAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments", "label": "Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments", "terseLabel": "Provisions (reversals), net" } } }, "localname": "StandardProductWarrantyAccrualIncreaseDecreaseForWarrantiesIssuedAndAdjustments", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_StandardProductWarrantyInstrumentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty, Instruments, Term", "label": "Standard Product Warranty, Instruments, Term", "terseLabel": "Instrument warranty term" } } }, "localname": "StandardProductWarrantyInstrumentsTerm", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_StandardProductWarrantyKitsAndAccessoriesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty, Kits And Accessories, Term", "label": "Standard Product Warranty, Kits And Accessories, Term", "terseLabel": "Kits and accessories warranty term" } } }, "localname": "StandardProductWarrantyKitsAndAccessoriesTerm", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_StockholdersEquityTrancheRight": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Tranche Right", "label": "Stockholders' Equity, Tranche Right", "terseLabel": "Tranche right value" } } }, "localname": "StockholdersEquityTrancheRight", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_TreasuryStockAcquiredNumberOfSharesPrepaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock Acquired, Number Of Shares Prepaid", "label": "Treasury Stock Acquired, Number Of Shares Prepaid", "terseLabel": "Stock underlying the prepaid forward (in shares)" } } }, "localname": "TreasuryStockAcquiredNumberOfSharesPrepaid", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "axdx_TwoPointFiveZeroConvertibleNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Five Zero Convertible Notes Due 2023 [Member]", "label": "Two Point Five Zero Convertible Notes Due 2023 [Member]", "terseLabel": "2.50% Convertible notes due 2023" } } }, "localname": "TwoPointFiveZeroConvertibleNotesDue2023Member", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_TwoPointFiveZeroNewConvertibleNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Five Zero New Convertible Notes Due 2023", "label": "Two Point Five Zero New Convertible Notes Due 2023 [Member]", "terseLabel": "New Notes" } } }, "localname": "TwoPointFiveZeroNewConvertibleNotesDue2023Member", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_WarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants Issued", "label": "Warrants Issued", "terseLabel": "Fair value of common stock warrant issued to related-party in connection with exchange transaction" } } }, "localname": "WarrantsIssued", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r805" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r806" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r807" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r802" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r804" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r737", "r866", "r887", "r888", "r889" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r256", "r257", "r402", "r433", "r766", "r768" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r204", "r262", "r273", "r280", "r352", "r520", "r521", "r522", "r536", "r537", "r560", "r563", "r566", "r567", "r643" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect of accounting changes" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r204", "r262", "r273", "r280", "r352", "r520", "r521", "r522", "r536", "r537", "r560", "r563", "r566", "r567", "r643" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r204", "r262", "r273", "r280", "r352", "r520", "r521", "r522", "r536", "r537", "r560", "r563", "r566", "r567", "r643" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r329", "r787", "r864", "r901" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r384", "r385", "r386", "r387", "r481", "r683", "r718", "r738", "r739", "r784", "r795", "r801", "r860", "r892", "r893", "r894", "r895", "r896", "r897" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r384", "r385", "r386", "r387", "r481", "r683", "r718", "r738", "r739", "r784", "r795", "r801", "r860", "r892", "r893", "r894", "r895", "r896", "r897" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r329", "r787", "r864", "r901" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r326", "r686", "r785", "r800", "r855", "r856", "r864", "r900" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r326", "r686", "r785", "r800", "r855", "r856", "r864", "r900" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r384", "r385", "r386", "r387", "r473", "r481", "r511", "r512", "r513", "r659", "r683", "r718", "r738", "r739", "r784", "r795", "r801", "r854", "r860", "r893", "r894", "r895", "r896", "r897" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r384", "r385", "r386", "r387", "r473", "r481", "r511", "r512", "r513", "r659", "r683", "r718", "r738", "r739", "r784", "r795", "r801", "r854", "r860", "r893", "r894", "r895", "r896", "r897" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r256", "r257", "r402", "r433", "r767", "r768" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r259", "r260", "r261", "r275", "r276", "r296", "r566", "r567", "r827", "r828", "r829", "r830", "r832", "r835", "r836" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r205", "r259", "r260", "r261", "r265", "r266", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r296", "r355", "r356", "r537", "r561", "r566", "r567", "r568", "r613", "r644", "r645", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r205", "r259", "r260", "r261", "r265", "r266", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r296", "r355", "r356", "r537", "r561", "r566", "r567", "r568", "r613", "r644", "r645", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r205", "r259", "r261", "r265", "r266", "r270", "r271", "r279", "r296", "r537", "r561", "r566", "r567", "r613", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r831", "r832", "r833", "r834", "r835", "r847", "r848", "r872", "r885", "r886" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Allowance For Credit Losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Net accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r228", "r229", "r230", "r232", "r239", "r240", "r813" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Reclassified debt securities available-for-sale balances" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r33", "r34", "r221", "r713", "r726", "r730" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r31", "r34", "r152", "r645", "r721", "r722", "r813", "r814", "r815", "r824", "r825", "r826" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r799" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Decrease in additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r7" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Contributed capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r520", "r521", "r522", "r824", "r825", "r826", "r871" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Contributed capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid-in capital (APIC) from recognition of substantial premium at which convertible debt instrument is issued.", "label": "Adjustment to Additional Paid-in Capital, Convertible Debt Instrument Issued at Substantial Premium", "negatedTerseLabel": "Capital contribution from related-party in connection with exchange transaction", "terseLabel": "Capital contribution from related-party in connection with exchange transaction" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r202", "r203", "r204", "r205", "r206", "r265", "r266", "r267", "r269", "r280", "r336", "r337", "r349", "r350", "r351", "r352", "r355", "r356", "r520", "r521", "r522", "r534", "r535", "r536", "r537", "r548", "r549", "r550", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r583", "r584", "r585", "r586", "r587", "r588", "r592", "r593", "r606", "r607", "r610", "r611", "r612", "r613", "r639", "r641", "r642", "r643", "r644", "r645", "r687", "r688", "r689", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r147", "r148", "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Equity-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r109", "r118", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrant issued to related-party" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r222", "r333", "r357", "r359", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r46", "r55", "r163", "r421" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of the debt discount", "verboseLabel": "Amortization of the debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r39", "r421", "r608", "r818" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r421", "r608", "r782", "r783", "r818" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive common stock instruments outstanding (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r55", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r171", "r183", "r215", "r253", "r313", "r317", "r322", "r348", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r551", "r553", "r582", "r799", "r858", "r859", "r890" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r209", "r227", "r253", "r348", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r551", "r553", "r582", "r799", "r858", "r859", "r890" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r153" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r87" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r88" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r341", "r367" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r90" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r89", "r342", "r711" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r86", "r340", "r367", "r705" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Fair Value", "verboseLabel": "Debt securities available-for-sale:" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r63", "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r57", "r212", "r759" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r812" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents, and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r52", "r57", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r52", "r162" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit", "verboseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r218", "r219", "r220", "r253", "r285", "r286", "r290", "r292", "r300", "r301", "r348", "r388", "r391", "r392", "r393", "r397", "r398", "r430", "r431", "r435", "r439", "r446", "r582", "r740", "r808", "r819", "r837" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r129", "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r129", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r865", "r874" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r175", "r189" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r100", "r381", "r383", "r733", "r857" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r824", "r825", "r871" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common Stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Shares Subscribed but Unissued", "terseLabel": "Agreement to purchase shares (in shares)" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r6", "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Value, Subscriptions", "terseLabel": "Purchase price" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r6" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.001 par value; 200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September\u00a030, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December\u00a031, 2021" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r35", "r234", "r236", "r241", "r706", "r714" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive loss", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r73", "r74", "r159", "r160", "r329", "r732" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r73", "r74", "r159", "r160", "r329", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r73", "r74", "r159", "r160", "r329", "r732", "r903" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r73", "r74", "r159", "r160", "r329" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Risk concentration" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r70", "r73", "r74", "r75", "r159", "r161", "r732" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r73", "r74", "r159", "r160", "r329", "r732" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r151", "r769" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Capital projects in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r863" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Deferred Revenue and Income Summary" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r448", "r449", "r469" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "verboseLabel": "Products and services not yet delivered" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenues recognized included in contract liabilities balances" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r4", "r173", "r184" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Carrying amount of convertible notes", "totalLabel": "Total convertible notes" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r2" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt, Current", "terseLabel": "Current portion of convertible notes" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r108", "r399", "r400", "r411", "r412", "r413", "r417", "r418", "r419", "r420", "r421", "r779", "r780", "r781", "r782", "r783" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible notes", "verboseLabel": "Non-current portion of convertible notes" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r792", "r794", "r902" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds", "verboseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r42", "r686" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r40" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Concentration of credit risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r71", "r329" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]", "terseLabel": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r59", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs", "verboseLabel": "Convertible notes value" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Warrants issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]", "terseLabel": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r59", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Notes exchanged" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r114", "r251", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r415", "r422", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r172", "r173", "r182", "r258", "r399", "r400", "r401", "r402", "r403", "r405", "r411", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r609", "r779", "r780", "r781", "r782", "r783", "r820" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r4", "r173", "r182", "r426" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Outstanding principal at par", "verboseLabel": "Outstanding principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r110", "r401" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (in usd per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r22", "r119", "r122", "r124", "r401" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r22", "r119", "r122", "r124", "r401" ], "lang": { "en-us": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "Debt Instrument, Convertible, Number of Equity Instruments", "terseLabel": "Debt instrument, convertible, number of equity instruments" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Stock price conversion threshold, percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r820" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "Debt forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r164", "r166", "r399", "r609", "r780", "r781" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r21", "r164", "r428", "r609" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r21", "r400" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r23", "r258", "r399", "r400", "r401", "r402", "r403", "r405", "r411", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r609", "r779", "r780", "r781", "r782", "r783", "r820" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Option two to convert" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Option one to convert" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Repurchase principal balance" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Repurchase of exchanged amount" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r23", "r119", "r123", "r124", "r125", "r163", "r164", "r166", "r181", "r258", "r399", "r400", "r401", "r402", "r403", "r405", "r411", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r424", "r609", "r779", "r780", "r781", "r782", "r783", "r820" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Contractual term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r163", "r166", "r861" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized debt issuance" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r840" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Realized gain (loss) from debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r841" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Maturities of Available-for-Sale Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r345", "r368", "r778" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Unrealized loss position of debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer", "negatedTerseLabel": "Contributions to deferred compensation plan" } } }, "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r165", "r861" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance discount" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r55", "r96" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r55", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r468", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r485", "r517", "r518", "r519", "r524", "r796" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Employee Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r135", "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of Equity-Based Compensation Expense" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r24", "r390", "r391", "r392", "r396", "r397", "r398", "r650", "r822" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Long-term debt related-party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r242", "r270", "r271", "r273", "r274", "r275", "r283", "r285", "r290", "r291", "r292", "r296", "r567", "r568", "r707", "r715", "r772" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r242", "r270", "r271", "r273", "r274", "r275", "r285", "r290", "r291", "r292", "r296", "r567", "r568", "r707", "r715", "r772" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r293", "r294", "r295", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r598" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Cost capitalized to inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r867" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized equity-based compensation cost, restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r867" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized equity-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Shares issuable upon exercise of stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r118", "r204", "r238", "r239", "r240", "r259", "r260", "r261", "r266", "r276", "r279", "r299", "r352", "r447", "r520", "r521", "r522", "r536", "r537", "r566", "r599", "r600", "r601", "r602", "r603", "r604", "r645", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r216", "r581", "r761" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity investments:", "verboseLabel": "Fair value of equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r716", "r845" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Realized gains or losses from equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r573", "r574", "r579" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r153", "r154", "r155", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurement" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Inputs Used to Calculate Estimated Fair Value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r413", "r474", "r475", "r476", "r477", "r478", "r479", "r574", "r656", "r657", "r658", "r780", "r781", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r573", "r574", "r576", "r577", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r413", "r474", "r479", "r574", "r656", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r413", "r474", "r479", "r574", "r657", "r780", "r781", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "verboseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r413", "r474", "r475", "r476", "r477", "r478", "r479", "r574", "r658", "r780", "r781", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "verboseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Estimated Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r413", "r474", "r475", "r476", "r477", "r478", "r479", "r656", "r657", "r658", "r780", "r781", "r792", "r793", "r794" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r578", "r580" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value on a Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid [Abstract]", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r617", "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease obligation" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r617" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r617" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease, non-current" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r881" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r618", "r623" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r616" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease assets, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r626", "r798" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate finance leases (%)" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r625", "r798" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term finance leases (years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r343", "r344", "r358", "r363", "r364", "r365", "r366", "r369", "r370", "r371", "r424", "r444", "r555", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r778", "r842", "r843", "r844", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r594", "r595", "r596", "r597" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r818" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss (gain) on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r55", "r111", "r112" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on extinguishment of debt", "terseLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r72", "r732" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic concentration" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r708", "r709", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r758", "r775" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]", "terseLabel": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r708", "r709", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionDomesticMember": { "auth_ref": [ "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r758", "r776" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic.", "label": "Geographic Distribution, Domestic [Member]", "terseLabel": "Domestic" } } }, "localname": "GeographicDistributionDomesticMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionForeignMember": { "auth_ref": [ "r708", "r709", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r758", "r777" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as foreign.", "label": "Geographic Distribution, Foreign [Member]", "terseLabel": "Foreign", "verboseLabel": "Outside the U.S." } } }, "localname": "GeographicDistributionForeignMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r41", "r253", "r313", "r316", "r321", "r324", "r348", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r582", "r774", "r858" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r37", "r169", "r176", "r192", "r313", "r316", "r321", "r324", "r709", "r774" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "negatedTerseLabel": "Pre-tax loss", "totalLabel": "Net loss before income taxes", "verboseLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/IncomeTaxesDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r254", "r528", "r529", "r532", "r541", "r543", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r255", "r278", "r279", "r312", "r527", "r542", "r544", "r717" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r237", "r525", "r526", "r529", "r530", "r531", "r533" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Deferred Tax" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities [Abstract]", "terseLabel": "Increase (decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r684", "r817" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue and income" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expense and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r287", "r288", "r292" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Issuable upon conversion of the notes (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r287", "r288", "r292" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "terseLabel": "Common stock issuable upon conversion of the Series A Preferred Stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestAndDividendsPayableCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest and Dividends Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestAndDividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r46", "r419", "r429", "r782", "r783" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense on convertible notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r48", "r420", "r782", "r783" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual coupon interest", "verboseLabel": "Contractual interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "negatedTerseLabel": "Interest expense related-party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of Interest Expense", "verboseLabel": "Schedule of Interest Expense in Connection with the Secured Note" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r247", "r249", "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r92", "r763" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r224", "r760", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://acceleratediagnostics.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r211", "r223", "r298", "r372", "r373", "r374", "r685", "r770" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r92", "r765" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r92", "r764" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r44" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r46" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedTerseLabel": "Amortization of investment discount" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r347", "r899" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r190" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r91", "r170", "r178", "r194", "r752" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r880" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseIncome": { "auth_ref": [ "r636" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.", "label": "Lease Income", "terseLabel": "Lease income" } } }, "localname": "LeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Facilities" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases as Lessee" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease obligations:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r881" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r881" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r627" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r878" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r878" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r630", "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Leases as Lessor" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r884" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Lessor lease term" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of lessor's sales-type leases.", "label": "Lessor, Sales-type Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LessorSalesTypeLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r253", "r348", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r552", "r553", "r554", "r582", "r773", "r858", "r890", "r891" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r174", "r186", "r799", "r821", "r846", "r875" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r210", "r253", "r348", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r552", "r553", "r554", "r582", "r799", "r858", "r890", "r891" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r16", "r820" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r16", "r820" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Long-lived Assets by Geographic Territory" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r4", "r173", "r184", "r412", "r427", "r780", "r781" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Loans - various interest" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r106", "r258", "r417" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r106", "r258", "r417" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r106", "r258", "r417" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r106", "r258", "r417" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r823" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r217" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Debt [Abstract]", "terseLabel": "Convertible Debt [Abstract]" } } }, "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r23", "r107" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r873" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividends" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r873" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Contractual term (in years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r873" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r873" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk free interest rates" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r865" ], "lang": { "en-us": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r248" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r248" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r52", "r53", "r56" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r38", "r56", "r177", "r191", "r208", "r233", "r235", "r240", "r253", "r265", "r270", "r271", "r273", "r274", "r278", "r279", "r289", "r313", "r316", "r321", "r324", "r348", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r397", "r398", "r568", "r582", "r774", "r858" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTerseLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentInLease": { "auth_ref": [ "r334", "r364", "r629", "r849" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases.", "label": "Net Investment in Lease, before Allowance for Credit Loss", "terseLabel": "Net investment in leases" } } }, "localname": "NetInvestmentInLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r207", "r263", "r264", "r267", "r268", "r280", "r281", "r282", "r338", "r339", "r353", "r354", "r538", "r539", "r540", "r564", "r570", "r571", "r572", "r589", "r590", "r591", "r614", "r615", "r640", "r646", "r690", "r691", "r692", "r725", "r726", "r727", "r728", "r730" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r64", "r202", "r203", "r204", "r205", "r206", "r262", "r265", "r266", "r267", "r269", "r273", "r280", "r296", "r336", "r337", "r349", "r350", "r351", "r352", "r355", "r356", "r520", "r521", "r522", "r534", "r535", "r536", "r537", "r548", "r549", "r550", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r583", "r584", "r585", "r586", "r587", "r588", "r592", "r593", "r606", "r607", "r610", "r611", "r612", "r613", "r639", "r641", "r642", "r643", "r644", "r645", "r687", "r688", "r689", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Standards that were recently adopted and standards not yet adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r59", "r60", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Fair value of new note from related-party issued in connection with the exchange transaction" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Loans - various interest", "verboseLabel": "Notes payable, other payables" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r313", "r316", "r321", "r324", "r774" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r621", "r798" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r617" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lessee lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r617" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r617" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r619", "r623" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r616" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r626", "r798" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (%)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r625", "r798" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r226", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r214" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r228", "r229", "r231" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Net unrealized gain (loss) on debt securities available-for-sale", "verboseLabel": "Net unrealized gain (loss) on debt securities available-for-sale" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r30" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtCurrent": { "auth_ref": [ "r2", "r3" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "OtherLongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash financing activities:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r49", "r85", "r244" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r246", "r868", "r869", "r870" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": { "auth_ref": [ "r131", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]", "terseLabel": "Nonqualified Cash Deferral Plan" } } }, "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based stock option expense", "verboseLabel": "Performance-based stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionRatio": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.", "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio (in shares)" } } }, "localname": "PreferredStockConvertibleConversionRatio", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "pureItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r430" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockShareSubscriptions": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Preferred Stock, Shares Subscribed but Unissued", "terseLabel": "Agreement to purchase preferred shares (in shares)" } } }, "localname": "PreferredStockShareSubscriptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Preferred Stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesSubscribedButUnissuedValue": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription received from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.", "label": "Preferred Stock, Value, Subscriptions", "terseLabel": "Aggregate purchase price" } } }, "localname": "PreferredStockSharesSubscribedButUnissuedValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and 3,954,546 outstanding as of September\u00a030, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r225", "r375", "r376", "r762" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r50" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r85", "r244", "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales of debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r50", "r145" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r50" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stocks under employee purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r785" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r852", "r877", "r879" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r853", "r879" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r809", "r851", "r876" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r99", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation": { "auth_ref": [ "r378", "r632" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of accumulated amortization, depreciation, depletion for physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation", "negatedTerseLabel": "Accumulated depreciation under operating leases" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation": { "auth_ref": [ "r853", "r883" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation", "totalLabel": "Net property and equipment under operating leases" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r97", "r213" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r98", "r188", "r712", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "verboseLabel": "Long-lived assets (excluding intangible assets)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r98", "r734", "r735" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross": { "auth_ref": [ "r200", "r201", "r377", "r632" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation", "terseLabel": "Instruments at cost under operating leases" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r243", "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "(Reversals) provisions, net" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r187", "r193", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade accounts receivable, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r34", "r36", "r239", "r599", "r603", "r604", "r813" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassified from out of accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r480", "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r199", "r649", "r650", "r889" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r480", "r649", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r889" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r647", "r648", "r650", "r651", "r652" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r816" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Payment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r150", "r195", "r898" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Shares issuable upon the release of RSUs", "verboseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r126", "r185", "r725", "r730", "r799" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Decrease in accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r204", "r259", "r260", "r261", "r266", "r276", "r279", "r352", "r520", "r521", "r522", "r536", "r537", "r566", "r721", "r723" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r309", "r310", "r315", "r319", "r320", "r326", "r327", "r329", "r467", "r468", "r686" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r472", "r771" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Deferred Revenue and Remaining Performance Obligations" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Contact period" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue expected to be recognized from remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r624", "r798" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r624", "r798" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Share price (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r329", "r838" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Total revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "auth_ref": [ "r631", "r637" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "terseLabel": "Present value of lease payments" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Sales-type Lease Receivables" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received", "totalLabel": "Total undiscounted cash flows" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four", "terseLabel": "2026" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One", "terseLabel": "2023" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r882" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three", "terseLabel": "2025" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two", "terseLabel": "2024" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Available-for-Sale Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r23", "r119", "r123", "r124", "r125", "r163", "r164", "r166", "r181", "r780", "r782", "r823" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Carrying Value of the Notes", "verboseLabel": "Schedule of Carrying Value of the Secured Notes" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r143", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r270", "r271", "r272", "r275", "r276", "r278", "r279", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r65", "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Schedule of Effect of Restatement" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax.", "label": "Schedule of Extinguishment of Debt [Table Text Block]", "terseLabel": "Schedule of Gain on Extinguishment" } } }, "localname": "ScheduleOfExtinguishmentOfDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r12", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Warranty Reserve" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r201", "r853", "r883" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block]", "terseLabel": "Schedule of Instruments at Cost and Accumulated Depreciation, Lessor" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r80", "r81", "r82", "r93" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r482", "r484", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r137", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Option Activity under the Company's Equity-Based Compensation" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of Outstanding Options and Options that are Exercisable (Vested)" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r115", "r116", "r117", "r119", "r120", "r121", "r123", "r124", "r125", "r126", "r218", "r219", "r220", "r300", "r430", "r431", "r433", "r435", "r439", "r444", "r446", "r784", "r808", "r819" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r306", "r307", "r308", "r313", "r314", "r318", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic and Revenue Disaggregation" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r810", "r811", "r862" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r785" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r54" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r796" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of\u00a0Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)", "terseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "terseLabel": "Number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of\u00a0Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance (in usd per share)", "periodStartLabel": "Outstanding, beginning balance (in usd per share)", "terseLabel": "Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r510", "r511", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r489", "r508", "r509", "r510", "r511", "r514", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r797" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Exercisable (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r622", "r798" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Warranty cost incurred" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty Reserve" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r218", "r219", "r220", "r253", "r285", "r286", "r290", "r292", "r300", "r301", "r348", "r388", "r391", "r392", "r393", "r397", "r398", "r430", "r431", "r435", "r439", "r446", "r582", "r740", "r808", "r819", "r837" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r28", "r118", "r204", "r238", "r239", "r240", "r259", "r260", "r261", "r266", "r276", "r279", "r299", "r352", "r447", "r520", "r521", "r522", "r536", "r537", "r566", "r599", "r600", "r601", "r602", "r603", "r604", "r645", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r259", "r260", "r261", "r299", "r686" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r59", "r60", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Extinguishment of convertible senior notes through issuance of common stock" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r27", "r118", "r119", "r126", "r416" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of shares to retire Convertible Senior Notes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r5", "r6", "r118", "r126", "r149" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r118", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r118", "r126", "r495" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r28", "r118", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of shares to retire convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r5", "r6", "r118", "r126", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r118", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from issuance of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r28", "r118", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Restricted stock awards released and exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "negatedTerseLabel": "Rescission of common stock (in shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r5", "r6", "r118", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Rescission of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r84", "r799", "r821", "r846", "r875" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance, amount", "periodStartLabel": "Beginning Balance, amount", "terseLabel": "Total stockholders\u2019 deficit ending balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofEffectofRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r130", "r252", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r445", "r447", "r556" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Technical equipment" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r196", "r197", "r198", "r331", "r332", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r343", "r344", "r424", "r444", "r555", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r842", "r843", "r844", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r29", "r127", "r128" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedTerseLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r202", "r203", "r204", "r205", "r206", "r265", "r266", "r267", "r269", "r280", "r336", "r337", "r349", "r350", "r351", "r352", "r355", "r356", "r520", "r521", "r522", "r534", "r535", "r536", "r537", "r548", "r549", "r550", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r583", "r584", "r585", "r586", "r587", "r588", "r592", "r593", "r606", "r607", "r610", "r611", "r612", "r613", "r639", "r641", "r642", "r643", "r644", "r645", "r687", "r688", "r689", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r710", "r792", "r902" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. Treasury securities", "verboseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r55" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized loss (gain) on equity investments", "verboseLabel": "Unrealized (loss) gain on equity investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/InvestmentsUnrealizedLossesorGainsonEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Unrealized Losses or Gains on Equity Securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Total commitments" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured obligations" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r76", "r77", "r78", "r302", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Shares issuable upon the exercise of the Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants fair value" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants issued, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r284", "r292" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r283", "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235172", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235116", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235144", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123422147&loc=d3e41457-112716", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919306-209978", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919379-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888252", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r802": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r803": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r804": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r805": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r806": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r807": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 101 0001628280-23-006315-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-006315-xbrl.zip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�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end